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 Abstract 
 
Introduction: Interactions between tumour cells and the immune system play a critical role 
in regulating tumour development. Therapeutic strategies that harness the immune system 
have shown variable responses in diffuse large B cell lymphoma (DLBCL) which suggests 
that the immune tumour microenvironment (TME) might determine which patients are likely 
to respond to immune-based therapies. However, the key determinants of the tumour 
microenvironment and the relative contribution of immune effector and inhibitory cells to 
lymphomagenesis are poorly understood. The loss of the antigen presentation and immune 
cell recognition molecules beta-2-microglobulin (Β2M) and CD58 by malignant cells is a 
frequent mechanism of immune evasion identified in DLBCL. The genetic events leading to 
Β2M and CD58 protein loss are not fully understood; mutations and copy number loss are 
present in only a proportion of cases and a significant number of wild type cases also show 
protein loss.  
 
Aim: This project sought to determine the effect of Β2M and CD58 expression on the 
infiltration and composition of immune cells in the TME of DLBCL and to investigate the 
mechanisms of Β2M and CD58 protein loss. 
 
Methods: Ninety-seven de novo systemic DLBCL FFPE tissue biopsies underwent targeted 
resequencing of the Β2M and CD58 exons and 5’ and 3’ UTRs (Illumina TSCA) in addition 
to quantitative gene expression of Β2M, CD58, immune effectors (CD4, CD8, CD56, CD137) 
immunosuppressive macrophage markers (CD68, CD163) and immune checkpoints (TIM3, 
LAG3, PD1, PDL1 and PDL2) (NanoString™ Technologies) and Β2M and CD58 copy 
number analysis by qPCR. Β2M promoter methylation by mass array (EpiTYPER®), 
immunohistochemistry (IHC) for the above markers and high-throughput T-cell receptor β 
sequencing (Adaptive Biotechnologies) were performed on a subset of cases. Sequencing 
and gene expression findings were validated against an external whole exome and 
transcriptome cohort of approximately 1000 DLBCL samples.  
 
Results: Β2M mutations were detected in 14/97 (14.4%) samples and had significantly 
lower Β2M gene expression compared to Β2MWT (p = 0.0094) and all showed B2M protein 
loss. However, protein loss was also observed in the majority of Β2MWT samples (31/40; 
77%). The Β2M promoter region was not differentially methylated compared to controls. 
B2M copy number analysis was limited by technical difficulties but did not show an 
association with gene or protein expression. These findings demonstrate that mechanisms 
other than mutation, copy number or methylation status contribute to loss of Β2M surface 
 expression in DLBCL and that Β2M gene expression provides a more robust assessment of 
intratumoural Β2M status. Consistent with this, there were no significant differences between 
Β2MMut/WT and expression of intratumoural immune markers, however Β2M gene expression 
was significantly associated and positively correlated with the gene expression of CD4, CD8, 
CD56, CD137, CD68, CD163, PD1, PDL1 and LAG3  (all p <0.01) and with the protein 
expression of CD4, CD8, CD137, PDL1 and LAG3 (all p <0.01). These findings are 
consistent with a co-ordinately regulated immune response and suggest adaptive immune 
resistance by malignant cells through the upregulation of checkpoint inhibitors. High Β2M 
gene expression was also significantly associated and correlated with a higher total number 
of intratumoural T cells (p = 0.0337, Spearman r = 0.34) and less TCR diversity (p = 0.0252, 
Spearman r = -0.34) compared to low Β2M gene expression, suggesting that clonal T cell 
expansions are more likely with intact antigen presentation. The validation cohort confirmed 
that Β2M gene expression correlated with immune cell infiltration and additionally showed 
that Β2M gene expression positively correlated with the gene expression of HLA Class I//II 
molecules and a range of regulatory, transport and assembly molecules involved in the 
antigen presentation pathway.  
 
Similar analyses were performed for CD58 and showed no significant associations between 
CD58Mut/WT and CD58 gene expression or immune effector or inhibitor gene or protein 
expression. CD58 gene expression was associated with the gene expression of CD4, CD8, 
CD56, CD68, PD1 and PDL1 (all p <0.01) but not protein expression. These findings were 
not confirmed by the validation cohort. CD58 IHC data could not be obtained due to technical 
limitations, which restricts our study on the role of CD58 expression on the TME. On the 
basis of our limited data and the validation cohort findings, there is no evidence to suggest 
that CD58 is a key determinant of the TME in DLBCL. 
 
Conclusions: Gene expression is a robust measure of Β2M quantification in the TME. Our 
findings indicate that high Β2M gene expression reflects an immunologically active or ‘hot’ 
tumor microenvironment in DLBCL characterised by higher levels of immune cell infiltration 
and a more clonal T cell infiltrate.  This data suggests that Β2M gene expression level could 
be used as a biomarker of an active intratumoural immune response in DLBCL and may 
help to stratify the selection of patients in whom immune-based therapies are more likely to 
be effective. 
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1. CHAPTER 1: Literature Review 
1.1. Introduction 
Diffuse large B cell lymphoma (DLBCL) is an aggressive B cell malignancy, accounting for 
approximately 30% of cases of Non-Hodgkin lymphoma (NHL) with an annual incidence of 
approximately 7/100 000 people, representing approximately 1600 new cases diagnosed in 
Australia each year.1-5 DLBCL can occur at any age although more commonly affects older 
adults, with a median age at diagnosis of 70 years.5 While the underlying cause of DLBCL 
remains unknown, immunosuppression is the most consistent predisposing factor.6-8 Most 
patients with DLBCL present with advanced disease at the time of diagnosis and while standard 
immunochemotherapy (R-CHOP) regimens can induce durable remissions in the majority of 
cases, approximately one third of patients do not respond to current treatments and ultimately 
die from either treatment refractory or relapsed disease.9-11 Therefore, there is an urgent need 
for the early identification of patients who are unlikely to respond to standard therapies to avoid 
their exposure to unnecessary toxicity and there is also an urgent need to develop more effective 
treatments for the poor response group. 
 
In the past two decades insight into the complexity and diverse molecular heterogeneity of 
DLBCL has emerged. Gene expression profiling (GEP) has identified prognostically 
significant subtypes of DLBCL differentiated on the basis of their cell of origin (COO).12  
Using this classification, germinal centre B cell (GCB)-like DLBCL, which has a GEP that 
resembles a normal germinal centre B cell has a superior 5-year overall survival (OS) of 60% 
with R-CHOP while activated B cell (ABC)-like DLBCL, which is characterised by chronic 
B-cell receptor activation and constitutive NFκB signaling has a poorer 5 year overall survival 
of 35%.12,13 The Type 3/Unclassifiable (UC) group has a 5 year OS of 39%.12  More recently, 
studies have distinguished prognostically relevant subtypes of DLBCL on the basis of co-
occurrence of genetic alterations which may lead to advances in targeted treatment for this 
disease.14,15 
 
In recent decades it has become well established that the immune system can facilitate cancer 
progression and inhibition and shape the immunogenicity of tumours, which makes the immune 
system an ideal target for manipulation in favour of cancer suppression and underpins the 
rationale for cancer immunotherapy.16 While advances in understanding the interactions 
between malignant cells and the immune system are being made, much remains to be learned 
regarding these processes and increasing attention has turned toward the tumour 
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microenvironment (TME) to provide answers to these questions. Understanding the immune 
component of the TME has led to the development of effective, targeted anti-cancer therapies 
including immune checkpoint inhibitors17-19 and while durable responses to checkpoint 
inhibitors have been observed in several malignancies20-25 including DLBCL,26-30 not all 
patients show a response. The variable responses suggest that differences in the immune 
microenvironment may hold the answers to understanding disease pathogenesis, resistance 
mechanisms and ultimately which patients are most likely to benefit from immune-based 
therapies. Therefore, key research questions are to identify the critical determinants of the 
tumour microenvironment and how these components may regulate tumourigenesis and affect 
responses to immune-based therapies.  
 
This review outlines what is currently known regarding the role of the immune system in 
malignancy and immune evasion mechanisms utilised by tumour cells. The emerging 
importance of the immune cell composition in the tumour microenvironment, with particular 
reference to DLBCL, is also discussed. These topics underpin my research project, which 
investigates the impact of reduced expression of the key immune cell recognition components 
beta-2 microglobulin (B2M) and CD58 by malignant B cells on the tumour microenvironment 
in DLBCL. This research is aimed at enhancing the understanding of the TME in DLBCL 
which may inform the identification of which individuals are likely to respond to therapeutic 
immune modulation.  
 
1.2. The Immune System 
1.2.1. Innate vs Adaptive Immune Response 
There are two main divisions of the immune system: innate and adaptive immunity, which 
reflect the specificity and rapidity of the host response generated following antigen exposure. 
The innate immune system is the host’s first line of defense against infection and consists of 
the plasma proteins forming the complement system and non-specific effector cells including 
natural killer (NK) cells, dendritic cells, macrophages, neutrophils and mast cells.31,32 In 
response to effector cell recognition of antigen through highly conserved pattern recognition 
receptors, the innate immune system generates a rapid, non-specific inflammatory response 
with the aim of containing and resolving infection.32 
In contrast, the adaptive response is mediated by CD4+ (T helper) cells , CD8+ (cytotoxic) T 
cells and B cells and is characterised by the development of antigen-specific effector and 
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memory cells via either humoural (antibody-generating) or cellular mechanisms.31,33 The 
adaptive response develops more slowly than the innate response, requiring the expansion of 
lymphocytes which contain receptors specific for the antigen being presented.31 T cell 
activation is required for the initiation of most adaptive immune responses.32 To enable T cell 
activation, antigenic peptide must be presented to the T cell receptor (TCR) in association with 
membrane-bound Major Histocompatibility Complex (MHC) molecules.  
1.2.2. The T cell receptor and Major Histocompatibility Complex 
T cells recognise cognate antigens though their surface T cell receptors (TCRs) which are 
highly variable and unique heterodimers composed of either αβ or γδ polypeptide chains 
formed in thymic development through the somatic recombination of variable (V), diversity 
(D) and joining (J) gene segments.34  Each chain has a constant and variable domain, the latter 
determines antigen-binding specificity and forms the site for antigen-MHC binding.34 The 
majority of TCRs are comprised of an α and β glycoprotein chain while the minority of T cells 
display an alternative receptor comprised of γδ chains, which recognise non-peptide antigens 
and act at the interface between innate and adaptive immunity.35 
TRA and TRG genes encode the TCR α and γ chains respectively and are composed of a 
variable (V), joining (J) and constant (C) region.36,37 TRB and TRD genes encode the TCRβ 
and δ chains and in addition to V and J segments, contain a diversity (D) region.36,37 The TCR 
antigen-binding sites are formed by three hypervariable complementarity-determining regions 
(CDR): CDR1, CDR2 and CDR3.38 The CDR3 is a highly diverse region which determines the 
structure and specificity of the TCR and therefore serves a critical role in the recognition of 
antigenic peptides presented by MHC.38 Due to CDR3 diversity, each CDR3 differs between 
T cell clones such that one CDR3 sequence represents a specific T cell clonotype.39,40   
The MHC locus encodes a series of highly polymorphic proteins, MHC Class I (encoded by 
HLA-A, -B and -C genes) and MHC Class II (encoded by HLA-DP, -DQ and -DR genes) 
which are central to the initiation and propagation of immune responses. In humans, the MHC 
complexes are also known as human leucocyte antigen (HLA) complexes. MHC Class I 
molecules are found on almost all nucleated cells and function to present peptides from 
endogenous antigen, including viral or tumour-derived antigens, to CD8+ cells. The MHC 
Class I complex is composed of three highly polymorphic alpha chains non-covalently 
associated with an invariant Β2M molecule, which is critical to the assembly and stability of 
the MHC Class I structure.32  In contrast, MHC Class II molecules are restricted to expression 
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on dedicated antigen presenting cells (APCs) and are comprised of two highly polymorphic 
alpha and beta chains.32 MHC Class II molecules function to present exogenous antigens to 
CD4+ cells, which generates further immune responses to an antigen.41  
The interaction between MHC-peptide complex and the TCR alone is insufficient for T cell 
activation. Additional interaction between ligands and receptors on the surface of the target 
cell and effector T cell, termed ‘co-stimulation,’ is required to activate the T cells. The quality 
and strength of the T cell response to antigen is mediated by the balance of co-stimulatory and 
co-inhibitory signaling.42  If no co-stimulatory signals are generated, despite the MHC - peptide 
-TCR interaction, a state of tolerance is induced which may lead to the anergy of clones 
recognising a particular antigen.43  
1.2.3. Recognition of Tumours by the Immune System 
1.2.3.1. Tumour-associated antigens  
Malignant cells can express antigens which distinguish them from non-diseased cells. Somatic 
mutations can give rise to antigens that are completely foreign to a host and are  known as ‘neo-
antigens’, which are capable of eliciting strong, tumour-specific immune response.44,45 Other 
tumour associated antigens (TAAs) are non-mutated but aberrantly expressed self-antigens 
which are less immunogenic than neo-antigens and are categorised into three subgroups: 1) 
overexpressed normal proteins 2) differentiation antigens and 3) proteins encoded by cancer 
germline genes (e.g: cancer testis-antigen).46-48 
The immune response against TAAs is initiated through antigen recognition by effector cells 
of the innate and adaptive immune system.47,49 In the innate system, nascent malignant cells 
can be detected through highly-conserved pattern-specific receptors on effector cells or through 
the detection of other cell-surface molecules such as stress-related genes and by tumour cell 
loss of surface MHC Class I expression.31 Following immune effector recognition, tumour cells 
may be destroyed by NK-mediated lysis or phagocytosed by macrophages and dendritic cells. 
The adaptive immune system may be stimulated through either the self-presentation of 
endogenously-derived tumour associated antigens on MHC Class I or through the presentation 
of exogenously processed antigen by APCs via MHC Class II. In some cases, tumour cells may 
lack MHC and the co-stimulatory molecules required to drive activation and clonal expansion 
of T cells and thus cannot be targeted directly by naïve T cells. In these cases, the adaptive 
immune system may recognise tumour cells through an indirect method known as ‘cross-
priming.’50,51 In this process, peripheral dendritic cells endocytose tumour antigens, migrate to 
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regional lymph nodes and present the peptides via MHC molecules to TCRs, resulting in T cell 
activation and the production of tumour-specific T cell clones capable of reacting directly with 
the tumour antigen.31,50,51  
1.2.3.2. Immune response to tumours 
The concept of ‘immunosurveillance’ was originally described by Thomas and Burnet in 1957 
who hypothesised that the immune system was capable of recognising and destroying 
malignant cells and that the failure of this process resulted in the diagnosis of cancer.52-54 This 
concept has since evolved to encompass a model known as ‘cancer immunoediting.’55 The 
concept of cancer immunoediting considers evidence from extensive mouse and clinical 
models and proposes that the immune system serves the dual roles of promoting and 
eliminating tumour development and actively shapes tumour immunogenicity.16,55-64 Crucial to 
the concept of cancer immunoediting is that T cells recognise tumour antigen through 
presentation by MHC molecules, which either causes the elimination or sculpting of a 
developing tumour.16 Cancer immunoediting is proposed to occur continuously throughout the 
development of a tumour but most prominently in the early stages before it is clinically 
detectable.55,65 Three sequential and dynamic phases are thought to comprise the 
immunoediting process: elimination, equilibrium and escape.66 In the elimination phase, 
effectors of the innate immune system recognise early transformed cells and are activated to 
either destroy the tumour cells or stimulate an adaptive immune response.67 Failure of the 
elimination phase allows the tumour cell to proceed to equilibrium.67 Equilibrium represents a 
dynamic balance between anti-tumour and pro-tumour cytokines which is mediated by the 
adaptive immune system and malignant clones that have survived elimination; selection 
pressures favour the development of tumour cells capable of surviving immune attack.67  
Escape is the process of proliferation and expansion by tumour cells which have gained the 
ability to evade immune recognition and destruction and results in clinically detectable 
malignancy.67 In summary, while the immune system can eliminate malignant cells, those 
tumours which have become detectable are likely to occur in the context of an immune system 
that has selected for weakly immunogenic clones and/or one that has established an 
immunosuppressive microenvironment.68  
Several studies describe mechanisms underlying the elimination and escape phases however 
the processes involved in maintaining tumour cells in a dormant state during equilibrium are 
less understood.16,69 The composition of the immune microenvironment has been implicated in 
maintaining a state of functional dormancy in murine sarcomas, however what determines the 
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immune milieu and what shifts the balance between elimination and equilibrium is unknown 
and requires further study.70,71 The increased incidence of NHL in immunosuppressed 
individuals, e.g: primary and acquired immunodeficiencies and post-transplant recipients 
supports the relevance of the immune microenvironment during cancer immunoediting.6,7,72  
1.2.4. Mechanisms of Immune Escape 
Several mechanisms may be utilised by malignant cells as a means of evading immune cell 
recognition and destruction which can be broadly considered within three distinct but 
functionally overlapping groups that affect tumour antigenicity, tumour immunogenicity and 
the generation of an immunosuppressive microenvironment.68 
Tumour cells may lose their antigenicity and thus evade recognition by the immune system 
through genetic defects or altered surface expression of antigen presentation molecules and 
proteins associated with antigen processing.16,73 In keeping with this, surface HLA and Β2M 
loss by malignant cells are frequent events in many solid malignancies and DLBCL, with 
underlying genetic aberrations identified in many cases.74-78 Additionally, recent evidence has 
identified epigenetic changes affecting the promoter regions of MHC and related genes with 
subsequent downregulation of MHC molecules in solid malignancies.79 Antigenicity can also 
be reduced through the selective loss of immunogenic antigens, resulting in a lack of peptides 
presented via MHC and reduced immune recognition of tumour.68 
Tumour cells can acquire mechanisms that dampen the anti-tumour immune response, i.e.: 
reduce their immunogenicity. For example, via the downregulation of co-stimulatory 
molecules which leads to T cell anergy and tolerance following engagement of the TCR 
without co-stimulation.73 Additionally, tumour cells may upregulate inhibitory receptor ligands 
on their cell surface which engage the corresponding T cell receptors and inhibit T cell function, 
termed adaptive immune resistance.80-82 T cell inhibitory receptors or immune ‘checkpoints’  
(including programmed death-1 (PD-1) and cytotoxic-T-lymphocyte-associated protein 4 
(CTLA-4)) serve a critical role in modulating T cell activation including maintaining 
physiological self-tolerance and limiting collateral tissue damage during normal T cell immune 
responses.80  Targeting these inhibitory pathways through receptor blockade is the basis for the 
development of checkpoint inhibitors, whereby adaptive immune resistance that leads to 
tumour-specific T- and NK cell inhibition is reversed with checkpoint blockade.81-83 
Checkpoint inhibition has been shown to be most effective in cancers expressing high levels 
of immune checkpoints and with a high level of intratumoural immune response84-88 which 
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highlights an emerging role for the immune microenvironment to identify which patients are 
most likely to benefit from immune-based therapies. 
A further mechanism of immune escape is the generation of an immunosuppressive 
microenvironment. The secretion of immunosuppressive and pro-angiogenic cytokines by 
tumour cells can  recruit immunosuppressive cells such as regulatory T cells (Tregs) and 
monocytic myeloid-derived suppressor cells (moMDSCs) to the area.16  These cells can secrete 
immunosuppressive cytokines which inhibit T cell function and limit anti-tumour 
responses.16,73 A recent study by our laboratory identified that PD-1+ve CD3-ve CD56bright CD16-
ve NK cells are increased in patients with DLBCL and classical Hodgkin lymphoma (cHL) 
compared to healthy participants, and that expansion of these cells, representing an exhausted 
NK cell population, may reflect an immune evasion strategy induced by malignant cells and 
mediated by moMDSC.89 
1.2.4.1. Deficient antigen presentation in DLBCL 
A landmark study by Challa-Malladi et al suggested that the downregulation of the antigen 
presentation and immune recognition molecules Β2M and CD58 by DLBCL cells is co-
selected for as a mechanism of immune escape in this malignancy.78  In this study, the genes 
encoding Β2M and CD58 were reported to be inactivated by mutations in 29% and 21% of 
DLBCL cases, respectively.78  Absent or aberrant surface protein expression of Β2M and CD58 
was identified in 75% and 67% of DLBCL biopsies, respectively, including those with biallelic 
and monoallelic gene mutations and normal alleles.78  The lack of surface Β2M expression was 
associated with a concurrent lack of MHC Class I molecule expression as determined by 
immunohistochemistry and the loss of CD58 surface expression was associated with reduced 
NK cell-mediated lysis of tumour cells in vitro.78  In 61% of all cases, concurrent loss of surface 
Β2M, HLA- Class I and CD58 protein was detected. Notably, mutations affecting both Β2M 
and CD58 were not detected in other forms of mature B cell NHLs analysed.78  This study also 
observed that 11/53 cases with normal Β2M alleles and 19/54 with normal CD58 alleles had 
absent or mislocalised surface protein, suggesting additional mechanisms for the inactivation 
of these genes. 
These findings suggest that DLBCL cell variants displaying a lack of both surface Β2M and 
CD58 are selected for during lymphomagenesis as a means of avoiding immune recognition 
and destruction by CD8+ and NK cells, effectors of the adaptive and innate immune systems.78  
MHC Class I alone is insufficient as a mechanism of immune escape, as NK cells are still able 
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to recognise and destroy these cells, while the additional loss  of CD58 permits immune escape 
from NK cell recognition.78  
1.2.4.1.1. Beta-2-microglobulin 
The MHC Class I molecule is a heterodimer composed of three highly polymorphic, 
transmembrane glycoprotein alpha chains which are non-covalently associated with Β2M, an 
invariant, soluble polypeptide which is essential for the assembly, stability and surface 
expression of MHC Class I.90  MHC Class I molecule assembly and association with antigenic 
peptides occurs in the endoplasmic reticulum.91-93 Any alpha chains that do not associate with 
Β2M in the endoplasmic reticulum are retained intracellularly and cannot be used to present 
antigen.92 As early as 1978, Arce-Gomez et al postulated that the loss of surface Β2M observed 
in Daudi cells, a Burkitt lymphoma cell line, may confer immune evasion advantage to the 
malignant cell.94 
Surface Β2M loss is reported in a range of malignancies including DLBCL, melanoma, lung, 
colorectal and cervical cancer.74,76,78,95-97 Additionally, deficient Β2M expression has been 
associated with poor prognostic outcomes in some malignancies which may reflect a more 
aggressive tumour due to enhanced immune evasion mechanisms. Amiot et al have shown that 
seven cases of non-Hodgkin’s lymphoma with reduced Β2M surface expression had higher 
tumour grade and poorer outcome while Shrout et al reported that decreased Β2M gene 
expression was a strong predictor of metastases in colorectal cancer.98,99 Riemersma et al have 
additionally reported the loss of MHC Class I expression in 60% of extranodal DLBCL cases 
with reduced or absent expression of Β2M detected in 35% and 20% of cases, respectively.100   
Loss of Β2M surface expression has been reported to occur through genetic aberrations 
affecting the corresponding gene located on chromosome 15, including inactivating mutations 
and loss of heterozygosity (LoH).101-103  In a landmark sequencing study Pasqualucci et al first 
described frequent inactivating mutations and deletions of the gene encoding Β2M in a cohort 
of DLBCL biopsies however surface Β2M expression was not examined in this study.104  
In addition to DLBCL, Β2M mutations have been reported in solid malignancies including 
melanoma and colorectal cancer and are associated with the loss of surface MHC Class I 
expression.75,105  In melanoma, a truncating mutation in Β2M resulting in the loss of surface 
MHC expression and the loss of surface Β2M have been implicated as acquired resistance 
mechanisms to immune-checkpoint blockade and T-cell immunotherapy, respectively.90,106 
Furthermore, D’Urso et al demonstrated a deletion of the Β2M 5’ coding region, ranging from 
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upstream of the transcriptional start site to immediately 5’ of exon 2 in FO-1, an HLA Class I 
deficient melanoma cell line.76  In conjunction with the identification of frequent mutations 
affecting the methionine initiation codon in DLBCL78 and Daudi cell lines, whereby point 
mutations of the initiation codon resulted in a lack of Β2M protein synthesis, despite an mRNA 
transcript being detectable107, the FO-1 findings suggest that the Β2M 5’ regulatory region and 
initiator codon are hotspots for genetic aberrations leading to Β2M protein loss. 
The effect of larger structural changes of Β2M have been described. Sade-Feldman et al 
analysed longitudinal biopsies in 17 patients with melanoma and observed Β2M genetic 
aberrations in approximately 29% of patients with progressive disease.108 They also found that 
Β2M LoH is enriched in patients non-responsive to anti-CTLA1 and anti-PD1 checkpoint 
inhibition and is associated with poorer overall survival.108 Additionally, in lung cancer a 
CRISPR-mediated Β2M knock-out mouse model demonstrated anti-PD-1 resistance and 
impaired CD8 cytotoxicity due to impaired MHC Class I antigen presentation.77 
Under normal physiological conditions, soluble Β2M is present at low levels in body fluids 
after being shed from the surface of nucleated cells.109 Serum Β2M is increased in many 
cancers, including haematological malignancies and can be used as a prognostic indicator in 
several subtypes of lymphoma.109 The mechanisms by which elevated Β2M levels confer 
prognostic significance in lymphoma are not clear but may reflect tumour burden and cell 
turnover, or unknown mechanisms at the level of the microenvironment.110 Serum Β2M levels 
at diagnosis have been shown in several studies to predict poor progression-free and overall 
survival in DLBCL.110-113 
1.2.4.1.2. CD58 
CD58 is a broadly distributed cell surface molecule, present on all peripheral blood cells, 
endothelial cells, smooth muscle cells  and fibroblasts.114 It serves as a ligand for the T- and 
NK cell surface receptor CD2 thereby facilitating attachment and cytotoxic activation of these 
key immune cells. Inhibition of NK-cell and cytotoxic T cell lysis has been observed using 
anti-CD58 monoclonal antibodies, which inhibit binding between CD58 and its receptor, 
CD2.115-117 
The role of CD58 in tumorigenesis has been reported in several studies. Archimbaud et al have 
demonstrated that in adult acute leukaemia, higher CD58 expression is significantly associated 
with complete response, longer overall and disease free survival.118  Recently, sequencing 
analysis of 125 peripheral T Cell lymphoma samples identified mutations targeting the genes 
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encoding CD58 and Β2M.119 This complements earlier work undertaken in adult T cell 
lymphoma samples, which showed that 29% of acute-subtype and 7% of chronic-subtype had 
genetic alterations of CD58 and likely represents a mechanism of immune escape in the 
transformation of this lymphoma.120 
Very little is known about the mechanisms underlying loss of CD58, which has been reported 
in DLBCL, Burkitt’s lymphoma cell lines, Hodgkin lymphoma and urothelial 
carcinomas.78,121,122 In addition to the genetic aberrations identified by Challa-Malladi et al in 
DLBCL, three genetic aberrations have been characterised in Hodgkin lymphoma cell lines: a 
splice site mutation in KMH2, homozygous deletions in SUPHD1 and stop gain mutation in 
DEV and all show loss of CD58 protein expression by flow cytometry.121 Only two of the 
mutated cell lines (KMH2 and SUPHD1) were associated with reduced CD58 mRNA levels, 
which may reflect the type of mutation seen in these cases.121,123,124 Also, while inactivating 
mutations were identified in 3 out of 7 cell lines by Schneider et al, these events were rarely 
seen in primary HRS cells.124  
Little is known about the impact of Β2M and CD58 genetic alterations on survival outcomes 
in DLBCL. Reddy et al characterised the genomic landscape of 1001 DLBCL samples and 
reported that Β2M mutations occurred in approximately 7% of all cases and were significantly 
enriched in the GCB COO subgroup.125 Missense mutations, truncating mutations and copy 
number loss were the most frequent types of Β2M genetic aberrations.125 Β2M-mutated 
DLBCLs had better 3 year overall survival (OS) compared to Β2M wild type, both overall 
(61/875) and in the GCB subset (33/703).125 Β2M mutation status was not associated with 
survival in the ABC (13/723) or UC (4/732) COO subtypes.125 CD58 mutations occurred in 
approximately 3% of cases and were associated with worse 3 year OS compared to CD58 wild 
type overall and in the GCB subgroup but were not associated with survival in the ABC or UC 
COO groups.125                                                                                  
1.2.4.2. Epigenetic Regulation in DLBCL 
Large-scale studies of B cell lymphomas have demonstrated that mutations affecting epigenetic 
and transcriptional modifiers with subsequent aberrant DNA methylation and changes in 
histone modification patterns are frequent events in B cell lymphomas.126 Epigenetic changes 
are frequent in DLBCL and have been implicated in lymphomagenesis, disease progression 
and tumour immune escape.127-131 
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DNA methylation is the most well-studied epigenetic modification and consists of the addition 
of a methyl group to carbon 5 of the cytosine within the dinucleotide CpG.132 This modification 
of a gene regulatory region, causing either hyper- or hypo- methylation is associated with 
respective gene silencing or expression and the degree of promoter methylation is usually 
inversely proportional to the amount of gene expression.131,132  
Using genome-wide DNA methylation Pan et al examined the DNA methylation landscape 
and intra-tumoural methylation heterogeneity in a cohort of 13 DLBCL cases with paired 
diagnostic and relapsed biopsies and demonstrated an association between increased DNA 
methylation and disease progression.131 In particular, intra-tumoural methylation heterogeneity 
at diagnosis was lower in non-relapsed patients compared to those who did relapse and the 
degree of heterogeneity predicted time to relapse.131 This was thought to represent clonal 
selection of malignant cells leading to the relapse. Additionally, they identified a relapse-
associated methylation signature characterised by a small number of differentially methylated 
regulatory elements, including genes potentially involved in tumour suppression such as the 
TGFβ receptor activity pathway.131 The authors postulated that epigenetic heterogeneity may 
support relapse in DLBCL and could be used as a predictor of relapse. 
Further studies have investigated aberrant polycomb repressive complex 2 (PRC2) catalytic 
activity in the pathogenesis of DLBCL. The PRC2 serves a fundamental role in the epigenetic 
regulation of cellular differentiation and development.133 The PRC2 subunit EZH2 catalyses the 
methylating lysine 27 of histone 3 (H3K27), a histone modification associated with 
transcriptional silencing of those histones bearing tri-methylated H3K27.134 EZH2 
overexpression and mutations have been implicated in many malignancies, including B cell 
lymphoma.133,135-138 EZH2 is required for normal B cell development and is upregulated in 
normal germinal center B cells where it has been shown to repress genes involved in 
differentiation and anti-proliferation and has consequently been implicated in 
lymphomagenesis.139,140 EZH2 gain-of-function mutations at Y641 have been reported in 
approximately 7% of follicular lymphoma and 21% of GCB-type DLBCL.135 These findings 
informed the development of small molecule EZH2 inhibitors which in a phase 1 clinical trial 
have recently been reported to show anti-tumour activity in patients with refractory B cell non-
Hodgkin lymphoma and advanced solid tumours.141  
Recently, Ennishi et al performed a comprehensive molecular analysis of mechanisms 
underlying MHC Class I and II surface loss and the effects on the immune microenvironment 
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in a cohort of 347 patients with de novo DLBCL.129 In this study, EZH2 mutations were 
significantly enriched in cases with loss of MHC Class I and/or II. Specifically, 77% of EZH2 
mutated cases had loss of either MHC Class I and/or II and reduced cytolytic T cell activity 
was observed in the EZH2 mutated cases with loss of MHC Class II expression.129 
Furthermore, in a murine model, EZH2 mutated lymphomas had less infiltrating T cells 
compared to non-mutated lymphoma.129  Importantly, the group also demonstrated that B cell 
lymphoma line (BCL1) cells transduced with EZH2Y641 showed increased tri-methylation of 
H3K27 at NLRC5 and CIITA promoters compared to non-mutated cells. As NLRC5 and 
CIITA are the transcriptional regulators of MHC Class I and II genes respectively, the results 
indicate that EZH2 epigenetically regulates MHC expression through the repression of 
MHCI/II transactivators with downstream effects on the number and activity of tumour-
infiltrating lymphocytes.129 Significantly, EZH2 inhibitors were shown to restore surface MHC 
expression in EZH2 mutated cells, which may also result in anti-tumour effects by increasing 
TILs in MHC-negative tumours.129  
Despite the detailed investigation into causes of MHC loss, neither Β2M promoter methylation 
nor the effect of EZH2 mutation on Β2M expression have been examined in solid malignancies 
or lymphoma. For those cases where there is MHC loss despite no underlying epigenetic or 
genetic aberrations in MHC-related genes, it is critical to know how changes in Β2M might be 
contributing to the loss. 
1.3. The Tumour Microenvironment  
Tumours develop and progress within an intricate local environment composed of immune 
cells, non-malignant cells, stromal and endothelial cells and extracellular matrix.31  Interactions 
between tumour cells, immune cells and other non-malignant cells in the microenvironment is 
increasingly recognised as critical to the development and progression of malignancy.142  
However, the key determinants that shape the immune microenvironment and the relative 
contributions of malignant and non-malignant cells to this process are not well characterised.143 
Advances in understanding the TME have led to the development of targeted immunotherapies 
for the treatment of solid and haematological malignancies144,18 and the logical progression of 
these discoveries is to look toward the TME to predict responses to treatment. Certainly in 
some solid malignancies, poor immune cell infiltration or a ‘cold’ immune microenvironment 
has been associated with inferior outcomes to conventional therapies.86,145,146 Additionally, 
checkpoint inhibition has been shown to be most effective in solid cancers expressing high 
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levels of immune checkpoints and in cancers with a high level of intratumoural immune 
response, which suggests that the checkpoint blockade is able to overcome local tumour-
mediated immunosuppression.84-88 
The immune cell composition of the tumour microenvironment has been shown to have 
prognostic significance in many malignancies.147 In many cancers, including DLBCL, 
colorectal cancer, melanoma and ovarian cancer, the presence of CD8+ tumour infiltrating 
lymphocytes (TILs) is of positive prognostic significance, with decreased numbers associated 
with poor overall survival.146,148-151 Infiltrating CD4+ cells have been associated with better 
prognostic outcomes in DLBCL.152,153 It is speculated that infiltrating lymphocytes represent 
activated, tumour-specific T cells which are attempting to control the disease however this 
remains to be determined.154 T cell infiltrates may also reflect accumulation in response to 
oncogenic signaling pathways or represent other T cell populations including Tregs and Th17 
cells, for which conflicting data exists regarding their association with prognostic outcomes.154-
156 Increased number of macrophages, specifically ‘M2’ macrophages have been associated 
with poor prognosis in a range of solid malignancies147 and DLBCL.157  
 
The importance of intratumoural T cells to lymphomagenesis was demonstrated in a landmark 
study by Afshar-Sterle et al who used a murine model to demonstrate that CD8+ T cells inhibit 
lymphoma development in the presence of mutations that are prevalent in DLBCL, and that 
rapid progression to lymphoma occurred with impairment of T cell function.158 In this study, 
mice harboring loss-of-function mutations in the tumour suppressor gene Blimp1 and activating 
mutations of the Bcl6 oncogene were infected with an oncogenic virus MHV-68, known to 
cause lymphoma in mice.158 Analysis of the Blimp1 deficient mice after 12-15 months showed 
only small numbers of Blimp1-deficient B cells present compared to Blimp1 positive cells in 
the normal control mice.158 The transfer of Blimp1 deficient B cells into mice lacking T cells 
resulted in the development of overt lymphoma, suggesting the T cell-mediated suppression of 
pre-malignant, Blimp1 deficient B cells.158 Additionally, T cell deplete, Bcl6 transgenic mice 
developed lymphoma within 2 -3 months after birth while Bcl6 transgenic mice with adequate 
T cells developed lymphoma following a latency period of >200 days.158 Using TCR analysis, 
the group determined that a polyclonal CD8+ T cell response, rather than a tumour antigen-
specific clonal response was responsible for the suppression of the pre-malignant B cells.158  
Further analysis suggested that TCR recognition of antigen, co-stimulation and FasL-mediated 
apoptosis are required for lymphoma suppression.158 
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Our laboratory has shed further light on the immune microenvironment in DLBCL. Keane et 
al reported that high CD4+ TILs are associated with better EFS and OS in DLBCL, 
independent of established prognostic scores (R-IPI).152 We have also quantified the net anti-
tumoural immunity in DLBCL by using gene expression to measure the ratio of intratumoural 
immune effector cells (T cells, NK cells) to immune inhibitor cells (‘M2’ macrophages, PD-1 
and PDL1) and showed that the ratio of immune effectors to inhibitors was associated with 
overall survival.157 In particular, a high ratio of effectors to inhibitors was associated with 
longer OS while a low ratio predicted poor overall survival and this was independent of existing 
prognostic scores.157 Recently we have reported on the intratumoural TCR repertoire in 
DLBCL and the relationship to the immune microenvironment. We identified that tumours 
with a highly dominant single T cell clone as determined by TCRβ CDR3 sequencing were 
associated with significantly inferior progression free and overall survival compared to tumours 
with a lower frequency of the dominant clone.159 The gene expression of immune checkpoint 
molecules was increased in samples with greater diversity implicating the TCR repertoire as a 
key determinant of the TME.152 More recently, in follicular lymphoma, our laboratory has 
demonstrated that tumours with a low degree of immune cell infiltrate were enriched for 
disease progression at 24 months, compared to tumours with a higher degree of intratumoural 
immune infiltrate.160 Additionally, those tumours with increased immune infiltrate had clonally 
expanded T cell populations, suggestive of an active, anti-tumoural immune response.160  
While much of this discussion has referred to the immune cells of the microenvironment, non-
immune components, such as vascular endothelial cells and fibroblasts also play an important 
a role in the TME and can shape the delivery of oxygen, nutrients and influence immune cell 
recruitment.161-164 Lenz et al showed that survival post treatment for DLBCL was influenced 
by immune and stromal cells in the microenvironment.165 In this study, approximately 400 
patients treated with R-CHOP (n = 233) or CHOP (n=181) had gene expression profiling 
performed on diagnostic biopsies and increased progression free and overall survival was 
observed for a stromal gene signature associated with extracellular matrix deposition and 
macrophage infiltration, while an unfavourable signature consisted of increased endothelial 
cells and angiogenesis.165 The studies described above highlight the TME as a promising target 
for gaining further understanding of tumorigenesis and to identify prognostic and theranostic 
markers. 
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1.4. Conclusion 
Escape from immune recognition is one of the hallmarks of cancer development. One 
mechanism of immune evasion is the downregulation of molecules involved in antigen 
presentation and immune recognition which has been reported as a frequent occurrence in 
DLBCL through the loss of surface Β2M and CD58 expression.78  
The role of the immune system in shaping the natural history of tumours has become well-
established and certainly great gains in the field of immunotherapy have been made in recent 
years through understanding the complex interactions between immune and malignant cells. 
However, much remains to be learned, including the determinants and predictors of response 
to immune-based therapies. Therefore, this study aims to identify key determinants of the 
tumour microenvironment in DLBCL which may have implications for stratification of patients 
in whom immune-based therapies are likely to be effective and for the 30% of patients with 
DLBCL who do not respond to standard therapies.  
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1.5. Aims and Significance of Project 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B cell malignancy and 
approximately 30% of patients do not respond to current treatments and ultimately die from 
the disease.9-11  Therefore, there is a pressing need to gain a better understanding of the disease 
to guide the rational development of effective therapies and predict an individual’s response to 
available treatments.  
Malignant cells can evade host immune recognition and destruction by several mechanisms, 
including the down-regulation of surface molecules involved in antigen presentation and 
stimulation of immune effector cells. Reduced surface expression of  beta-2-microglobulin 
(B2M) a component of the antigen-presentation complex MHC Class I and CD58,  an adhesion 
molecule involved in the binding and activation of NK and T cells have been observed in >60% 
of DLBCL.78  It is unknown what effect decreased expression of these molecules has on the 
immune response against the malignant cells. This project aims to investigate the relationship 
between B2M and CD58 expression by malignant DLBCL cells and the corresponding immune 
infiltrate in the tumour microenvironment of DLBCL. 
 
Overarching Hypothesis 
 The expression of the antigen presentation and immune cell recognition components 
Β2M and CD58 by malignant cells are key determinants of the intratumoural immune 
cell infiltrate in the tumour microenvironment of diffuse large B cell lymphoma  
Aims 
1. To determine the relationship between genetic aberrations of the immune cell 
recognition components  Β2M and CD58 and the intratumoural infiltration of immune 
effector and immune inhibitor cells in the TME of DLBCL. 
2. To determine the effect of Β2M and CD58 protein expression by DLBCL cells on the 
quantification of immune effectors and inhibitors in the TME. 
3. To determine the effect of Β2M and CD58 expression on the clonal distribution of 
intratumoural T cells in the TME of DLBCL
17 
 
2. CHAPTER 2: Materials and Methods 
2.1. Sample Selection and Preparation 
Formalin-fixed paraffin embedded (FFPE) diagnostic tissue biopsies of de novo systemic 
DLBCL were obtained from three sites: Princess Alexandra Hospital, Brisbane QLD Australia, 
Canberra Hospital, Garran ACT and the Australian Leukaemia and Lymphoma Group (ALLG) 
Discovery Centre. Grade IIIB follicular lymphoma and cases arising from transformed disease, 
HIV-positive or post-transplant patients were excluded. FFPE biopsies of non-diseased lymph 
nodes obtained commercially and through local pathology services were included as controls.  
Clinical data was available on this cohort as previously described.157 The majority of these 
samples had undergone TCRβ chain clonal analysis159 and quantification of immune effector 
and inhibitor gene expression157 using the NanoString nCounter® platform (Seattle, USA) 
during previous laboratory projects. These samples were selected for additional testing to 
generate further data on the immune microenvironment of DLBCL. See Table 2-1 for total 
cohort sizes.  
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Method/s Sample number 
Gene expression 193 
Targeted resequencing 97 
Immunohistochemistry 46 
B2M IHC (TMA + single sections) 67 
T cell receptor sequencing 106 
B2M promoter methylation* 40 
Copy number analysis (B2M/CD58)* 49/40 
Serum B2M* 32 
Final Cohort Sizes 
GE + NGS 88 
GE + IHC 46 
GE + TCR 66 
GE + NGS + IHC 30 
GE + NGS + IHC + TCR 21 
GE + NGS + B2M IHC + TCR 44 
 
Table 2-1: Individual sample number and total cohort sizes for each method performed: gene 
expression (GE) using the NanoString nCounter® platform; targeted resequencing (NGS) using the 
Illumina TSCA assay; B2M and immune cell protein expression by immunohistochemistry (IHC) on 
tissue microarrays (TMAs) and B2M IHC on an additional cohort of single tissue sections; T cell 
receptor - β (TCR) analysis performed using the Adaptive Biotechnologies immunoSEQ platform; B2M 
promoter methylation using the EpiTyper® array; copy number analysis (CNA) using quantitative PCR 
and serum B2M performed at diagnosis. * All samples that underwent promoter methylation and CNA 
and had serum B2M levels performed had undergone GE and TS and are included in these categories 
for the final cohort sizes. Further detail is provided in the corresponding result chapters for these assays. 
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2.1.1. Targeted resequencing cohort 
160 FFPE DLBCL samples that had previously undergone immune effector cell and immune 
inhibitory cell quantitative gene expression were shortlisted for targeted resequencing by the 
availability of stored DNA or the ability to re-extract DNA from available tissue. Stored DNA 
samples had been extracted using the Ambion RecoverAll Total Nucleic Acid Isolation Kit for 
FFPE (Foster City, USA). Samples requiring further extraction underwent DNA extraction 
using the Qiagen AllPrep DNA/RNA FFPE Kit (Hilden, Germany) as per manufacturer 
instructions.  
Before sequencing it was necessary to confirm that the extracted DNA was of sufficient quality 
to perform sequencing library preparation. A real-time quantitative PCR (qPCR) quality 
control assessment was performed using the commercial Illumina ‘Infinium HD FFPE QC 
Assay Protocol’ (San Diego, USA.) Using this method, DNA quality was determined by 
subtracting the crossing point (Cq) of the commercial QC template from the crossing point of 
each sample, to give a ‘δCq’ value.  Illumina reports that a δCq value of ≤ 4 is associated with 
libraries of sufficient quality and quantity to provide reliable sequencing data.166 
97/160 DLBCL samples and 21 normal lymph node controls had sufficient quality and quantity 
of DNA (minimum 250ng in 15uL) for sequencing and were submitted to the University of 
Queensland Centre for Clinical Genomics (UQCCG) for processing. 
2.1.2. Validation Cohort 
Targeted resequencing and gene expression findings were validated against a cohort of 1001 
DLBCL samples that had undergone whole exome sequencing using a customised capture-
based method (Agilent, California, USA) and transcriptome sequencing using RNASeq 
(KapaBiosystems, Massachusetts, USA).125 The cohort comprised clinically annotated cases of 
de novo DLBCL uniformly treated with rituximab-based regimens.125 Tissue biopsies were 
predominantly FFPE with a smaller number of frozen samples. The sequencing data had been 
uploaded to the European Genome-Phenome archive (EGA), accession number 
EGAS00001002606 and was obtained and used with permission from the authors. 
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2.1.3. Immunohistochemistry cohort 
52 FFPE DLBCL samples, which were planned to undergo targeted resequencing and had 
previously undergone immune effector and inhibitor gene expression quantification had 
archived tissue blocks retrieved from storage at the Princess Alexandra Hospital to perform 
immunohistochemistry (IHC).  Haematoxylin and eosin (H&E) staining was performed on 
each sample to confirm the presence of lymphoma and adequacy of the specimen. Six samples 
had either insufficient tissue or were too crushed to permit further analysis. The remaining 46 
samples plus six non-diseased lymph node controls underwent tissue microarray formation; 
two pieces of non-haematopoietic tissue were included for orientation and to serve as negative 
controls on subsequent staining. Tissue microarray construction was chosen over individual 
tissue sections to enable the economical immunohistochemical staining of a large number of 
samples with a large number of antibodies. To maximise tumour representation, TMAs were 
constructed in triplicate using 2mm tissue cores and this was performed by the Queensland 
Institute of Medical Research Histology Facility, Figure 2-1. A single tissue section on a 
microscope slide was obtained from the Canberra Hospital for an additional 27 samples, which 
had also undergone targeted resequencing and immune effector and inhibitor gene expression 
profiling. 
 
 
   
Figure 2-1:  Tissue Microarrays. A) Photograph of a TMA block. Each 2mm core corresponds to a 
DLBCL sample or control. TMAs were made in triplicate, i.e.: three x 2mm cores were taken from the 
original tissue block and incorporated into three separate TMA blocks. B) TMA sections stained with 
different antibodies. White gaps represent absent tissue; while all positions on the TMA grid were filled 
at construction, these variably became exhausted during sectioning as not all cores were the same 
starting length. This resulted in the varied number of samples stained for each antibody. 
A)                                                                   B) 
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2.1.4. Copy number variation cohort 
54 FFPE DLBCL samples from the Princess Alexandra and Canberra Hospital cohorts were 
shortlisted for Β2M and CD58 copy number variation (CNV) analysis on the basis of having 
undergone targeted resequencing and gene expression quantitation. These samples underwent 
DNA extraction using the AllPrep DNA/RNA FFPE Kit (Qiagen) as per manufacturer 
instructions prior to CNV analysis. 
2.1.5. Β2M promoter methylation cohort 
Remaining DNA from 52 FFPE DLBCL samples from the Princess Alexandra and Canberra 
Hospital cohorts plus DNA from 5 non-diseased lymph node controls were shortlisted for 
quantitative methylation analysis of the Β2M promoter region. These samples had also 
undergone Β2M targeted resequencing, gene expression quantitation and 
immunohistochemistry. 
40/52 DLBCL samples met the minimum DNA input requirement (500ng in 25uL) for 
quantitative methylation analysis and were submitted to the Australian Genomic Research 
Facility (AGRF) for testing. 
2.1.6. Serum B2M cohort 
Thirty-two cases from the Princess Alexandra Hospital that had undergone targeted 
resequencing and gene expression analysis had serum B2M levels performed in the diagnostic 
pathology laboratory at diagnosis. These values were obtained through a search of the 
diagnostic laboratory information system for relevant cases and compared against B2M 
mutation status, gene and protein expression. 
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2.2. Targeted Resequencing  
2.2.1. Sequencing panel design 
A customised targeted resequencing panel was designed to sequence the 5’ and 3’ untranslated 
(UTR) regions and coding regions of Β2M and CD58 using the Illumina Truseq Customised 
Amplicon (TSCA) v 1.5 assay. The TSCA technology used oligonucleotide probes to target 
and capture regions of interest followed by next generation sequencing (NGS) and allowed 
1536 amplicons to be multiplexed in a single reaction.  
This method was chosen over alternatives (including hybrid capture-based assays or whole 
exome sequencing) as it was fully customisable, highly targeted and economical and being an 
amplicon-based assay, was suitable for working with FFPE samples which often yield small 
quantities of degraded and fragmented DNA. Additionally, as only a small genomic region of 
interest was being interrogated, higher read depths could be obtained resulting in greater 
sensitivity of the assay to rare and low allelic burden variants.  
In addition to Β2M and CD58, the coding regions of 45 other genes were also sequenced, Table 
2-2. These genes were selected following review of the literature for genes known to be mutated 
in DLBCL and were included to gain an impression of the mutational burden of each tumour, 
which emerging evidence indicates may be a predictive biomarker for response to 
immunotherapy in some solid tumours.167,168  
The TSCA design covered 144 436 base pairs (bp) with a 98% breadth of coverage of the target 
region, a read depth of 300x and a short amplicon length of 175bp to minimise the risk of poor 
amplicon binding due to degraded FFPE DNA. Library preparation and sequencing were 
performed by the UQCCG using 2x150bp paired-end runs on the Illumina Miseq desktop 
sequencer.  
2.2.2. Alignment and variant calling 
Bioinformatics support for read alignment, variant calling and data analysis was obtained 
through the University of Queensland Diamantina Institute (UQDI). Reads were aligned to the 
hg19 human genome with Novoalign v3.02.08 (Novocraft). Variants were called using 
MuTect2 v3.6169; only non-synonymous variants assigned a ‘high’ or ‘moderate’ predicted 
effect by SnpEff170 were considered significant. Additionally, variants were discarded if: 1) 
they were present in the Genome Aggregation Database (gnomAD) at a frequency greater than 
1% or detected in the normal lymph node controls and thus likely to be single nucleotide 
polymorphisms 2) covered by less than 20 reads and 3) had a variant allele frequency (VAF) 
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of less than 10%; this arbitrary threshold was chosen to minimise the background artefact 
inherent in sequencing FFPE DNA while still aiming to detect low-frequency variants. 
Insertion and deletion realignment and base quality score recalibration were applied using 
GATK v3.4.171  
Mutational burden was calculated using the formula: (n/NF)*100 000, where n is the total 
number of mutations detected in for each sample (filtered as outlined above), NF is the total 
number of sequenced bases covered by at least 10 reads, used as a normalisation factor to 
account for differences in sequencing coverage between samples and 100 000 was an arbitrary 
value used to give round numbers.  
We did not enumerate the percentage of tumour content prior to sequencing although given 
that collection of the biopsies was targeted to malignant tissue and that all were sufficient for 
histological diagnosis the samples were reasonably expected to be enriched for the malignant 
cell population. It is possible that if the tumour fraction was low relative to normal cells, some 
mutations may not have been detected. Additionally, if mutations were present at a level below 
our filtering threshold of 10% VAF they would not have been detected. In consideration of 
tumour heterogeneity due to normal cell content, the contribution of normal cells to the 
mutation burden was minimised by excluding single nucleotide polymorphisms as described 
above. 
The mutational status of Β2M and CD58 was compared to their gene and protein expression 
(where available), immune effector and inhibitor gene and protein expression and TCR 
repertoires. Β2M and CD58 mutation status was also compared to the overall mutation burden 
for each sample. 
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Gene Function Genes 
Immune Response 
Β2M, CD58, BCL6, CARD11, CCL3, CD70, CD79B, MYD88, 
TNFAIP3, TNFRSF14 
Methylation EP300, EZH2, MLL2, MLL3, TET2 
Cell signalling 
CXCR4, DTX1, GNA13, PIK3CA, PTPN11, PTPN22, PTEN, 
STAT3, TRAF2, TRAF3, TRAF5 
Cell cycle and apoptosis BIRC3, CCND2, CCND3, CDKN2A, MYC, TP53 
Growth & differentiation 
BTG1, BTG2, CREBBP, ETS1, KRAS, FOXO1, NOTCH2, PIM1, 
SGK1 
Other MEF2B, SPEN, TMSB4X, TNFRSF11 
 
Table 2-2:  Genes included in the targeted resequencing panel. The 5’ and 3’ UTRs and all coding 
regions were sequenced for the B2M and CD58 genes given that they were the focus of the study. All 
exons were sequenced for the remaining genes on the panel. 
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2.3. Sanger Sequencing Validation 
2.3.1. Primer design 
Β2M and CD58 variants identified by NGS were validated by Sanger sequencing which was 
performed by the AGRF.  Primers were designed using Primer3 software 
(http://bioinfo.ut.ee/primer3-0.4.0/). Primers were designed to cover the exon in which the 
variant was detected and to generate a product with a maximum length of 200bp to compensate 
for the fragmented DNA of FFPE samples, Table 2-3. 
Designs were checked with Basic Local Alignment Search Tool (BLAST; 
https://blast.ncbi.nlm.nih.gov/Blast.cgi) to confirm there was no sequence homology between 
the regions of interest and the remaining genome. 
2.3.2. Primer optimisation 
Primers were purchased from Sigma LifeScience (Darmstadt, Germany) and were optimised 
using the following PCR conditions: 
PCR Master Mix reagents and volumes (20uL reaction): 
DNA template (30ng, total) 2uL 
dTNP (2.5mM) 2uL 
Buffer (10x) 2uL 
AmpliTaq DNA polymerase 0.1uL 
Primers (forward) 10uM 0.2uL 
Primers (reverse) 10uM 0.2uL 
H2O 13.5uL 
 
Thermal cycler conditions:  
95°C 3 mins 
95°C 30 sec 
52°C 30 sec 
72°C 30 sec 
72°C 7 mins 
 
PCR amplified test samples plus a negative control for each primer pair (DNA from  non-
diseased lymph node controls which underwent NGS and were confirmed not to contain the 
x 40 cycles 
26 
 
variant of interest) and  primers were submitted to the AGRF for purification and Sanger 
sequencing in a 96-well plate format. Data was returned as sequencing files and UQDI 
Bioinformatics support was engaged for the interpretation of results.  
 
 
Table 2-3:  Sanger sequencing primer sequences covering Β2M and CD58 exons. Capital letters 
indicate exon sequences while lower case letters indicate intronic sequences. 
 
Gene Forward primer sequence Reverse primer sequence 
Β2M Exon 1A aacgggaaagtccctctctc AAGAGAGAGTAGCGCGAGCA 
Β2M Exon 1B GGCATTCCTGAAGCTGACA gaagtcacggagcgagagag 
Β2M Exon 2A gggagaaatcgatgaccaaa TGAAACCCAGACACATAGCAA 
Β2M Exon 2B CTCACGTCATCCAGCAGAGA Tctttttcagtgggggtgaa 
Β2M Exon 3A TTTCATCCATCCGACATTGA ATCTTGGGCTGTGACAAAGT 
Β2M Exon 3B gaattcacccccactgaaaa atgggatgggactcattcag 
Β2M Exon 4A tgttcctgctgggtagctct cttacCTCCATGATGCTGCTT 
Β2M Exon 4B tccactgtctttttcatagATCG gggaacatgaccctgtagga 
CD58 Exon 1A gagtggaagcgcgaagac GTCGCTCCCAGCAACCAT 
CD58 Exon 1B AGGCGGTGCTTGAACTTAGG gcaggcttcactcacCAAA 
CD58 Exon 1C GACGAGCCATGGTTGCTG gtccccacccgtctctgat 
CD58 Exon 2A cttcctgtattttgtgtcagcag AAGGCACATTGCTTGGTACA 
CD58 Exon 2B TCAGCTGTTTTTCCCAACAA GATAGTGAGGCTACCTGACACAG 
CD58 Exon 2C AAAGGATAAAGTTGCAGAACTGG tggaatactcacCAAGCACA 
CD58 Exon 2D ATGAAATGGAATCGCCAAAT aaaggagaaaaccctgacaaca 
CD58 Exon 3A aggaggttgcgagctcttc AAGTCCTCGATGGCTGTTGT 
CD58 Exon 3B CCAATGCATGATACCAGAGC GGTTGTCAAAATGATTGATGATG 
CD58 Exon 3C AAAATACAGTGTACTCTTAGCAATCCA tcaaaattgtgaaccttgtgtt 
CD58 Exon 4A aataagcaaaccgcaaggtg gcatacatacCATTCATATACAGCA 
CD58 Exon 4B GCACTTATACCCATACCATTAGCA cccacacacgtaaagcaaaa 
CD58 Exon 5 gcctctaataggcagtcagtaactc tctggcttcccaagtaatgg 
CD58 Exon 6A gagggtaattaagactcctggtc AGTTACATTTCCAACAGTTGTTCA 
CD58 Exon 6B CAGAAGATGAAGACAACAGCAT AAAGCAAGCACCTAGTCATATAATAA 
CD58 Exon 6C GCATTAGTTTTGGCTGTCATCA gcaagggagaaagagtatagatttta 
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2.4. Copy Number Variation 
Β2M and CD58 CNVs were determined by quantitative PCR using QuantiTect SYBR green 
dye (Qiagen). Β2M primers were designed within intron 1 and generated a 97bp product. CD58 
primers were designed to span intron 2 and exon 3 and generated a 97bp product, Table 2-4 . 
Each gene was interrogated by two sets of primers to exclude that intermediate results were not 
due to limitations of a single primer pair. 
For both genes a 7-point standard curve was generated using SUDHL4, a Β2M and CD58 copy 
number neutral DLBCL cell line78 (ATCC, USA). For Β2M, SUDHL2, a DLBCL cell line with 
a monoallelic deletion78 was used as a negative control (ATCC, USA). For CD58, KARPAS-
1106P, a PMBCL cell line with biallelic deletions172 was used as a negative control (CellBank, 
Australia).  
Quantitative PCR was run on the QuantStudio 7 Flex Real-Time PCR System (Life 
Technologies, Carlsbad, USA). Samples were run in triplicate and absolute DNA copies for 
each sample were extrapolated from the standard curves and compared to 20 non-diseased 
lymph node controls.  
Copy number was reported as neutral, loss or gain. Copy number variation is frequently defined 
as copy number neutral if two copies of a gene are detected and copy number loss and gain if 
less than or greater than two copies of a gene are detected, respectively. These definitions 
assume a diploid sample. Tumour cells are heterogeneous due to diverse genetic aberrations 
including variations in ploidy and cannot be assumed to be diploid. To account for potential 
aneuploidy in our cohort, non-whole number copy values within the approximate range 2 ± 1 
were accepted as copy number neutral and outside of these ranges, gain and loss, respectively.  
As tumour samples contain varying degrees of non-malignant cells, cases with a high normal 
cell content may mask the detection of underlying genetic abnormalities in malignant cells. We 
performed CNA on whole tissue sections and while some of these cases (n=30) had IHC for 
immune cells performed on TMAs, the TMA cores were enriched for tumour and did not 
represent the surrounding stroma or non-involved tissue in the full section. Therefore, we did 
not quantify the non-malignant cell content of the CNA cohort using the TMA IHC as it was 
unlikely to be representative for all samples. Consequently, we may have false negative copy 
number results due to an unknown but high quantity of normal cells and acknowledge this as a 
limitation of the method. 
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PCR conditions: 
DNA template Β2M: 20ng  CD58: 25ng  
Primer concentration Β2M: 200 nM CD58: 200nM  
Thermal cycler conditions:   
50°C 2 mins  
95°C 15 min Initial denaturation 
94°C 15 sec Denaturation 40x 
58°C 30 sec Annealing 40x 
95°C 15 sec Melt curve 
60°C 1 min Melt curve 
95°C 15 sec Melt curve 
 
 
  
 
 
Table 2-4: Copy number variation primer sequences for Β2M and CD58 
 
 
 
 
 
 
 
 
 
 
Gene Forward primer sequence Reverse primer sequence 
Β2M  atttggccagagtggaaatg ccaagttagccccaagtgaa 
CD58  AAGTCCTCGATGGCTGTTGT GAGTCTCTTCCATCTCCCACA 
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2.5. Β2M Promoter Methylation 
DNA methylation of promoter regions results in the transcriptional repression or ‘silencing’ of 
genes.  Malignant cells can exhibit marked changes in methylation of cytosine at CpG 
dinucleotides and silencing of tumour suppressor genes plays a key role in cancer 
development.173,174  
2.5.1. EpiTYPER® principle 
EpiTYPER® is a high-resolution, quantitative mass spectrometry-based bisulfite sequencing 
method for region-specific DNA methylation analysis.175  The main advantages of this method 
are that it provides rapid, sensitive and reproducible quantification of CpG sites and can analyse 
up to 85% of sites within a target region down to approximately 5% differences in methylation 
within a methylation range of 10-90%.176 
This method is particularly useful for analysing a small number of sites over a large number of 
samples176 which in conjunction with the targeted and quantitative nature of the technique made 
it the most appropriate method for our data analysis. This is a highly-specialised assay and was 
performed by the AGRF. 
In this technique, genomic DNA undergoes bisulfite-conversion and PCR amplification using 
primers for the CpG regions of interest.176 The PCR product is transcribed and RNA fragments 
are cleaved at uracil residues, producing fragments of different size and mass; methylation 
results in a 16Da change in mass for each site.176 The products are loaded into a MALDI-TOF 
mass spectrometer which detects signal patterns indicating non-methylated and methylated 
cleaved DNA and compares signal intensity to calculate the relative amount of methylation.176  
 
2.5.2. EpiTYPER® assay design 
The Β2M promoter region is 885bp in length and contains 72 CpG sites. Primers were designed 
by AGRF to cover the CpGs in this region using 250bp amplicons to account for the fragmented 
FFPE DNA. The assay design was predicted to cover approximately 75% of CpG sites within 
the promoter. On completion of testing a report was provided by the AGRF indicating the 
percent methylation at each CpG site for each sample along with an ‘Epigram,’ a plot allowing 
the visualisation of methylation per sample on a scale of 0%-100%. Methylation results were 
compared to Β2M mutational status and gene and protein expression data. 
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2.6. Gene Expression Analysis 
Gene expression analysis had been performed using the automated NanoString Technologies 
nCounter® platform (Seattle, USA) using RNA extracted from the DLBCL sample cohort in 
work previously conducted by our laboratory. 
NanoString technology allows digital and non-amplified quantitation of mRNA targets using 
direct capture by fluorescent barcodes.177 Gene expression level is measured by counting and 
tabulating the number of times a barcode for a gene of interest is detected.178 Raw data 
undergoes normalisation using internal controls provided by NanoString and the final data 
output consists of a numerical count for each gene of interest in each sample. This technology 
is sensitive and reproducible for the precise quantification of mRNA, is applicable to FFPE 
specimens and can be highly multiplexed, allowing for up to 800 targets to be measured 
simultaneously.179  The platform can accept small input quantities and has minimal laboratory 
set-up time. All of these factors made using the NanoString technology ideal for our sample 
cohort (FFPE specimens) and our simultaneous investigation into multiple immune genes. 
A customised-probe set of 96 genes had been developed during a previous project by the 
laboratory to obtain gene expression data in the DLBCL cohort.157 For the current study of the 
tumour microenvironment, analysis was focussed on the following genes on the basis of being 
markers for immune effectors and immune inhibitory cells or checkpoint molecules.  
 Immune effectors: B2M, CD58, CD4, CD8, CD56 and CD137  
 Immune inhibitors: CD68, CD163, TIM3, LAG3, PD1, PDL1 and PDL2  
Gene expression data were analysed against Β2M and CD58 mutation and expression status 
and overall mutational burden and were compared to the protein expression status of the same 
genes, where available. 
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2.7. Immunohistochemistry 
2.7.1. Antibody selection 
In addition to Β2M and CD58, the following antigens were chosen for staining on the basis of 
being markers for immune effectors and immune inhibitory cells or immune checkpoints.  
 Immune effectors: CD4, CD8, CD56 and CD137  
 Immune inhibitors: CD68, CD163, TIM3, LAG3, PD1, PDL1 and PDL2  
Antibodies against CD4, CD8, CD56, CD68, CD163 and PD-1 were already in diagnostic use 
with Pathology Queensland. Commercial antibodies against Β2M, CD58, CD137, TIM3, 
LAG3, PDL1 and PDL2 were purchased. Antibodies were chosen for purchase if they had been 
validated for use with formalin-fixed samples and where possible, if there was literature to 
describe optimal staining conditions and to confirm successful use. CD20 was used to confirm 
that the majority of cells in each TMA core were malignant (all ≥ 50%). 
2.7.2. Antibody optimisation and staining  
For the antibodies not already in diagnostic use, optimal concentrations and staining conditions 
were titrated by expert scientists in the Histology department at the Princess Alexandra 
Hospital, Table 2-5. 
TMAs were sectioned at 4um thickness onto labelled, coated microscope slides and oven-dried 
at 60°C for 15-20 minutes prior to staining. Subsequent staining of the TMAs for each antigen 
was performed using the automated Ventana Discovery Ultra analyser using the OptiView 
DAB IHC detection kit v5 (Roche, Basel, Switzerland). All sections were counterstained with 
hematoxylin and dehydrated with ethanol and xylene prior to mounting. The CD58 and PDL2 
antibodies could not be optimised thus protein expression data is not available for these 
antigens. 
During attempted optimisation, the first CD58 antibody trialled (ab117626, Abcam) yielded 
non-specific staining patterns only. The second antibody trialled (AF1689, R&D systems) had 
been used by Challa-Malladi et al78 to obtain CD58 expression data in DLBCL. This antibody 
had not been our first preference as it was incompatible with the automated Ventana workflow 
due to the requirement for an anti-goat secondary antibody. Due to this, it needed to be 
optimised manually, which is a labour-intensive process. Following the failure of the Abcam 
antibody, we purchased the R&D Systems antibody. Initial attempts at manual optimisation by 
an expert Histopathology scientist and myself yielded non-specific staining only. The staining 
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method used in the Challa-Malladi paper was requested from the corresponding author and 
applied. Despite following this method, only non-specific staining was obtained.  As there were 
no other CD58 immunohistochemistry antibodies on the market at the time and exhaustive 
attempts at optimisation had proved unsuccessful, we decided to abandon CD58 protein 
staining. Possible reasons for the second antibody failing despite successful use elsewhere 
include antibody batch differences and tissue age, tissue type and fixation differences. 
Attempted optimisation of the PDL2 antibody yielded only weak and non-specific staining 
which was not possible to interpret. At the time there were no other PDL2 
immunohistochemistry antibodies available commercially, so PDL2 protein staining was not 
pursued further. 
In addition to the TMAs, 27 individual tissue sections obtained from the Canberra Hospital 
underwent Β2M immunohistochemistry to increase the size of the cohort on which Β2M 
protein expression data was available. 
Antibody Name Description Dilution  Manufacturer 
Β2M (A0072) Rabbit polyclonal  1:1000 Dako 
CD58* (ab117626) Mouse monoclonal N/A Abcam 
CD58* (AF1689) Goat polyclonal N/A R&D Systems 
CD4 (SP35) Rabbit monoclonal 1:15  Cell Marque 
CD8 (C8/144B) Mouse monoclonal 1:25  Dako 
CD56 (123C3) Mouse monoclonal 1:75 Invitrogen 
CD137 (BBK-2) Mouse monoclonal 1:100 ThermoFisher 
CD68 (PG-M1) Mouse monoclonal 1:200 Dako 
CD163 (MRQ-26) Mouse monoclonal 1:50 Cell Marque 
PD1 (MRQ-22) Mouse monoclonal 1:600 Cell Marque 
PD-L1 (SP263) Rabbit monoclonal Pre-diluted Ventana 
PDL-2/B7-DC* (MAB1224) Mouse monoclonal N/A R&D Systems 
LAG3 [EPR4392(2)] (ab180187) Rabbit monoclonal 1:2000  Abcam 
TIM3 (ab185703) Rabbit polyclonal 1:20 Abcam 
CD20 (L26) Mouse monoclonal 1:1000 Dako 
 
Table 2-5: Antibodies used for immunohistochemistry 
 
33 
 
2.7.3. Immunohistochemistry scoring 
Immune effector cells, immune inhibitory cells and immune checkpoints in the TMA cores 
were quantified by assessing protein expression through immunohistochemistry. The cellular 
distribution of staining (i.e: on non-malignant immune cells versus malignant cells) was based 
on cytological assessment and knowledge of the normal distribution of antigen staining. Each 
TMA included normal lymph nodes as positive controls and staining was repeated if normal 
staining patterns were not observed. Samples were excluded from analysis if they were deemed 
uninterpretable due to non-specific staining or artefact. All antigens had one TMA scored 
manually by both the candidate and Dr Birch to ensure consistency (discrepancies were 
discussed and resolved by consensus) and to allow validation of the subsequent automated 
scoring method.  
B2M IHC was scored by quantifying the percentage of tumour cells showing protein loss and 
assessing whether abnormal protein localisation (i.e: non-membrane) was observed. Both 
normal lymph node samples included on the TMAs and non-malignant cells in the each tissue 
core or section were used as positive controls. B2M protein loss was defined as negative B2M 
membrane staining, given that membrane-bound protein is functionally relevant to intact 
antigen presentation. As a binary measure, the objective description of ‘positive’ versus 
‘absent’ staining is more likely to be reproducible. In contrast, B2M staining intensity, while 
potentially biologically important, was not scored given the relative inexperience with this 
antibody, possible diminution of antigenicity due to technical factors (e.g. fixation and age) 
which could be inconsistent between samples and, the subjective nature of interpretation, all of 
which may limit reproducibility of results and thus the ability to reach definitive conclusions.  
We did not define a minimum number of B2M-negative tumour cells required for the tumour 
to be described as having B2M loss due to consideration that tumour samples are sub-clonal 
and any degree of loss could potentially be, or become, functionally relevant to immune escape. 
However, we did make the distinction between complete absence (100%) and partial (<100%) 
loss in recognition that complete loss may exert a distinct biological effect. Other studies varied 
in their definition of loss: Challa-Malladi et al did not report their minimum threshold for loss, 
others accepted only a complete absence of tumour cell staining as negative and others broadly 
acknowledged and illustrated heterogeneous loss.78,100,180 
B2M IHC was scored manually and in duplicate for TMAs (except for four samples, due to 
technical issues or core loss) and in singleton for the whole tissue sections. All scoring was 
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performed independently by the candidate and Dr Simone Birch with discrepancies reviewed 
together and resolved by consensus. The average percentage of B2M-negative malignant cells 
between TMAs was taken. For cases with B2M-negative cells on one core and no B2M-
negative cells in the other core, this was noted and the sample was treated as showing B2M 
protein loss. While scoring was not formally blinded to the underlying mutation status of these 
samples, it was undertaken separately and temporally far removed from analysis of the 
sequencing data.  
Visiopharm® (Hoersholm, Denmark), an automated and quantitative digital image analysis 
software, was chosen to manage the significant amount of immunohistochemistry data 
generated, i.e.: 52 samples stained for 11 antigens in triplicate, resulting in a total of 1716 
samples to score. This software was available at the Translational Research Institute 
Microscopy Core Facility but had not been optimised for analysis of TMAs. To validate this 
method against the existing standard of manually quantifying immunohistochemistry data, one 
of each triplicate TMAs for each stained antigen underwent manual scoring and values were 
compared against the automated counts.  
The following information was recorded in an Excel spreadsheet for each sample using both 
the manual and automated counting methods: TMA number, sample identification and co-
ordinates, the percentage of positive-staining cells, whether tumour cells were antigen positive 
(where relevant) and any comments relevant to the analysis, including the presence of artefact 
or a missing sample core at that location. For Β2M, the quantification of protein loss and 
abnormal staining patterns was recorded. For samples scored with Visiopharm®, the numerical 
detection settings were recorded. 
2.7.4. Visiopharm® 
To perform automated scoring, stained TMA slides were scanned using the Olympus Slide 
scanner VS120 at 40x magnification. Each electronic image was imported to the Visiopharm® 
software and labelled with the antigen and TMA number, for example: CD8_TMA2. For each 
file, it was first necessary to define the sampling array as a TMA and instruct the software to 
recognise each sample core. Visiopharm® was then manually trained to recognise individual 
cells by selecting a small region of interest (ROI) containing several positive and negative cells 
and background staining; the program was not able to distinguish cells based on other criteria, 
including size.  The software was manually instructed as to which cells were positive and 
negative within the ROI and what non-specific staining to ignore. The software was then tested 
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to see whether it could make these calls correctly, compared to manual assessment. The 
sensitivity of detection was manually adjusted until the software was consistently detecting 
positive and negative cells correctly, at which point the detection algorithm was applied to the 
entire core, yielding the number of positive and negative cells present in the sample, Figure 
2-2. 
It was anticipated that once the software was trained, the detection algorithm could be applied 
to at least the entire slide and ideally all TMA slides to accurately and rapidly provide 
quantitative immunohistochemistry data, which would significantly save time when compared 
to the existing manual scoring method. In practice, the detection settings for one sample core 
could not be applied to another sample core as this led to either underestimation or 
overestimation of the number of cells present. This was predominantly due to staining 
variability between cores, arising from differences in staining intensity, sample age and tissue 
artefact (e.g.: folds, creases, non-specific staining). Due to this, the software had to be trained 
to recognise each individual core on each individual slide. As this was a markedly labour-
intensive process, all samples were quantitated in duplicate, relying on the triplicate only if the 
duplicate scores differed greatly. The cut-off that determined whether the triplicate score was 
required was arbitrary and differed between antigens but in most cases was a greater than 10% 
difference between cores. The final score was determined by taking the average of replicates. 
Despite the Visiopharm® process requiring significant manual input it was reasonable to 
consider that future software advances may permit the distinction of cells based on size and 
account for inter-staining variability and that this method might therefore become practical in 
the future. Thus, the method was seen to completion as there remained utility in comparing its 
performance against the existing manual counting method.  Visiopharm® analysis for Β2M 
staining was not possible; the ubiquitous protein distribution prevented the software from 
distinguishing discrete cells, which was required to yield accurate counts. Therefore, Β2M 
scoring was performed entirely manually.  
2.7.5. Limitations 
The original aim of the IHC experiments was to use co-staining to obtain co-localisation data 
between malignant cells and the distribution of immune effectors and inhibitors based on the 
expression of Β2M and CD58.  IHC is a useful technique for detecting positive or negative 
antigen staining in a tissue section but it is one-dimensional, has limited capacity for 
multiplexing and cannot provide co-localisation information. IHC can provide limited 
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information on the co-expression of two antigens, but this is only possible when the antigens 
of interest show different cellular distribution (e.g.: nuclear versus membrane) to enable 
distinction by light microscopy.  
In this project morphological criteria (e.g. cell size and nuclear characteristics) were used to 
determine whether membrane antigen expression was on malignant versus non-malignant cells. 
This was aided by the distinct morphology of DLBCL cells which are generally readily 
distinguishable from surrounding non-malignant cells and that they were confirmed to be the 
dominant cell type in the TMA cores as demonstrated by CD20 staining. The most difficult 
morphological distinction was between lymphoma cells and macrophages, which are often 
large cells but do not usually have the nuclear atypia of malignant cells. While the expected 
expression profile for each antigen was considered at the time of scoring, e.g. CD163 was 
expected to be positive on cells of monocyte/macrophage lineage, some antigens could 
potentially have been expressed on both immune and malignant cells (e.g: LAG3 and PDL1) 
and if using morphological criteria only, misattribution of the positive-staining cell type could 
occur. In this instance, co-staining with PAX5 a B cell lineage-specific and nuclear marker 
could have been performed to distinguish the malignant cells and is recognised as a limitation 
of this project. Distinguishing B2M loss on malignant versus non-malignant cells based on 
morphological criteria was less problematic, even at low level, given that B2M membrane 
expression is almost ubiquitous due to its critical role in MHC Class I function, thus loss would 
not be expected on non-malignant cells. 
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A)                                                                               B) 
C)                                                                                 D) 
E)                                                                                F) 
Figure 2-2: Visiopharm analysis optimisation. A) Low magnification of scanned sample core for analysis. B) A 
small region of interest (ROI) is selected to contain representative cells for initial training. C) Software is instructed to 
recognise positive staining cells (blue) and negative staining cells (green) with adjustment of sensitivity as required. 
D) The ROI is expanded to confirm the software can accurately recognise other positive and negative cells. E) The 
ROI is expanded to cover the entire tissue section. F) The software enumerates total positive and negative cells and 
provides these values as exportable data. 
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2.8. T-cell Receptor Sequencing 
T-cell receptor-β (TCRβ) sequencing had been performed by Adaptive Biotechnologies® 
(Seattle, USA) on DNA extracted from the DLBCL sample cohort in work previously 
conducted by our laboratory.159  
This cutting-edge technology was only commercially available through Adaptive 
Biotechnologies® immunoSEQ assay which utilised a bias-controlled, multiplexed PCR 
amplification assay with deep sequencing of the CDR3 variable chain to provide specific and 
quantitative information on the TCRβ repertoire of each sample.  
As the CDR3 sequence is unique to a particular clone of cells, information on intratumoural T-
cell quantity and diversity could be obtained from this technology, which was highly relevant 
to the current investigation of the tumour microenvironment in DLBCL. 
A limitation of the TCRβ sequencing is that it provides information based on CDR3 sequences 
only and is not able to distinguish between CD4 or CD8 cells or other T cell subsets, whose 
relative proportions may have a functional impact on the tumour microenvironment. 
The metrics reported by Adaptive Biotechnologies® were available through the cloud-based 
tool immunoSEQ Analyzer and for each sample included: 
 The total number of T cells present as measured by the total number of TCRs 
sequenced. This number included functional and non-functional TCRs. 
 All unique TCR sequences, that is, each T cell clone was counted once and thus gave 
an estimate of how many clones were present in the TCR repertoire. This included 
functional and non-functional TCRs. Functional TCRs were further reported as 
‘productive uniques’ or sample ‘richness.’  
 Clonality, which was a statistic normalised for sample size and sequencing depth and 
indicated how much of a sample’s TCRs were composed of clones. Clonality was 
reported on a scale of 0-1, where 0 = each clone appeared once and 1 = one clone only 
was present in the sample. 
The previously obtained T cell metrics were subsequently analysed against Β2M and CD58 
mutation and expression status and overall mutational burden.  
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2.9. Statistical analysis 
Statistical analyses were performed using GraphPad Prism v 7.04 for Windows (San Diego, 
USA). Two-tailed Mann-Whitney or Kruskal-Wallis test with Dunn’s correction were used to 
compare continuous variables. The Fischer’s Exact and Chi-squared tests were used to compare 
categorical variables. Correlations were performed using the Spearman rank correlation. 
Overall survival was calculated from the time of diagnostic biopsy to the date of death or last 
follow-up. Kaplan-Meier curves and the Log-rank test were used for survival comparison. 
Statistical significance was set at p < 0.05.  
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3. CHAPTER 3: Relationship between Β2M and CD58 gene aberrations 
and immune effector and inhibitor gene expression in the TME of 
DLBCL 
3.1. Abstract 
Aim: To determine the relationship between genetic aberrations of the immune cell recognition 
components  Β2M and CD58 and the intratumoural infiltration of immune effector and immune 
inhibitor cells in the TME of DLBCL. 
Methods: Formalin-fixed paraffin embedded (FFPE) tissue biopsies underwent: targeted re-
sequencing and copy number analysis by qPCR of Β2M and CD58, gene expression 
quantification of Β2M, CD58 and immune effector and inhibitors using the NanoString® 
platform, immunohistochemistry for Β2M and immune effector and inhibitors to determine 
protein expression and Β2M promoter methylation analysis. A subset of cases had serum Β2M 
levels performed at diagnosis. An external cohort of approximately 1000 DLBCL cases with 
whole transcriptome and exome sequencing was used to validate findings. Data was analysed 
with GraphPad Prism v7.04 using Mann-Whitney test for continuous and Fischer’s Exact Test 
or Chi-squared test for categorical variables. Survival comparison was performed using the 
Log-rank test. Statistical significance was set at p < 0.05. 
Results:  Seven Β2M variants were detected in 14/97 (14.4%) samples. Β2MMut samples had 
significantly lower Β2M gene expression compared to Β2MWT (p = 0.0094). Β2M gene 
expression was significantly lower in samples with Β2M protein loss (p = 0.0308). All Β2MMut 
samples showed a degree of protein loss but loss was also observed in the majority (31/40; 
77%) of Β2MWT samples. There were no significant differences between Β2MMut/WT and 
expression of intratumoural immune markers however Β2M gene expression was significantly 
associated and positively correlated with the gene expression of CD4, CD8, CD56, CD137, 
CD68, CD163, PD1, PDL1 and LAG3 and with the protein expression of CD4, CD8, CD137, 
PDL1 and LAG3. Gene expression findings were confirmed in the validation cohort which also 
demonstrated that Β2M gene expression was significantly associated and positively correlated 
with the gene expression of HLA Class I and II molecules, MHC Class I regulatory molecules 
and Β2M transport and assembly molecules. The Β2M promoter region was not differentially 
methylated compared to controls. There were no significant differences between Β2M and 
CD58 copy number and protein expression however these results were limited by small cohort 
size and technical difficulties. 
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Nine CD58 variants were detected in 8/97 (8.2%) samples. Only one sample contained both 
Β2M and CD58 mutations. There were no significant associations between CD58Mut/WT and 
CD58 gene expression or immune effector and inhibitor gene or protein expression. CD58 gene 
expression was significantly associated and positively correlated with CD4, CD8, CD56, 
CD68, PD1 and PDL1 gene expression but not protein expression.  
Conclusion: Β2M and CD58 mutation frequencies were consistent with published literature 
and were essentially mutually exclusive. The frequency of Β2M initiation codon mutations is 
consistent with this region being a known mutation hotspot.  
We identified a significant relationship between Β2M mutation status and Β2M gene and 
protein expression, in which Β2M mutated cases had lower gene expression and all had protein 
loss. Protein loss was also observed in the majority of wild type cases, consistent with 
mechanisms other than mutation status contributing to loss of surface expression. For technical 
reasons, we could not reliably determine whether copy number alteration contributed to protein 
loss. The Β2M promoter region was not differentially methylated compared to controls 
indicating that this is not a mechanism of Β2M downregulation.  
High Β2M gene expression levels were associated with higher levels of immune cell 
infiltration, HLA molecules, HLA Class I regulatory molecules and Β2M transport and 
assembly molecules, consistent with a ‘hot’ or immunologically reactive tumour 
microenvironment. This suggests the presence of an adaptive immune response and that Β2M 
gene expression level could be used as a biomarker of an active intratumoural immune response 
in DLBCL, which may help stratify the selection of patients in whom immune-based therapies 
are more likely to be effective.  
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3.2. Introduction 
Interactions between tumour cells and non-malignant cells in the tumour microenvironment are 
crucial to the development and progression of malignancy and the immune system plays a 
critical role in regulating tumour development.68,181 Therapeutic strategies that harness the 
immune system, for example adoptive T cell therapies and immune checkpoint inhibitors have 
shown promise in the treatment of several malignancies20-25 including DLBCL,26-30 however 
not all patients show a response. This heterogeneity of response suggest that changes at the 
level of the immune microenvironment may hold the answers to understanding disease 
pathogenesis, resistance mechanisms and ultimately which patients are most likely to benefit 
from immune-based therapies. However, the key determinants of the tumour 
microenvironment and the relative contribution of immune effector and inhibitory cells and 
checkpoint molecules to tumorigenesis and in particular, lymphomagenesis, are poorly 
understood.182 
Mutation burden, immune infiltration, expression of checkpoint inhibition molecules, 
neoantigen heterogeneity and HLA Class I genotype are factors that have been shown to 
predict response to immune checkpoint therapy.167,183-186 For effective immunotherapy, 
immune cells must be able to recognise tumour-associated peptides presented by malignant 
cells in association with the MHC Class I complex, thus loss of MHC and MHC-related 
molecules by malignant cells is an acquired mechanism of immune evasion.187 
A landmark paper by Challa-Malladi et al in 2011 demonstrates that the loss of the antigen 
presentation molecules Β2M and CD58 by malignant cells is a frequent event in DLBCL and 
may be co-selected for in the pathogenesis of DLBCL as an immune escape mechanism.78 In 
that study, 29% of cases contained a genetic alteration affecting the Β2M gene, either mutations 
(12.6%) or copy number loss (24.7%) and the frequency of aberrations was comparable 
between COO subtypes.78 Additionally, 75% of cases showed aberrant Β2M protein 
expression, including protein loss or abnormal localisation; this was most often associated with 
underlying inactivating mutations, however 34% of Β2M wild type cases also showed Β2M 
protein loss.78 Loss of Β2M protein expression was confirmed to be associated with loss of 
MHC Class I surface expression using immunohistochemistry.78 21% of DLBCL cases 
contained genetic alterations affecting the CD58 gene, including nonsense, frameshift, splice 
site or in frame deletions (6.8%) and copy number loss (19.8%).78  Overall, loss of CD58 
surface expression was observed in 67% of DLBCL cases, including all cases with biallelic 
alterations, 87% of cases with monoallelic and 54% of cases with normal CD58 alleles.78 
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Loss of surface MHC Class I is frequently observed in DLBCL100 and the underlying molecular 
defects resulting in its loss are heterogeneous, including: mutations, deletions and loss of 
heterozygosity of MHC Class I molecules and Β2M; transcriptional downregulation of HLA 
Class I genes; post translational inhibition of HLA Class I mRNA and hypermethylation of 
MHC Class I genes.188-194 Ennishi et al recently showed in a cohort of approximately 300 
DLBCL cases that EZH2 mutations were enriched in cases with MHC Class I and II loss and 
that MHC expression was restored using EZH2 inhibitors.129  EZH2 is the catalytic component 
of the Polycomb Repressive Complex 2, resulting in the transcriptional repression of target 
genes via methylation195  In DLBCL it is thought that EZH2 mutations result in the 
downregulation of the MHC Class I and II transcriptional activators NLRC5 and CIITA, 
respectively resulting in reduced expression of these genes.129 
It is not known whether similar mechanisms underlying HLA Class I loss also account for Β2M 
protein loss, including in wild type cases. Interestingly, Daudi cells (a Burkitt lymphoma line) 
contain mutations affecting the Β2M initiator methionine codon and lack surface Β2M and 
HLA protein expression, however Β2M mRNA transcripts are detected which suggests that 
post-transcriptional or post-translational mechanisms contribute to surface loss in these 
cases.107 Very little is known about the mechanisms underlying loss of CD58, which has been 
reported in DLBCL, Burkitt’s lymphoma cell lines, Hodgkin lymphoma and urothelial 
carcinomas.78,121,122 
The effect of Β2M and CD58 genetic alterations on the immune microenvironment of DLBCL 
is unknown. It is important to identify the mechanisms underlying these methods of immune-
escape to understand the pathogenesis of the disease and to potentially inform the rational 
design and administration of immunotherapies and the monitoring of disease response to 
treatment. 
This chapter sought to determine the relationship between genetic aberrations and gene 
expression of Β2M and CD58 and the quantification of immune effectors and immune 
inhibitory cells and checkpoint molecules in the TME of DLBCL. Additionally, Β2M promoter 
methylation status was assessed to investigate whether Β2M surface expression in DLBCL 
may be regulated at the epigenetic level. The relationship between tumour mutation burden and 
the immune microenvironment composition was also examined.  
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3.3. Β2M Results 
3.3.1. Β2M variants 
Targeted resequencing identified 15/97 (15%) samples with a total of 11 Β2M variants, which 
underwent Sanger sequencing validation. One variant was not detected by Sanger sequencing 
despite adequate primer performance and a variant allele fraction (VAF) of 0.22 (22%), which 
is above the lower limit of detection (approximately 10%) for Sanger sequencing. This variant 
was taken to be a false positive by NGS and excluded from analysis. Three variants (VAFs 
>10%) were not detected due to poor primer performance; one sample had insufficient DNA 
for repeat while the remaining two samples had similarly poor performance on repeat and were 
likely due to suboptimal primer design. Re-designing the primers was considered however as 
all three cases harboured additional B2M mutations and were thus already included in the 
mutated cohort, this was not undertaken. Only validated variants were included for analysis, 
resulting in a total of 7 Β2M variants in 14 samples, Table 3-1 and Table 8-1. 
The methionine initiation codon was the most frequently mutated site, with substitutions 
occurring at each amino acid and converting methionine to either lysine, arginine, valine or 
isoleucine in 10/14 (71%) of Β2M-mutated samples. These findings are consistent with this 
region being a known mutation hotspot. These mutations were predicted to result in a lost start- 
site and mutations at this location have been shown to result in a loss of Β2M protein 
expression107. Two frameshift variants and one missense and splice donor variant were also 
detected. Two samples contained two mutations: one had two methionine initiation codon 
mutations and the other harboured an initiation codon and frameshift mutation. 
Lymph2Cx gene expression profiling for COO classification revealed that three Β2M mutated 
samples were ABC-like, seven were GCB-like, two were unclassified (UC) and two were 
unknown. The COO subgroups were compared for enrichment in mutations and no significant 
difference in mutation status between groups was detected (n = 65: 18 x ABC, 35 x GCB, 12 
x UC; p = 0.8241; Chi-squared test). 
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Variant Identification 
VAF (range if present 
in >1 sample) 
Variant 
Classification 
Number of 
Samples 
NM_004048: g.45003745 A>G 0.45 Start lost 1 
NM_004048: g.45003746 T>A, G 0.1-0.8 (median 0.3) Start lost 9 
NM_004048: g.45003747 G>C 0.28 Start lost 1 
NM_004048: g.45003767 CT>C 0.22-0.3 (median 0.26) Frameshift 2 
NM_004048: g.45003779 T>A 0.37 Missense 1 
NM_004048: g.45003780 ACT>A 0.46-0.57 (median 0.51) Frameshift 2 
NM_004048: g.45003813 T>C 0.35 
Splice donor 
variant 
1 
 
Table 3-1: Validated Β2M variants with corresponding variant allele frequency (VAF), predicted 
effect by SnpEFF and the number of samples containing each mutation. 
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3.3.2. Β2M mutation status vs Β2M gene and protein expression 
The relationship between Β2M mutation status and Β2M gene and protein expression was first 
assessed. Samples with Β2M mutations had significantly reduced gene expression compared 
to Β2M wild type (Β2MMut n=14, Β2MWT n=74, p = 0.0094), Figure 3-1 (A). Β2M gene 
expression was significantly lower in samples with Β2M protein loss (Β2Mloss n = 40, 
Β2Mnormal n = 11, p = 0.0308), Figure 3-1 (B). All Β2MMut samples with IHC (8/8) showed 
Β2M protein loss. Of these, the six samples with a B2M initiation codon mutation varied in the 
expression of B2M protein. One sample had complete B2M loss while the remaining five had 
between 50-90% loss, suggesting that the unaffected allele was able to generate a protein 
product in these cases. Protein loss was also observed in the majority of Β2MWT samples 
(31/40; 77%) consistent with mechanisms other than mutation status contributing to loss of 
Β2M surface expression.  
The relationship between Β2M mutation VAF and Β2M gene and protein expression was next 
assessed. Individual VAF values showed a significant inverse correlation with Β2M gene 
expression (Spearman r = -0.58, p = 0.0207), Figure 3-1 (C). As all Β2M mutated samples 
showed protein loss, VAFs were compared against the amount of loss. There was no significant 
correlation between Β2M mutation VAF and the amount of protein loss (Spearman r = 0.35, p 
= 0.3487), Figure 3-1 (D). The analyses using VAF must be interpreted with caution given 
that the tumour cell content of these samples was unknown and the results would be affected 
by the contribution of normal DNA. Further to this, we tried to determine whether Β2M 
mutations were heterozygous or homozygous and early or late clonal events using VAF but 
could not reliably make these assessments due to the lack of matched normal samples and 
inherent tumour heterogeneity.  
As EZH2 Y641 (murine) mutations were shown to be enriched in DLBCL with MHC loss129 
we assessed the relationship between EZH2 mutation and Β2M protein loss in this cohort. All 
EZH2 mutated cases with Β2M protein data showed loss (n = 14; 17 mutations). Five samples 
contained missense mutations at the Y646 hotspot while the remaining mutations were either 
missense (n = 9) or truncating mutations (n = 3). Further studies would be required to assess 
the biological significance and functional effect of the EZH2 mutations seen in this cohort. 
In summary, these data revealed a significant relationship between Β2M mutation status and 
Β2M gene and protein expression whereby mutated cases had lower gene expression, which 
was inversely proportional to VAF, and all mutated cases had protein loss. In all samples, those 
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with Β2M protein loss had lower gene expression than those without protein loss. As 77% of 
Β2M wild type samples displayed protein loss, this data indicates that Β2M gene expression is 
more informative than mutation status in predicting protein expression and that mechanisms 
additional to mutations contribute to protein loss. 
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Figure 3-1: Relationship between Β2M mutation status, gene and protein expression. A) Β2M mutated cases had lower gene expression compared to 
Β2M wild type (MW; p = 0.0094). B) Β2M gene expression was lower in cases with Β2M protein loss compared to normal protein expression (MW; p = 
0.0308). C) There was a moderate, inverse correlation between the variant allele fraction (VAF) of B2M mutations and Β2M gene expression (Spearman r = -
0.58, p = 0.0207). D) All B2M mutated cases had protein loss but there was no significant correlation between VAF and the amount of Β2M protein loss 
(Spearman r = 0.35, p = 0.3487). Abbreviation: MW = Mann-Whitney. Mean with SD shown. 
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3.3.3. Β2M mutation status vs immune gene and protein expression  
The relationship between Β2M mutation status and the quantification of immune effector and 
inhibitor cells in the TME was next assessed.  
Samples were grouped by Β2M mutation status (Β2MMut n=14, Β2MWT n=74) versus gene 
count for each immune effector: CD4, CD8, CD56, CD137 and inhibitor molecule: CD68, 
CD163, LAG3, TIM3, PD1, PDL1 and PDL2. There were no significant differences between 
Β2MMut/WT and gene expression of any immune markers.  
Similarly, samples were grouped by Β2M mutation status (Β2MMut approx n=7, Β2MWT approx 
n=22) status versus the amount of CD4, CD8, CD56, CD137, CD68, CD163, LAG3, PD1 and 
PDL1 positive cells quantified by immunohistochemistry. There were no significant 
differences between Β2MMut/WT and the protein expression of these immune markers. 
The Β2M mutated group was then examined more closely by comparing the number and type 
of Β2M mutations to the gene and protein expression of Β2M and immune markers. Neither 
the number of mutations (one n = 12 versus two n = 2) nor the presence of an initiation codon 
mutation (n = 10) or a frameshift mutation (n = 3) were associated with differences in Β2M 
gene expression or the gene expression of immune markers between groups.  
While recognising the limitations of assessing VAF, the VAF of Β2M mutations was not 
significantly correlated with gene or protein expression of immune markers; the latter analyses 
were limited by incomplete immunohistochemistry data which varied between markers of 
interest, ranging from between 5 - 9 samples with data. 
Significant limitations of these analyses were that group sizes were small and not all samples 
had immunohistochemistry data. These factors prevented analysis of the relationship between 
mutation number and mutation type to the amount of Β2M protein loss and the protein 
expression of immune markers. Additionally, the effects of the Β2M missense and splice donor 
mutation could not be assessed as only one sample contained each of these mutations.  
In summary, this data showed no relationship between the Β2M mutation status, number or 
type and immune gene and protein expression. 
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3.3.4. Β2M gene expression vs immune gene and protein expression 
In view of the earlier findings which indicated that Β2M gene expression may better predict 
Β2M protein expression, the relationship between Β2M gene expression and immune effector 
and inhibitor gene and protein expression was thoroughly examined.  
Β2M gene expression was stratified into ‘high’ and ‘low’ expression by the 50th percentile (n 
= 88; difference between groups p < 0.0001). Β2M gene expression was associated with and 
positively correlated with CD4, CD8, CD56, CD137, CD68, CD163, LAG3, TIM3, PD1, 
PDL1 and PDL2 gene expression, Table 3-2, Figure 3-2 and Figure 3-3. 
For the samples that had immunohistochemistry data, Β2M gene expression was again 
dichotomised into ‘high’ and ‘low’ gene expression by the 50th percentile (n = 29; difference 
between groups p < 0.0001). Β2M gene expression was associated and positively correlated 
with CD8, CD137, PDL1 and LAG3 protein expression, Table 3-2 and Figure 3-4.  Β2M gene 
expression was associated with but not correlated with CD56 protein expression. In contrast to 
the gene expression findings for CD4, CD68, CD163 and PD1, there were no significant 
associations between Β2M gene expression and protein expression of these markers. 
Given the positive correlation between B2M and immune cell gene expression and that the 
latter are associated with favourable outcomes in some malignancies, we performed a survival 
comparison between samples with high versus low B2M gene expression, based on the median 
expression value  (n = 126). Using Kaplan-Meier curves, no significant differences in overall 
survival based on B2M gene expression were observed (median survival not defined; HR 
1.035, CI 0.5118 to 2.092; Log-rank test, p = ns).  
In summary, these findings reveal that high Β2M gene expression is associated with an 
increased immune cell infiltrate in the TME of DLBCL, consistent with a co-ordinately 
regulated immune response and suggesting an adaptive immune response to immune effector 
activation. 
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   Immune Marker Correlation Significance 
G
en
e 
ex
p
re
ss
io
n
  
CD4 0.63 **** 
CD8 0.65 **** 
CD56 0.28 ** 
CD137 0.58 **** 
CD68 0.67 **** 
CD163 0.34 *** 
LAG3 0.7 **** 
TIM3 0.71 **** 
PD1 0.56 **** 
PDL1 0.71 **** 
PDL2 0.69 **** 
P
ro
te
in
 
ex
p
re
ss
io
n
  
CD8 0.69 **** 
CD137 0.62 *** 
LAG3 0.71 **** 
PDL1 0.68 **** 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
Table 3-2: Β2M gene expression is positively correlated with immune effector (blue) and inhibitor 
(red) gene and protein expression. Spearman correlation.  
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Figure 3-2: Relationship between Β2M gene expression and immune marker gene expression. Β2M gene expression is associated with gene expression 
of immune effector cells (A – D), tumour-associated macrophages (E, F) and checkpoint inhibitor molecules (G-K; next page). Mann-Whitney. Mean with SD 
shown. 
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Figure 3-2 continued 
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Figure 3-3: Β2M gene expression is associated with a co-ordinate immune response. A) Immune effector, immune inhibitor and immune checkpoint gene 
expression in the DLBCL discovery cohort was quantified by NanoString. Green = low and red = high gene expression. Unsupervised hierarchical clustering identifies 
a spectrum of immune gene expression with ‘hot’ (high immune infiltrate) to the right and ‘cold’ (low immune infiltrate) to the left, while housekeeping genes (bottom 
four rows) show no clustering. B) Stratification of samples by the top and bottom quartiles of Β2M gene expression highlighted the clustering of immune genes 
irrespective of their functional roles. Blue = low and red = high gene expression. 
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Figure 3-4: Relationship between Β2M gene expression and immune marker protein expression. Β2M gene expression is associated with protein 
expression of key immune effector cells (A–D) and checkpoint inhibitor molecules (E, F). Mann-Whitney. Mean with SD shown.
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3.3.5. Validation of Β2M findings  
We compared our findings to an external whole exome sequencing (WES) and transcriptome 
(RNASeq) data set on 1001 systemic DLBCL125 cases. In this validation cohort, Β2M 
mutations were detected in 144 (16%) samples, consistent with our findings. The number of 
Β2M mutations ranged from 1-7 per sample and 38/144 (26%) contained more than one 
mutation. 30/144 (21%) of samples harboured mutations affecting the methionine initiation 
codon. This number was lower than our own finding (71%) and likely reflects differences in 
the lesser sequencing depth of WES compared to our panel and differences in sample size. Our 
sample size was small which can lead to an overestimation of effect size that is ameliorated in 
a cohort of 1001 samples. However, the WES data had consistently poor coverage over the 
start of exon 1, due to the known problem of poor primer binding in this GC-rich region. We 
sequenced the 5’ UTR of Β2M in addition to the coding regions thus the increased amplicon 
coverage in this region would have minimised the effect of poor primer binding. Additionally, 
the depth of coverage obtained with targeted resequencing is greater than for WES, allowing 
us to obtained more detailed information on this region.  
 
The validation cohort did not confirm our finding that Β2M mutated samples had lower Β2M 
gene expression compared to wild type, which may in part be due to the poor coverage and 
failure to detect mutations in the initiation codon. The validation cohort did confirm that there 
were no statistically significant differences between Β2M mutation status and gene expression 
of most immune markers, except for CD8 and PDL2 which was lower and higher in Β2M 
mutated cases (p = 0.0166 and p = 0.0002), respectively. 
 
Β2M gene expression was stratified into high and low by the median value and compared to 
the gene expression values for key immune genes. The validation cohort confirmed our 
findings that high Β2M gene expression was significantly associated and positively correlated, 
albeit weaker, correlated with CD4 (p <0.0001), CD8 (p <0.0001), CD137 (p <0.0001), CD68 
(p <0.0001), CD163 (p <0.0001), PDL1 (p <0.0001), PDL2 (p <0.0001), TIM3 (p <0.0001) 
and LAG3 (p <0.0001).  A significant correlation but no association was identified between 
Β2M gene expression and CD56 (p = 0.0652) and PD1 (p = 0.0632) gene expression, Table 
3-3. 
The validation cohort confirmed our finding that B2M gene expression was not associated with 
differential survival outcome. Using Kaplan-Meier curves, median survival was not 
significantly different between cases with high Β2M gene expression compared to low Β2M 
gene expression (9.32 vs 9.85 years, 95% CI 0.7326 to 1.222; Log-rank test, p = ns). 
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Differences in survival outcomes by Β2M gene expression status within each cell-of-origin 
subgroup was also examined (GCB, ABC and UC) and no differential survival outcomes were 
observed within any of these groups. In summary, the validation cohort confirmed our finding 
that high Β2M gene expression is significantly associated and correlated with increased 
immune effector and immune inhibitor gene expression, consistent with a co-ordinately 
regulated immune response.  
 
Due to tumour heterogeneity, we are not able to know whether the gene expression of immune 
checkpoints is arising from malignant cells196 or immune cells in the TME without further 
characterisation. We do know that Β2M initiation codon mutations result in loss of Β2M 
surface protein,107 and all of our cases with these mutations showed significant protein loss, 
thus the presence of these mutations in conjunction with immune checkpoint overexpression 
likely reflects an adaptive immune evasion mechanism. In this situation, the malignant cells 
may either acquire or be selected for the ability to downregulate Β2M protein expression to 
counter a robust T cell infiltration or they may upregulate checkpoint molecules to induce T 
cell anergy as an additional method of immune escape. 
 
Immune Marker Correlation Significance 
CD4 0.211 **** 
CD8 0.324 **** 
CD56 0.077 * 
CD137 0.248 **** 
CD68 0.378 **** 
CD163 0.295 **** 
LAG3 0.244 **** 
TIM3 0.301 **** 
PD1 0.084 * 
PDL1 0.429 **** 
PDL2 0.443 **** 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
 
 
 
Table 3-3: The validation cohort 
confirms that Β2M gene expression is 
positively correlated with immune 
effector (blue) and inhibitor (red) gene 
expression. Spearman correlation 
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3.3.6. Ancillary gene analysis 
The validation cohort was also used to investigate genes that were not included on our 
customised panels but which may be relevant to Β2M expression, in particular the HLA genes 
and ancillary genes involved in Β2M regulation, assembly and transport. 
As with previous analyses, Β2M gene expression was stratified into high and low by the 50th 
percentile. High Β2M gene expression was significantly associated and positively correlated 
with HLA A, -B and -C and HLA DP, -DQ and -DR gene expression (Mann Whitney all p 
<0.0001), Table 3-4. Β2M gene expression was significantly associated and positively 
correlated with the gene expression of its transcriptional regulators197,198 NRLC5 and IFN-γ 
(Mann Whitney all p <0.05), Table 3-4. 
TAP1, TAP2, TAPBP, CALR, CANX and PDIA3 genes are involved in the assembly, peptide 
loading and transport of the Β2M and MHC Class I complex to the cell surface through the  
endoplasmic reticulum.199  Β2M gene expression was associated with and positively correlated 
with these genes (Mann Whitney all p < 0.05), Table 3-4. Β2M mutation status was not 
associated with any differences in gene expression for the aforementioned genes. There were 
no mutations detected in TAP1, TAP2 or TAPBP. There were no significant differences in the 
mutation status of CALR, CANX and PDIA3 and Β2M gene expression. 
This data expands our previous findings by showing that Β2M gene expression is 
significantly associated and correlated with increased gene expression of: HLA Class I and II 
molecules, HLA Class I regulatory molecules and Β2M transport and assembly molecules. 
Together, the data shows that high Β2M gene expression is associated with an overall increased 
immune infiltrate with gene expression markers of an active immune response. The co-ordinate 
increase in immune checkpoint molecules strongly suggests the presence of an adaptive 
immune response by the DLBCL cells. 
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Gene Correlation Significance 
HLA A 0. 539 **** 
HLA B 0.638 **** 
HLA C 0.429 **** 
HLA DPA1 0.491 **** 
HLA DR 0.532 **** 
HLA DQA1 0.255 **** 
NLRC5 0.104 ** 
IFNγ 0.343 **** 
TAPBP 0.139 **** 
TAP1 0.122 *** 
TAP2 0.194 **** 
CALR 0.176 **** 
CANX 0.462 **** 
PDIA3 0.297 **** 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-4: Β2M gene expression is 
correlated with HLA molecules, HLA 
Class I regulatory molecules and 
Β2M transport and assembly 
molecules. The strongest correlations 
are seen with the HLA Class I genes. 
Spearman correlation 
61 
 
3.3.7. Β2M Copy Number Variation 
Analysis of copy number variation in our cohort was performed to investigate other 
mechanisms that may account for the Β2M protein loss observed in wild type (non-mutated) 
cases. 49 samples underwent CNV analysis by qPCR with construction of a standard curve 
using SUDHL4, a Β2M copy number neutral DLBCL cell line78 and non-diseased lymph node 
samples as controls. 21 (52%) DLBCL samples and 7 (35%) controls had indeterminate results, 
Table 8-2 (raw data). A second set of primers was used to exclude that these poor results were 
due to limitations of a single primer pair, with minimal improvement. Therefore, the 
indeterminate findings were likely due to degraded DNA although we could not exclude the 
possibility of biallelic gene deletion in some of the samples. The indeterminate cases were 
excluded from analysis. Of the remaining 28 DLBCL cases, 20 (71%) had copy number loss 
(CNL), 4 (20%) were copy number neutral (CNN) and four (20%) had copy number gain 
(CNG). 4/20 samples with CNL had concurrent Β2M mutations. 
There were no statistically significant differences between copy number variation, including 
the samples with both copy number loss and mutations and Β2M gene expression or Β2M 
protein expression (Kruskal-Wallis p = 0.4888; Fisher’s Exact Test p >0.9999), Figure 3-5.  
Our results for copy number loss were higher than reported in the literature. Using high density 
SNP array Schmitz et al reported CNL in 15% of a cohort of approximately 500 DLBCL 
samples14 (11% heterozygous loss, 4% homozygous loss) while Challa-Malladi et al reported 
loss in 24% of cases in a combined cohort of 101 DLBCL samples and cell lines (40% 
homozygous loss) using FISH and high density SNP array.78 
Given that our findings were inconsistent with the literature, we wanted to validate them via 
an alternative method however we were limited to using bioinformatics algorithms due to the 
lack of DNA remaining for further testing. Copy number analysis using software designed to 
detect copy number variants (CNVs) from amplicon resequencing data was attempted using 
the OncoCNV200 and CNVPanelizer201 programs and with the CANOES202 and ichorCNA203 
tools, which are reported to be useful for the detection of low coverage CNVs (by WES and 
WGS, respectively). The ichorCNA program failed to process the data and the remaining tools 
yielded inconsistent results and did not confirm the qPCR CNV findings.  
Due to the small number of samples tested, the high number of indeterminate results, the 
discrepancy between our CNV findings and the literature and the inability to validate our 
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findings using an alternative method, it is not possible to be confident in our qPCR CNV results 
or draw meaningful conclusions from this data.  
 
 
Figure 3-5: Relationship between Β2M gene expression and copy number status and copy 
number loss plus mutation status. There was no difference in Β2M gene expression due to copy 
number status or copy number with mutation status. Kruskal-Wallis test with multiple comparisons p = 
0.3899. CNL = copy number loss, CNN = copy number neutral, CNG = copy number gain, Mut = 
mutation. 
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3.3.8. Β2M Promoter Methylation 
As our copy number data was limited and the literature suggests that copy number change does 
do not fully account for surface Β2M loss in non-mutated cases, we assessed Β2M promoter 
methylation to determine whether hypermethylation resulting in gene silencing was a 
mechanism accounting for the Β2M protein loss, including in non-mutated cases. 
Forty DLBCL samples and 5 lymph node controls underwent quantitative methylation analysis 
using the EpiTYPER® high-resolution, quantitative mass spectrometry-based bisulfite 
sequencing method. The Β2M promoter region contained 72 CpG sites of which approximately 
25 (34%) successfully had methylation status determined. Given that adjacent CpG sites 
generally show the same degree of methylation204 it was considered that 34% coverage 
sufficiently represented methylation in this region. The average methylation across CpG sites 
for the assay internal negative control was 0.03 (3%) and positive control 0.87 (87%). For 
normal lymph node controls the average methylation across all CpGs was 0.03 (3%; median 
0.03; range 0.00-0.07) while DLBCL samples had an average methylation of 0.05 (5%; median 
0.05; range 0.02-0.12) and overall were not considered to be differentially methylated 
compared to the controls, Figure 3-6. 
There is no literature regarding cut-off values to define 'negative,' 'weak' or 'strongly' 
methylated CpG regions for this method. Additionally, it is difficult to define reproducible cut-
offs when studying cancer due to the inherent heterogeneity of samples, including the presence 
of non-malignant cells. Nonetheless, the samples in this cohort with higher methylation scores 
were examined more closely and were defined as those samples having average methylation 
values >2SD (>9%) from the cohort mean. Two samples fell into this category, with average 
methylation scores 0.11 and 0.12. One sample had normal Β2M protein staining and the other 
did not have Β2M staining performed thus meaningful conclusions could not be drawn. 
A relevant limitation of this assay is that the precision for quantifying methylation differences 
as low as 5% is only valid between a methylation range of 10-90%.176,205 As our results are 
below this range the sensitivity to detect differences is reduced but is unlikely to change the 
observation that controls and samples are not differentially methylated.  
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Figure 3-6: Graphical representation of Β2M methylation data, provided by AGRF from the 
EpiTyper analysis software. Each circle represents an individual CpG site. The colour scale ranges 
from red (0% methylation) to yellow (100% methylation). Control samples have ‘LN’ prefix. It is 
evident that samples are not differentially methylated compared to controls. The Β2M_11 amplicon 
failed in 5 samples, and these have been excluded from further analysis due to incomplete data. 
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3.3.9. Serum Β2M  
Elevated serum Β2M has been shown to predict for poor progression-free and overall survival 
in DLBCL113,206 and other B-cell malignancies207,208 but the mechanisms accounting for these 
inferior outcomes remain unclear.110 Therefore, we next assessed the relationship between 
mutation status, gene expression and serum Β2M in a subgroup of 32 cases in our cohort that 
had serum Β2M measured at diagnosis. 
Serum Β2M ranged from 1.0 - 13.1 mg/L per sample with a reference range of 1.0 - 3.0 mg/L 
and 10/32 cases had an elevated serum Β2M level using this reference range. Nine samples 
harboured Β2M mutations and the serum Β2M level was not significantly different between 
mutated versus non-mutated cases (n = 9 vs 23; p = 0.90).  
Serum Β2M was next compared to Β2M gene expression. There was a trend towards a weak 
positive correlation between serum Β2M and Β2M gene expression but this did not reach 
statistical significance (Spearman r = 0.34; p = 0.0556). There was no association between 
serum Β2M level and Β2M expression when stratified by normal (<3.0mg/L) or elevated 
(>3.0mg/L) serum Β2M levels (p = 0.18). 
Serum Β2M was next compared to Β2M protein expression. There was no significant 
difference in serum Β2M level compared to samples with or without protein loss (n = 18 vs 6; 
p = 0.73). For those cases which demonstrated protein loss, there was no correlation between 
serum Β2M levels and the amount (%) of protein loss (Spearman r = -0.2; p = 0.28) nor any 
association between ‘high’ or ‘low’ protein loss, when stratified by the median value (60%; p 
= 0.28). 
As serum Β2M levels have been thought to possibly reflect the TME in lymphoma110 we 
assessed the relationship between serum Β2M and the gene and protein expression of immune 
markers in this cohort. Serum Β2M was not correlated or associated with the gene or protein 
expression of any immune effector or immune inhibitor markers or checkpoint molecules when 
stratified by normal (<3.0mg/L) or elevated (>3.0mg/L) serum Β2M levels.  
In summary, this data did not demonstrate any significant relationships between Β2M mutation 
status, Β2M gene and protein expression and normal versus elevated serum Β2M levels. 
Additionally, no significant relationships between immune markers and serum Β2M levels 
were identified, thus further studies are required to determine the causes of elevated serum 
Β2M in DLBCL and other B cell malignancies. 
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3.4. CD58 Results 
3.4.1. CD58 variants 
Targeted resequencing identified 11/97 (11%) samples with a total of 11 CD58 variants, which 
underwent Sanger sequencing validation. One variant was not detected by Sanger sequencing 
despite adequate primer performance and a variant allele fraction (VAF) of 0.52 (52%), which 
is above the lower limit of detection (approximately 10%) for Sanger sequencing. This variant 
was taken to be a false positive by NGS and excluded from analysis. The remaining variant 
(VAF 0.17) was not detected due to poor primer performance and had insufficient DNA for 
repeat or consideration of re-designing the primers. Only validated variants were included in 
the analysis, resulting in a total of 9 CD58 variants in 8 samples, Table 3-5 and Table 8-3. 
The methionine initiation codon was the most frequently mutated site, with substitutions 
occurring at two amino acids and converting methionine to either glutamate or isoleucine in 
2/8 (25%) of CD58-mutated samples. Three frameshift and nonsense variants and one splice 
donor variant were also detected. One samples contained two mutations: a frameshift and 
nonsense mutation at adjacent codons H21 and C22, respectively. One sample contained both 
a CD58 and a Β2M mutation. 
Lymph2Cx gene expression profiling for COO classification identified three CD58 mutated 
samples as GCB-like, two ABC-like, two UC and one was unknown. The COO subgroups were 
compared for enrichment in mutations and no significant difference in mutation status between 
groups was detected (n = 65: 16 x ABC, 32 x GCB, 10 x UC; p = 0.7362; Chi-squared test). 
Variant Identification VAF  
Variant 
Classification 
Number 
of 
Samples 
NM_001779: g. 117078654 A>T 0.2 Nonsense 1 
NM_001779: g. 117064599 G>T 0.43 Nonsense 1 
NM_001779: g. 117064606 C>G 0.52 Splice site  1 
NM_001779: g. 117078708  GTTACGTTTACA >G 0.36 Frameshift 1 
NM_001779: g. 117087037 GAC>G 0.64 Frameshift 1 
NM_001779: g. 117113529 G>T 0.28 Nonsense 1 
NM_001779: g. 117113531 AGT >A 0.28 Frameshift 1 
NM_001779: g. 117113592 C>T 0.4 Start lost 1 
NM_001779: g. 117113594 T>C N/A* Start lost 1 
 
Table 3-5: Validated CD58 variants with corresponding variant allele frequency (VAF), predicted 
effect by SnpEFF and the number of samples containing each mutation. * VAF is not available for 
this sample due to post-analysis technical reasons. 
67 
 
3.4.2. CD58 mutation status vs CD58 gene expression 
The relationship between CD58 mutation status and CD58 gene expression was first assessed 
and no statistically significant association was found (CD58Mut n=8, CD58WT n=80, p = 
0.2096).  
To confirm this finding, CD58 gene expression was stratified into ‘high’ and ‘low’ groups by 
the 50th percentile (n = 88; difference between groups p < 0.0001) and there was no difference 
in mutation frequency between these groups (p > 0.9999).  No correlation between CD58 
mutation VAF and CD58 gene expression was observed (Spearman r = -0.61, p = 0.1115), 
noting that these results may be confounded by tumour heterogeneity. The relationship between 
CD58 mutation status and CD58 protein status could not be assessed due to the absence of 
CD58 protein data by immunohistochemistry.  
3.4.3. CD58 mutation status vs immune gene and protein expression  
The relationship between CD58 mutation status and the quantification of immune effector and 
inhibitor cells in the TME was next assessed.  
Samples were grouped by CD58 mutation status (CD58Mut n=8, CD58WT n=80) versus gene 
count for each immune effector: CD4, CD8, CD56, CD137 and inhibitor molecule: CD68, 
CD163, LAG3, TIM3, PD1, PDL1 and PDL2. There were no significant differences between 
CD58Mut/WT and gene expression of any immune markers.  
Similarly, samples were grouped by CD58 mutation status (CD58Mut n=3, CD58WT approx 
n=25) versus the amount of CD4, CD8, CD56, CD137, CD68, CD163, LAG3, PD1 and PDL1 
positive cells quantified by immunohistochemistry. There were no significant differences 
between CD58Mut/WT and the protein expression of these immune markers but the small number 
of CD58Mut (n=3) samples makes it highly unlikely that an effect would have been detected.  
The CD58 mutated group was then examined more closely by comparing the type of CD58 
mutation to the gene expression of CD58. Frameshift (n = 3), nonsense (n = 2) and initiation 
codon mutations (n = 2) were not associated with differences in CD58 gene expression between 
groups. Given the small cohort size, mutation type was not compared against the gene 
expression of immune markers as obtaining a meaningful result was unlikely. 
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3.4.4. CD58 gene expression vs immune gene and protein expression 
Given the lack of evidence that CD58 mutation informed gene expression or the immune 
infiltrate in DLBCL, we focussed on assessing the relationship between CD58 gene expression 
and immune effector and inhibitor gene and protein expression. 
CD58 gene expression was stratified into ‘high’ and ‘low’ expression by the 50th percentile (n 
= 88; difference between groups p < 0.0001). CD58 gene expression was significantly 
associated and positively correlated with CD4, CD8, CD56, CD68, PD1, PDL1 and PDL2 gene 
expression. CD58 gene expression was significantly correlated but not associated with LAG3 
and TIM3 gene expression. There was no significant relationship between CD58 and CD163 
gene expression, Figure 3-7 and Table 3-6. 
For the samples that had immunohistochemistry data, CD58 gene expression was dichotomised 
into ‘high’ and ‘low’ by the 50th percentile (n = 29; difference between groups p < 0.0001). 
There were no significant associations between CD58 gene expression and CD4, CD8, CD56, 
CD137, CD68, CD163, LAG3, PD1 or PDL1 protein expression, in contrast to the findings 
observed for gene expression. 
3.4.5. Validation of CD58 findings  
Using the validation cohort, CD58 mutations were detected in 56 (8%) samples, consistent with 
our findings. The number of CD58 mutations per sample ranged from 1-2 and 12/56 (21%) 
contained more than one mutation. Frameshift mutations were the most frequent mutation type 
followed by missense, nonsense and splice site mutations. The methionine initiation codon was 
mutated in two samples; one sample contained two mutations.  
 
In contrast to our own data, which showed no association between CD58 mutation status and 
gene expression, the validation cohort demonstrated that CD58Mut (n=56) cases had higher 
CD58 gene expression compared to CD58WT (n=718) (p=0.0240). It would be interesting to 
explore the mechanism underlying this observation, including whether it may be due to 
heterozygous mutations with compensatory overexpression by the unaffected allele. 
 
The validation cohort confirmed that CD58 mutation status was not associated with the gene 
expression of any immune markers. When CD58 gene expression in the validation cohort was 
stratified into ‘high’ and ‘low’ expression by the 50th percentile (n = 774; difference between 
groups p < 0.0001) no significant differences in the gene expression of immune markers were 
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observed. This contrasts with our findings which did show an association between CD58 and 
immune marker gene expression however the discrepancy is likely due to our small cohort size. 
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Figure 3-7: Relationship between CD58 gene expression and immune marker gene expression. CD58 gene expression is significantly associated with 
gene expression of immune effector cells (A – C), macrophages (D) and checkpoint inhibitor molecules (E-G). There was no significant association with 
LAG3, TIM3 and CD163 gene expression (H-J). Mann-Whitney. Mean with SD shown 
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Figure 3-7 continued
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Immune 
Marker 
Correlation Significance 
CD4 0.43 **** 
CD8 0.37 *** 
CD56 0.43 **** 
CD137 0.41 *** 
CD68 0.42 **** 
PD1 0.32 *** 
PDL1 0.35 *** 
PDL2 0.43 **** 
LAG3 0.23 * 
TIM3 0.33 ** 
CD163 0.20 NS 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-6: CD58 gene expression is 
positively correlated with immune effector 
(blue) and immune inhibitor (red) gene 
expression. Spearman correlation. 
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3.4.6. CD58 Copy Number Variation 
CD58 copy number analysis was performed to assess the effect on CD58 gene expression. 40 
samples underwent CNV analysis by qPCR with construction of a standard curve using 
KARPAS 1106P, a large cell lymphoma cell line with biallelic CD58 loss 172 and non-diseased 
lymph node samples as controls. 28 samples (70%) and 9 (53%) controls had indeterminate 
results and one sample and one control were excluded due to insufficient data points, Table 
8-4 (raw data). A second set of primers was used to rule out that the indeterminate results were 
due to limitations of a single primer pair, with only minimal improvement. Therefore, the 
indeterminate findings were likely due to degraded DNA although we could not exclude the 
possibility of biallelic gene deletion in some of the samples. Of the indeterminate samples, 5/9 
controls and 17/28 samples were also indeterminate for Β2M CNV, indicating that a degraded 
sample was the most likely explanation for the poor results. 
The indeterminate cases were excluded from analysis. Of the remaining 13 cases, 10 (77%) 
had copy number loss, 2 (15%) were copy number neutral and one (7%) had copy number gain. 
1/10 samples with CNL had a concurrent CD58 mutation. 
Due to the small group sizes, the uncertainty regarding the reliability of results and the inability 
to confirm these findings using an alternate method, there was no utility in performing 
statistical analyses to assess for differences between CD58 CNV in this cohort. 
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3.5. Tumour Mutation Burden 
In solid tumours, tumour mutation burden (TMB) is emerging as a predictive biomarker for 
response to immune checkpoint blockade.168,209,210 In our cohort, 86 samples had tumour 
mutation burden calculated from targeted resequencing data. TMB ranged from 0 - 133 
mutations per sample with a median value of 5.2, see Table 8-5 for raw data. 
The relationship between Β2M and CD58 mutations and TMB was first assessed. There was 
no significant difference in overall mutational burden between Β2M mutated (n=14) and Β2M 
wild type (n = 75) samples (p = 0.0942) or CD58 mutated (n = 8) and CD58 wild type (n = 81) 
samples (p = 0.5110).   
The relationship between Β2M and CD58 gene expression and TMB was next assessed. TMB 
was dichotomised into high and low by the median value (5.2; n = 43 vs 45, difference between 
groups p <0.0001) and compared against gene expression for Β2M and CD58. A high TMB 
was significantly associated with reduced Β2M gene expression (p = 0.0328). This may 
indicate that Β2M expression is reduced as an adaptive mechanism by tumour cells to prevent 
immune cell recognition in the setting of increased neoantigen load. In support of this finding, 
TMB was compared to CD4, CD8, CD56, CD137, CD68, CD163, PD1, PDL1, PDL2, LAG3 
and TIM3 gene expression and showed that high TMB was significantly associated with 
reduced CD4 (p = 0.0072), CD68 (p = 0.0363) and PDL1 (p = 0.0162) expression and showed 
a trend toward reduced TIM3 (p = 0.0587) gene expression, suggesting reduced immune 
infiltration in the setting of a high TMB with low Β2M expression. There was no difference 
between TMB and CD58 expression (p = 0.1097).  
A significant limitation of this TMB assessment was the small gene panel used. WES is widely 
accepted as the gold standard for TMB assessment and while targeted resequencing panels 
would provide a more convenient measure, recent literature has demonstrated that panel size is 
critical for the accurate determination of TMB.211,212 In particular, one large in silico study of 
TCGA data suggested that panel sizes between 1.5-3 Mbp are ideal for TMB estimation, with 
smaller panels unsuitable for reliable TMB estimates.211,212  Our panel was approximately 
0.1Mbp in size. We thus attempted to confirm our findings using the WES data in the validation 
cohort but encountered technical challenges which prevented this. Firstly, normal controls were 
not included in this dataset which meant that the false positive rate for mutation calling would 
likely be high. Additionally, exome coverage was unevenly distributed which made it 
technically challenging to determine the number of megabases sequenced for each sample, 
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which is required for the TMB calculation. At best only approximate values for mutational 
burden could have been calculated however given the uncertainty regarding the values 
obtained, this was not undertaken. 
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3.6. Discussion 
Β2M and CD58 mutations and copy number loss are frequent events in DLBCL although the 
effect of these changes on the composition of the immune microenvironment has not previously 
been established.78,125 The hypothesis being tested in this project was that the intratumoural 
infiltration of immune effector and inhibitor cells would be increased in proportion to the level 
of intratumoural Β2M and CD58 expression in DLBCL, which is affected by the mutational 
status of these genes. The data confirms this for Β2M but not for CD58. The inability to 
demonstrate and association for CD58 may be due to limitations of sample size. 
This project firstly sought to assess the relationship between genetic aberrations of Β2M and 
CD58 and the gene and protein expression of these molecules, to understand biological factors 
which may contribute to the downregulation of these proteins in DLBCL. Additionally, genetic 
aberrations of Β2M and CD58 and the gene expression of these molecules were compared to 
the gene and protein expression of immune effector and inhibitory molecules to assess for 
relationships that may define the immune microenvironment in DLBCL.  
A key finding of this project is the identification of a significant relationship between Β2M 
mutation status and Β2M gene and protein expression, in which Β2M mutated cases had lower 
gene expression and all mutated cases had protein loss. The validation cohort did not confirm 
the relationship between Β2M mutation and reduced Β2M gene expression, however this may 
simply reflect differences in sequencing methodology rather than a true loss of effect due to 
the larger cohort size. This location is a mutational hotspot in DLBCL, with the WES data 
detecting variants in just 21% of samples compared to our 71%. It is reasonable to consider 
that the lack of variant detection in this region contributed to the lack of relationship identified 
between mutation and gene expression status in the validation cohort. 
As with previous studies78 a significant proportion of Β2M wild type cases also showed protein 
loss indicating that mutational status is not the only cause of protein loss in DLBCL. To 
investigate this further we performed copy number analysis however due to significant sample 
failure, the resultant small data set is likely underpowered to detect any effects of CNV on 
protein loss. Pursuing other methods for CNV detection (e.g.: droplet digital PCR) was limited 
by the lack and poor quality of residual DNA. While fluorescent in situ hybridisation (FISH) 
is an alternative method for determining CNV we did not have residual tissue available to 
permit this testing and it was infeasible to try and obtain more from the original diagnostic 
specimens. Therefore we were limited to applying bioinformatics algorithms to our sequencing 
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data to obtain copy number information but despite trialling several programs we were 
unsuccessful in obtaining data and were thus unable to obtain robust copy number information 
for this cohort. Given the recent evidence implicating methylation changes in the loss of surface 
MHC expression in DLBCL129 we investigated whether Β2M may also be regulated at the 
epigenetic level. Our results showed that Β2M promoter was not differentially methylated 
compared to normal controls. Therefore additional mechanisms including: structural variants, 
post-transcriptional or post-translational modifications, genetic aberrations in the 
transcriptional regulators NLRC5 or CIITA or genomic aberrations of HLA Class I genes may 
account for the Β2M loss seen in non-mutated cases. 
Another key finding is that Β2M gene expression is associated and positively correlated with 
gene expression of the key immune effector and inhibitor molecules: CD4, CD8, CD56, 
CD137, CD68, CD163, LAG3, TIM3, PD1, PDL1 and PDL2. Β2M gene expression was also 
associated with the protein expression of CD8, CD56, CD137, PDL1 and LAG3. Thus we have 
shown that high Β2M gene expression is associated with an increased immune cell infiltrate in 
the TME of DLBCL. These findings were confirmed using RNASeq data from the validation 
cohort. In addition, this cohort revealed that high 
Β2M gene expression was significantly associated and correlated with increased gene 
expression of: HLA Class I and II molecules, HLA Class I regulatory molecules (NLRC5, IFN-
y) and Β2M transport and assembly molecules (TAP1, TAP2, TAPBP, CALR, CANX, 
PDAI3). 
Taken together, the findings reveal that Β2M mutations result in reduced Β2M gene expression 
which is associated with loss of Β2M protein expression and reduced immune effector and 
inhibitor gene and protein expression, leading to an immunologically ‘cold,’ or inert, tumour 
microenvironment. As a significant number of non-mutated samples had low gene expression 
and loss of protein expression, gene expression rather than mutation status is the more 
informative marker of an immune response in DLBCL. In particular, high Β2M gene 
expression is associated with high gene and protein expression of key immune effectors and 
inhibitors, reflecting a ‘hot’ TME with a robust anti-tumoural immune response.  
These findings suggest an adaptive immune response in DLBCL, whereby an active anti-
tumour immune response is countered by a tumour cell’s ability to exploit normal anti-
inflammatory and immune-limiting processes to evade T cell mediated attack, for example, 
through the upregulation of PDL1 with ligation to PD-1 on antigen-specific T cells.42,81,82 This 
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process is the basis for the successful development of checkpoint inhibitors, in which adaptive 
immune resistance mechanisms that lead to tumour-specific T cell inhibition are reversed with 
checkpoint blockade.81,82 In addition, checkpoint inhibition has been shown to be most 
effective in solid cancers expressing high levels of immune checkpoints and in cancers with a 
high level of intratumoural immune response.84-88  These findings have implications for our 
own data and suggest that using Β2M gene expression as a marker of co-ordinate and adaptive 
immune response and as a more robust surrogate for Β2M protein expression may help stratify 
the selection of patients in whom immune-based therapies are more likely to be effective. 
CD58 mutations are associated with poor survival in DLBCL125 and have been reported to be 
more common in the ABC subtype of DLBCL which may account for the association with poor 
prognosis,78 although this has not been confirmed by other groups.14 A major limitation of my 
study is the sample size; while 97 samples were sequenced only eight samples harboured 
validated CD58 variants. Due to this small sample size, the analysis is likely underpowered to 
detect significant results. An additional limitation of this study is the lack of protein data by 
immunohistochemistry, which prevents full analysis of the relationship between mutation 
status, gene expression and protein expression. In view of these limitations, the CD58 findings 
must be interpreted with caution. On the basis of our limited data and the validation cohort 
findings, there is no evidence to suggest that CD58 is a key determinant of the TME in DLBCL. 
This project expands on previous work undertaken by our laboratory157 in characterising the 
immune microenvironment in DLBCL and contributes new knowledge to the field by revealing 
that high Β2M gene expression is a marker of a ‘hot,’ immunologically active tumour 
microenvironment in DLBCL. This suggests that B2M gene expression may be a potential 
predictive biomarker of response to novel immune-based therapies that require intact antigen 
presentation to function. While establishing the utility of B2M as a predictive biomarker was 
beyond the scope of this project, which aimed to provide detailed information on how B2M 
expression may affect the TME, it is certainly worthy of future investigation. To establish B2M 
gene expression as a predictive biomarker of immune-based therapy response, prospective 
studies will be required to examine the relationship between B2M gene expression levels and 
clinical response to immune-based therapies.42,81,82,84-88
79 
 
4. CHAPTER 4: Relationship between the protein expression of Β2M 
and CD58 and immune effectors and inhibitors in the TME of 
DLBCL 
4.1. Abstract 
Aim: To determine the effect of Β2M and CD58 protein expression by DLBCL cells on the 
quantification of immune effectors and inhibitors in the TME. 
Method: 46 FFPE DLBCL tissue biopsies on TMAs underwent IHC staining for Β2M, 
immune effectors (CD4, CD8, CD56 and CD137) and immune inhibitor markers (CD68, 
CD163, TIM3, LAG3, PD1 and PDL1) on the Ventana Discovery Ultra. 27 single tissue 
sections also underwent Β2M IHC. CD58 and PDL2 IHC was attempted but these antibodies 
could not be optimised due to non-specific staining and no suitable alternatives were 
commercially available. Staining was compared to normal lymph node controls. IHC 
quantitation of immune markers was performed using Visiopharm® image analysis software 
and validated against manual scoring. Β2M staining was scored manually to detect negative 
tumour cell staining, quantify the percentage of negative staining and to qualitatively assess for 
abnormal staining patterns. Data was analysed with GraphPad Prism v7.04 using Mann-
Whitney test for continuous variables and Fischer’s Exact Test or Chi-squared test for 
categorical variables. Survival comparison was performed used the Log-rank test. Statistical 
significance was set at p < 0.05. 
Results: Loss of Β2M membrane staining by malignant cells was observed in 40/50 cases 
(80%) and ranged from 3-100%, with a median of 67% loss. Β2M protein loss on malignant 
cells showed inter- and intra-tumoural heterogeneity. Β2M protein status was not significantly 
associated or correlated with the gene or protein expression of immune markers, however due 
to sample loss from tissue exhaustion only 25 out of an original 46 samples had both Β2M and 
immune marker IHC to enable analysis. Therefore, the small cohort size was likely 
underpowered to identify significant relationships. Visiopharm® provided scores that were 
generally acceptable when compared to manual assessment but still required significant 
operator input and was markedly more labour intensive. For these reasons, it was not 
considered superior to the established method for this project. 
Conclusion: Our findings confirmed that Β2M surface protein loss was a frequent event in 
DLBCL and demonstrates inter- and intra-tumoural heterogeneity, which raises further 
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questions regarding the functional impact of this loss including its role in the efficacy of 
immune-based therapies. Significant relationships between Β2M protein status and immune 
markers were not observed, however this analysis was limited by a small cohort size. The 
current findings therefore support those from the previous chapter which indicate that Β2M 
gene, rather than protein, expression is the better marker of an intratumoural immune response 
in DLBCL. 
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4.2. Introduction 
Malignant cells can evade host immune recognition and destruction by several mechanisms, 
including the down-regulation of surface molecules involved in antigen presentation (e.g.: 
Β2M and HLA molecules) resulting in the inability to present antigen and permitting escape 
from T-cell mediated destruction.213  In recent years, characterisation of the tumour immune 
microenvironment has become increasingly relevant to the investigation of malignancy 
including the identification of targetable molecules and predictive markers of treatment 
response.82,214,215 
In their landmark paper, Challa-Malladi et al observed that HLA Class I loss was a frequent 
event in DLBCL and was attributable to deletions and mutations of the Β2M gene in 
approximately 50% of cases.78 In their study, Β2M surface expression by 
immunohistochemistry mirrored that of HLA Class I and the dependence of HLA expression 
on Β2M was confirmed by functional studies in which HLA Class I was re-expressed following 
the restoration of Β2M expression in Β2M null cell lines.78 These findings are confirm the 
critical role that Β2M plays in the assembly and stability of the HLA Class I complex. A 
significant number of Β2M wild type cases also showed loss or mislocalised Β2M and HLA 
Class I expression suggesting that other genetic mechanisms contribute to these changes.78   
Surface HLA Class I loss has been independently associated with poor prognosis and reduced 
CD8+ TILs in solid malignancies.180,216,217 In DLBCL, Rimsza et al showed that loss of MHC 
Class II (HLA-DR) was associated with poor survival, independent of other prognostic factors 
and these cases showed reduced CD8+ TILs, suggesting reduced immunosurveillance.41 
Ennishi et al expanded upon this to show that CD4+ and CD8+ cells were lower in MHC-
negative GCB-DLBCL compared to MHC positive tumours although these differences were 
not observed in ABC-DLBCL.129 In samples with MHC Class II loss, CD4+/PD1+ and FOXP3+ 
subsets were significantly lower.129 The prognostic role of TILs was also investigated and 
showed that low CD4+ TILs were associated with worse outcome, especially in GCB subgroup 
while there was no prognostic impact of CD8+ TILs.129 They assessed combined prognostic 
effect of MHC II and CD4+ cells in GCB subtype and found that the group with poorest 
outcomes had concurrent loss of MHC Class II and low CD4+ cells.129 These findings support 
earlier work by Keane et al which showed that high CD4+ TILs were associated with better 
EFS and OS in DLBCL, independent of standard prognostic scores (R-IPI).152 In addition to 
the prognostic significance of TILs, emerging evidence indicates that a lack of intratumoural 
T cells confers resistance to immune checkpoint blockade.218-220 
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Similar to Β2M, surface CD58 loss occurs in >60% of DLBCL cases including approximately 
50% of CD58 wild type samples although underlying mechanisms leading to loss of expression 
are unknown.78  As the majority of cases of DLBCL have been shown to lack both surface 
Β2M and CD58, a feature not demonstrable on other types of B cell lymphoma studied, it has 
been suggested that the loss is co-selected for the combined protective effects against cytotoxic 
and NK mediated lysis.78 
Given the evidence for the co-selection of Β2M and CD58 loss in DLBCL and the role of TILs 
as a prognostic and predictive biomarker, we sought to investigate the effect of Β2M and CD58 
protein expression on the immune cell composition in the tumour microenvironment of 
DLBCL.  
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4.3. Β2M Immunohistochemistry Results 
4.3.1 Β2M protein quantification and distribution 
50 DLBCL tissue samples had successful Β2M staining and were first assessed for the amount 
and distribution of Β2M protein on malignant cells, Figure 4-1 and Table 8-6 (raw data). 25/50 
samples consisted of TMA cores and the staining was assessed in duplicate for all but four 
cases, which had either lost duplicate cores during processing or were deemed unsuitable due 
to non-specific staining or artefact and these were assessed in singleton. 25/50 samples were 
whole tissue sections and assessed in singleton. Β2M staining on malignant cells was compared 
to non-malignant cells in each core and staining on normal lymph node positive control 
sections. B2M protein loss was defined as negative B2M membrane staining. 
Complete loss of malignant cell B2M expression was observed in 9/50 (18%) cases, partial 
loss was observed in 31/50 (62%) cases and normal B2M expression was present in 10/50 
(20%), see Figure 4-1 (A, B) for representative images. While we did not define a minimum 
number of B2M-negative tumour cells required for the tumour sample to be described as 
showing B2M loss, given the range observed (3-100%; median 67%) and the likely functional 
impact of the amount of loss on tumour immune escape, we distinguished those with complete 
and partial loss. Cases with partial loss (range 3- 99%) were further classified by quartile with 
ranges as follows: 4th 99-80%, 3rd 60-80%, 2nd 15-60% and 1st 3-15%. Overall, both the 
absence of membrane B2M staining and the quantitative amount of loss were scored given the 
likely biological impact on immune escape due to overall differences in these values. 
Β2M protein loss was not uniform between or within samples; percentages of protein loss 
varied between TMA cores and in one case, Β2M protein loss was observed in one duplicate 
but not the other, Figure 4-1 (E-G). This phenomenon was confirmed in the single tissue 
sections, making it more likely to be a true representation of intratumoural heterogeneity rather 
than spurious technical artefact, Figure 4-1 (I-K). Other sections showed heterogeneity of 
intratumoural B2M expression due to a striking difference between membrane-negative tumour 
cells and membrane-positive non-malignant cells, which may contribute to the gene expression 
findings discussed below, Figure 4-1 (L). 
B2M-positive membrane, cytoplasmic and Golgi/perinuclear staining distributions were 
observed. Cytoplasmic and Golgi staining were defined as mislocalised protein expression by 
Challa-Malladi et al and were identified in 20% of their cohort with either underlying 
monoallelic genetic changes or wild type alleles.78 It was technically very difficult to 
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distinguish true diffuse cytoplasmic staining from non-specific background staining in the 
absence of membrane staining thus we did not score cytoplasmic staining in this cohort to avoid 
false positives. Cases with Golgi staining were more clearly distinguished and was detected in 
4/50 (8%) samples, Figure 4-1 (H). No cases with Golgi staining distribution had underlying 
B2M mutations however, and acknowledging the limitations of CNV assessment in this cohort, 
one sample showed copy number loss, one had copy number gain and the remaining cases were 
either indeterminate or not performed. 
As discussed in chapter 3, protein status was compared to mutation and gene expression of 
Β2M. All Β2MMut samples with IHC data showed protein loss, ranging between 50 – 100% 
(median 80%), which was not related to mutation type or variant allele frequency.  
Additionally, 31/40 Β2MWT samples showed protein loss, ranging from 3-100% (median 65%). 
Β2M gene expression showed a weak, inverse correlation with the percentage of B2M protein 
loss; samples with low Β2M gene expression had a greater amount of Β2M protein loss than 
those with high Β2M gene expression (r = -0.3, p = 0.0089). When the B2M gene expression 
for all cases showing B2M protein loss (i.e: complete and partial grouped together) was 
compared to those with normal staining, those with loss had significantly lower gene 
expression that those with normal protein expression, see Figure 3-1 (B). However when the 
distinction was made between complete or partial loss (the latter either grouped together or by 
quartiles) no significant differences in gene expression were observed between these subgroups 
and normal staining Figure 4-2 (A, B). When samples with protein loss were stratified into 
‘high’ and ‘low’ groups based on the median percentage of loss (67%), those with the greater 
percent loss had significantly lower gene expression compared to samples with no Β2M protein 
loss (p=0.0425) and showed a trend towards lower gene expression than those with less protein 
loss (p=0.07), Figure 4-2 (C). A reason for the weak relationship between B2M protein and 
corresponding gene expression is that while the protein findings were restricted to malignant 
cells, the gene expression counts also had contribution from normal intratumoural cells, as 
illustrated in Figure 4-1 (L). 
The amount of protein loss (complete versus partial) was not significantly different between 
COO subtype by Lymph2Cx. Survival data was available for 46 patients and comparisons were 
performed between samples showing any loss versus no loss and between samples showing 
complete, partial and no loss. No significant differences in overall survival based on protein 
expression was observed (median survival not defined; Log-rank test, all p = ns).
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Figure 4-1: Representative photographs of B2M staining on DLBCL cells. A) - H) TMA cores, I) - L) full sections (overleaf). A) Positive membrane 
staining with no loss, background lymphocytes are included for comparison. B) Complete loss. C) and D) are duplicates of the same case showing no 
membrane loss in C) and membrane-negative tumour cells in D). E) - G) Individual cases showing partial loss: tumour cells show both positive membrane 
staining in addition to varying degrees of negative staining. H) Abnormal Golgi staining distribution. I) and J) are low and high power fields of a single 
section displaying discrete regions of membrane-negative and positive tumour cells. K) Heterogeneous negative and weak membrane staining. L) Membrane-
negative tumour cells interspersed with numerous membrane-positive non-malignant cells. Magnification x40 for all except I) x20 
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 Figure 4-1 continued 
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Figure 4-2: B2M protein status versus gene expression. A) There was no significant difference in B2M gene expression between samples showing complete, 
partial or no B2M protein loss or B) when further categorising those with partial loss into quartiles (Q1-4). C) In contrast, when stratified by the median percent 
loss, samples with greater (‘hi’) loss had significantly lower gene expression compared to samples with no loss and showed a trend towards significantly lower 
gene expression than those with less (‘lo’) protein loss. Manny-Whitney and Kruskal-Wallis tests. Mean with SD shown.
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4.3.2 Β2M protein expression vs immune marker quantification 
The relationship between Β2M protein status and immune gene and protein expression was 
next assessed, to determine whether Β2M protein expression may serve as a marker of a co-
ordinate immune response in the same manner as Β2M gene expression.  
Immune cell staining was assessed by comparing to staining in normal lymph node control 
sections and quantification was performed by counting the total number of positive-staining 
cells per sample, in duplicate Table 8-7 (raw data). LAG3 and PDL1 were expressed by tumour 
cells in some samples. In cases with LAG3-positive tumour cells, the analyses were performed 
with and without the malignant cells included in the total positive cell count, with no difference 
in findings. Due to the diffuse nature of the PDL1 staining it was not possible to reliably 
distinguish between tumour cell and lymphocyte positivity, which may limit the interpretation 
of the PDL1 findings.  
The percentage of B2M protein loss (0-100%) was not correlated with the gene expression of 
any immune markers (n = 49; CD4, CD8, CD56, CD137, CD68, CD163, PD1, PDL1, PDL2, 
LAG3, TIM3; Spearman correlation all non-significant) and was not associated with these 
markers when categorised by complete, partial or no loss (Kruskal-Wallis tests all p = ns).  
Only one sample with complete B2M loss also had immune cell IHC performed. This sample 
was combined with those with showing partial loss (range 5-100%) to examine the effect on 
immune cell protein expression (n=17). This combined group was compared to samples with 
no B2M protein loss (n=8) and showed no significant associations or correlations between B2M 
protein expression and the protein expression of immune markers (n = 25; CD4, CD8, CD56, 
CD137, CD68, CD163, PD1, PDL1, LAG3, TIM3; Spearman correlation and Mann-Whitney 
tests all non-significant). Given the small size of these groups, they were not sub-categorised 
(e.g. stratifying by the median percent of loss as for gene expression analyses) for further 
analysis.  
These results are in contrast to the Β2M gene expression findings which showed strong 
association and correlation to immune markers. Given that Β2M gene expression correlates 
with Β2M protein expression (albeit weakly) and that the majority of immune marker gene 
expression correlates with their respective protein expression (Table 4-1) the most likely 
explanation for the lack of relationships to Β2M protein status is the relatively small number 
of samples assessed. While 46 samples underwent staining for immune markers, not all of these 
samples yielded a full set of results for comparison against Β2M staining. This was 
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predominantly due to tissue exhaustion during sectioning while other cases were excluded if 
they were deemed uninterpretable due to non-specific staining or artefact. These sample losses 
were unanticipated but for future TMA projects, the number of cores per slide could be 
increased to buffer against inherent sample loss, however this comes at the cost of needing to 
use smaller tissue cores which may reduce the tissue representation obtained. 
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CD4 0.41 * 
CD8 0.69 **** 
CD56 0.39 * 
CD163 0.72 **** 
LAG3 0.83 **** 
TIM3 0.62 ** 
PDL1 0.74 **** 
CD137, CD68, PD1 = NS 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
 
 
 
 
 
 
Table 4-1:  Gene expression is positively correlated with protein expression of key immune effectors 
(blue) and inhibitors (red). CD137, CD68 and PD1 were not significantly correlated (yellow). 
Spearman correlation. 
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4.4. Visiopharm® Method Validation 
The standard method for protein quantification by immunohistochemistry is manual 
assessment. As a significant number of samples had to be scored in this project (>1000) we 
sought to use a newly available automated counting method to more efficiently obtain the data. 
The Visiopharm® method had not previously been used thus required validation against the 
standard manual method.  
One TMA for each of the nine immune markers was scored both manually and by Visiopharm® 
and these values were used for the method comparison, Table 8-8 (raw data). Automated 
imaging technology is not used in our diagnostic laboratory network and literature regarding 
the validation of manual versus automated counting methods is lacking. In the diagnostic 
laboratory validations are performed on new immunohistochemistry antibodies prior to use. 
For these validations, a series of known positive and negative cases are stained with the new 
antibody and compared to the expected results, however no formal statistical analyses are 
performed. This validation process was not entirely applicable to our automated method 
comparison given that an operator is involved with training the software to recognise positive 
and negative staining such that there would be no false positive or false negative cases. We 
therefore performed Spearman correlation, linear regression and Bland-Altman plots, which 
are well established analyses of method comparison. With little literature in this setting to 
provide guidance, limits of acceptability were set at a minimum of a moderate correlation (r = 
0.6 or higher) and minimal bias (within +/- 1). It is acknowledged that the limits set for these 
research purposes are less stringent than those applied in the diagnostic setting. All analyses 
which used immunohistochemistry data were performed using the automated counts and for 
those antigens with values outside of the acceptable limits, findings were confirmed using 
manual counts. The exception to this was for Β2M, which was solely assessed by manual 
review. 
All plots were manually inspected to see where correlation was lost and where bias was 
greatest. For most antigens correlation was weakest and bias greatest at higher counts. 
Spearman r was above the acceptable limits in all cases except for PD1, Table 4-2. The 
strongest explanation for the variability in correlation values and the co-efficient of 
determination (r2) was stain quality, Table 8-9. For example, CD8 had strong, clear membrane 
staining that was easily delineated from background negative staining and it was therefore 
relatively simple to train the software to correctly identify true positive staining. In contrast, 
CD4 and CD163 had strong membrane staining plus weaker cytoplasmic and non-specific 
91 
 
background staining which made it difficult to teach the software to distinguish true and non-
specific positive staining, Figure 4-3. Most scores for CD56 were ≤0% hence the linear 
regression is represented by a straight line with r2 1.0. Manual scores for TIM3 were similarly 
low thus scoring with Visiopharm® was not performed. Bland-Altman plots demonstrated that 
bias was generally between +1/-1 except for the marked exceptions of CD68 (+5) and PDL1 
(+12) which was also most likely due to the staining properties of these antibodies, Table 8-10. 
While Visiopharm® provided scores that were generally acceptable when compared to the 
established method, it proved to be more labour-intensive than anticipated. This method 
required operator input to train the software to recognise positive staining and ignore 
background staining. Ideally these settings could then be applied across the entire TMA slide, 
achieving rapid and reproducible quantitation of protein staining. However, due to differences 
in tissue quality and staining intensity between cores on the TMA, the software needed to be 
re-trained for each sample on each slide. Thus only semi-automated scoring was achieved and 
the process took significantly longer than manual counting. For this reason, Visiopharm® was 
not considered superior to the established method for this project, however it is appreciated 
that it may be useful in other settings, for example detecting and enumerating different cell 
types on whole tissue sections.   
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CD4 0.84 0.34  
CD8 0.90 0.91  
CD56 N/A 1.0  
CD137 0.66 0.77  
CD68 0.66 0.53  
CD163 0.66 0.29  
PD1 0.47 0.42  
PDL1 0.83 0.61  
LAG3 0.83 0.50  
Table 4-2: Comparison of 
manual versus Visiopharm 
counting methods demonstrates 
a moderate to strong Spearman 
correlation in the majority of 
cases.  
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Figure 4-3: Comparison of different IHC 
staining patterns and quality. A) CD8 shows 
clear membrane positivity without background 
staining which made it relatively simple to 
train the software to distinguish positive and 
negative cells. B) CD4 and C) CD163 show 
both strong membrane staining plus weaker 
cytoplasmic and non-specific background 
staining which made difficult to train 
Visiopharm® to discern true from false 
positive staining. The variable staining 
required that analysis settings had to be 
optimised for each sample and each antibody. 
Magnification x40.  
C) 
B) 
A) 
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4.5. Discussion 
Β2M surface protein loss is a frequent event in DLBCL although the effect of this loss on the 
composition of the immune microenvironment is not known.78  In the previous chapter we 
showed that Β2M gene expression was associated with the gene and protein expression of 
immune effectors and inhibitors, reflecting a ‘hot’ TME. In this chapter we tested the 
hypothesis that intratumoural infiltration of immune effector and inhibitor cells would be 
proportional to the level of intratumoural Β2M protein expression in DLBCL.  
The key findings were that overall, Β2M protein loss was observed in 80% of all DLBCL cases 
examined, including all mutated samples and 73% of Β2M wild type cases. These figures are 
higher than reported in the literature (approximately 60% overall)78 and several reasons may 
account for this discrepancy. Firstly, we did not set a minimum threshold for the percentage of 
B2M-negative cells before labelling the tumour as showing loss, and in some cases had as few 
as 3% negatively-staining cells per sample. Other studies in DLBCL varied in their approach: 
Challa-Malladi et al did not report if they had a minimum threshold and Riemersma et al only 
scored tumours as negative in the complete absence of tumour staining.78,100  Studies in 
melanoma again did not provide definitions for negative tumours but did acknowledge and 
illustrate heterogeneous loss.90,180,221 Only Challa-Malladi et al reported a total percentage of 
B2M-negative tumour samples and as their threshold for defining loss was unknown this would 
almost certainly be a major cause of the discrepancy with our values. 
Also, the Β2M wild type samples in other studies were confirmed not to have copy number 
variants. Due to the technical reasons discussed in chapter three, we cannot exclude that our 
B2M wild type (non-mutated) cases don’t have these underlying aberrancies but given the 
reported frequency of these abnormalities it is likely that they are present in some cases. 
Therefore our wild type cohort is likely to be overestimated, which would contribute towards 
our observation of protein loss being higher in wild type cases than previously reported. 
Additionally, we attempted to minimise other sources of variability by using the same antibody 
clone as previous studies78,100 however there are inherent sources of variation in 
immunohistochemistry, including the type of tissue examined (fresh frozen vs fixed), the 
fixative used (formalin vs other), the duration of fixation, delays in fixation and the age of the 
sample before staining. We excluded samples that were clearly affected by staining artefact or 
that did not contain B2M-positive non-malignant cells. Therefore, while technical artefact 
should reasonably be considered as a potential confounder, and certainly the risk of this was 
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our rationale for not quantifying staining intensity, for the purposes of distinguishing positive 
versus negative staining it would likely exert only a minor contribution to the discrepancy 
between ours and published values.  
Another potential contribution to the differences in percentage of samples showing B2M loss 
is heterogeneity of sample type. Our cohort and Riemersma et al exclusively studied tissue 
biopsies, while Challa-Malladi et al and the melanoma studies used a combination of tissue 
biopsies and cell lines. These sample types differ in their on-going selection pressures which 
could possibly result in different patterns of B2M expression.  
Another finding was that Β2M protein expression was not uniform within biopsies as samples 
showed partial and heterogeneous loss. When interpreting this finding it is important to note 
that 50% of our samples were cores from an original tumour biopsy and incorporated into TMA 
while 50% were full tumour sections. IHC was performed on both TMA cores and tissue 
sections and the findings were treated equally despite the inherent bias in TMA cores which 
are pre-selected to be enriched for tumour cells and can only provide a snapshot of the tumour 
section. The partial loss and intratumoural heterogeneity was observed on TMAs and single 
tissue sections, confirming that the observation is a true reflection of intra-tumoural 
heterogeneity rather than a consequence of technical artefact unique to the TMAs due to their 
additional preparation and handling. The observed B2M protein intratumoural heterogeneity is 
unsurprising given that selection pressures favour the outgrowth of clones with survival 
advantages and the finding does raise interesting questions regarding whether the efficacy of 
immune-based therapies will vary depending on the degree of Β2M loss, including the overall 
percentage of negative tumour cells and the reduction in antigen density per cell, which will 
require further studies to assess. For future studies investigating the amount of intratumoural 
B2M loss, examining whole tissue sections rather than TMAs will reduce the impact of 
sampling bias. 
We found that Β2M gene expression was inversely, albeit weakly, associated with the 
percentage of protein loss which has not been previously described in the literature, however 
the correlation between mRNA and protein expression has been reported for MHC Class I and 
II.129 The weak relationship between B2M protein and corresponding gene expression may be 
explained by the fact that not all of the quantified B2M gene expression originated from the 
malignant cells. As the samples for gene expression analysis were full tissue sections, non-
malignant cells would contribute to the measured B2M gene expression and the extent of this 
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would vary between tumours. The malignant cells would be the dominant cell type in the 
samples, explaining the weak relationship observed, however a direct comparison between 
malignant cell B2M gene and protein levels would need to occur in either a pure malignant cell 
population or at single-cell level.  
In contrast to our finding in chapter 3, which showed that Β2M gene expression was associated 
with immune cell protein expression, we found no association between Β2M protein expression 
and immune cell protein expression, however, the immunohistochemistry cohort size (n = 25) 
was small.  Given that membrane protein expression, rather than gene expression exerts the 
functional effect integral to antigen presentation and in view of the strength of associations 
found for gene expression it would be prudent to re-examine these findings in a larger cohort, 
ideally using full tissue sections and more advanced imaging technology such as multispectral 
immunofluorescence to obtain objective, digitally quantified and detailed spatial information 
(see below).  
In this chapter we also trialled Visiopharm®, an automated digital imaging software to  capture 
the vast amount of IHC data generated for this project and compared it against the established 
method of manual scoring. While Visiopharm® performed adequately when compared to the 
established method, it was much more labour intensive than manual, light microscopy counting 
due to the significant operator input required to train the software to correctly recognise cells. 
For example, while it might have taken 30 minutes to manually score a TMA slide, it could 
take more than 1.5 hours to assess using Visiopharm®, depending on the stain and tissue 
quality. Additionally, the software was not able to distinguish between staining on benign 
versus malignant cells and as such, the user needed to be technically proficient at identifying 
the different cell types and interpreting IHC staining, the latter to allow for correct training of 
the software. For these reasons, Visiopharm® was not superior to the established method for 
this project, noting that it may be useful for other TMA projects with less inter-sample staining 
artefact or for full tissue sections with more discrete regions of differently staining cell types.  
IHC is a valuable tool in the diagnostic and research settings however its utility is limited to a 
two-dimensional analysis of tissue sections by permitting the detection and quantification of, 
at most, two antigens per stain. Multiplexed immunofluorescence (mIF) of up to seven 
antigens222,223 has emerged as a sophisticated technique for immune microenvironment 
profiling and provides insight on the immunophenotype and spatial arrangement of multiple 
cell types simultaneously, all within a single tissue section.160,224-226 
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NanoString have developed the GeoMx™ digital spatial profiling (DSP) platform based on 
their nCounter®  barcode technology which allows TME profiling of tissue sections through 
highly multiplexed digital quantification of RNA and protein targets.227 Future studies should 
utilise either mIF or DSP to advance our understanding of the composition, spatial relationships 
and differences in gene expression profiles of effector cells in the TME of DLBCL. 
In summary, in this we confirmed that B2M membrane loss was a frequent event in DLBCL 
and identified that loss shows inter- and intra-tumoural heterogeneity, leading to further 
questions regarding the functional impact of this loss and in particular, for the efficacy of 
immune-based therapies. The existing findings therefore support those from the previous 
chapter indicating that Β2M gene, rather than protein, expression is the better marker of an 
intratumoural immune response in DLBCL.
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5. CHAPTER 5: Relationship between Β2M and CD58 expression and 
the clonal distribution of intratumoural T cells in the TME of 
DLBCL 
5.1. Abstract 
Aim: To determine the effect of Β2M and CD58 expression on the clonal distribution of 
intratumoural T cells in the tumour microenvironment of DLBCL. 
Methods: 56 DLBCL FFPE samples which had targeted resequencing and gene expression 
data underwent high throughput T cell receptor-β (TCRβ) sequencing by Adaptive 
Biotechnologies® using the immunoSEQ assay (Seattle, USA). Quantitative metrics regarding 
the number and clonality of intratumoural T cells were provided for each sample. Data was 
analysed with GraphPad Prism v7.04 using Mann-Whitney test for continuous variables and 
Fischer’s Exact Test or Chi-squared test for categorical variables. Statistical significance was 
set at p < 0.05. 
Results: T cell metrics were analysed against Β2M and CD58 mutation and expression status, 
and tumour mutational burden. High Β2M gene expression was associated with a higher total 
number of intratumoural T cells and less T cell diversity compared to low Β2M gene 
expression. Neither Β2M mutation status or protein expression was associated with 
intratumoural T cell number or clonality. Tumour mutation burden did not correlate with the 
number or clonality of intratumoural T cells. CD58 mutation status and gene expression was 
not associated with the number or clonality of intratumoural T cells. 
Conclusion: We have shown for the first time that Β2M gene expression is proportional to the 
number of intratumoural T cells and inversely proportional to T cell diversity in DLBCL. This 
is consistent with our earlier finding that high Β2M gene expression reflects a ‘hot’ or 
immunologically active TME and expands on this to suggest that clonal T cell expansions are 
more likely with intact antigen presentation. Future studies should investigate which T cell 
subsets undergo clonal expansion and assess the functional state of these cells for anti-tumour 
reactivity.  
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5.2. Introduction 
On-going studies of the tumour microenvironment (TME) in solid tumours and lymphoma 
continue to reveal a complex interplay between malignant and non-malignant cells which shape 
the composition of the TME and can determine the natural history of a tumour.228 Immune 
cells, including tumour-infiltrating lymphocytes (TILs) are critical to this process and are 
associated with clinical outcomes in many malignancies.  
T cells recognise antigenic peptide via unique T cell receptors (TCR) whose diversity and 
specificity are determined by highly variable complementarity-determining regions (CDRs). 
The CDR3 of the TCRβ chain is crucial to T cell recognition of antigenic peptide bound to 
MHC complexes. The T cell mediated immune response is a complex process in which naïve 
T cells first encounter  antigen presented by cognate MHC Class I:peptide complex and through 
co-stimulatory signalling between the APC and the T cell, undergo activation and 
proliferation.34  Following activation, effector T cells mediate the cytotoxic destruction of 
target cells upon encountering cognate MHC Class I:peptide complexes.34  In this manner, T 
cells can recognise and eliminate malignant cells through the recognition of tumour-associated 
peptides presented by MHC molecules. This process is continually shaped by stimulatory and 
inhibitory signals and under normal circumstances, immune checkpoint molecules provide a 
negative feedback mechanism following T-cell activation to regulate immune responses and 
prevent auto-immunity.229  Tumour-specific T cells are considered important mediators of anti-
tumour immunity in the setting of immune-based therapies.184,230,231 The total number of T cells 
with different TCRs (clones) in a system is known as the ‘T cell repertoire’ and can be 
characterised and quantified using high throughput sequencing of the CDR3.232  
TILs, in particular CD8+ T cells and Th1-oriented CD4+ T cells have demonstrated favourable 
prognostic value in many solid malignancies and studies investigating their use as a predictive 
marker for response to immune checkpoint blockade are on-going.148,149,228,233-240  However in 
some solid malignancies, notably renal cell carcinoma, increased TILs are paradoxically 
associated with poor outcomes which may be due to immune dysfunction and upregulation of 
checkpoint inhibition molecules by TILs in these cases.228,241-243  Early work in DLBCL 
showed that the percentage of activated cytotoxic T cells, as assessed by granzyme B 
immunohistochemistry, was associated with inferior progression-free and overall survival in a 
cohort of 63 patients predominantly treated with CHOP.244  Interestingly, the number of non-
activated (granzyme B negative) CD3+ T cells did not correlate with clinical outcome.244  This 
group also identified that the percentage of activated T cells was significantly lower in cases 
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that had lost MHC I surface expression by IHC compared to MHC I-positive cases.244  Despite 
this finding, the loss of MHC Class I expression did not correlate with clinical outcome. It must 
be noted that this was early work and was unable to investigate the role that T cell exhaustion 
and upregulation of immune checkpoints by either TILs or malignant cells may have served in 
the association between activated T cells and poor outcome. 
Our laboratory has shed further light on the importance of intratumoural immunity in DLBCL. 
Keane et al 2013 observed that  high CD4+ TILs are associated with better EFS and OS in 
DLBCL, independent of standard prognostic scores (R-IPI) in patients treated with R-
CHOP.152  In this study, even with very good R-IPI scores, CD4+ TILs still stratified for 
favourable outcomes.152  We have also quantified the net anti-tumoural immunity in DLBCL 
by using gene expression analysis to measure the ratios of intratumoural immune effectors (T 
cells, NK cells) to immune inhibitors (‘M2’ macrophages, PD-1 and PDL1) and showed that 
the ratio of immune effectors to inhibitors was associated with overall survival.157  Specifically, 
a high ratio of effectors to inhibitors was associated with longer OS while a low ratio predicted 
poor overall survival and this was independent of existing prognostic scores.157  Recently we 
have examined the intratumoural TCR repertoire in DLBCL and its relationship to the immune 
microenvironment in a retrospective cohort of 92 patients with DLBCL treated with R-CHOP. 
In this study, tumours with a highly dominant single T cell clone as determined by TCRβ CDR3 
sequencing were associated with significantly inferior survival compared to tumours with a 
lower frequency of the dominant clone (4-yr OS 60.0% vs 79.8%; 4-yr PFS 46.6% vs 
72.6%).159  EBV-positive DLBCL was shown to have larger but more clonal (i.e.: less diverse) 
intratumoural T cell populations compared to EBV-negative DLBCL, consistent with a 
targeted response against viral antigens, and similarly showed inferior outcomes.159 Gene 
expression of immune checkpoint molecules was increased in samples with greater diversity 
implicating the TCR repertoire as a key determinant of the TME.159  
Given the demonstrated prognostic significance of TILs and the observation that TILs are 
reduced in the setting of tumour MHC downregulation41,129,180,216,217,244 we sought to 
investigate the effect of Β2M expression on the TCR repertoire in DLBCL. This chapter tests 
the hypotheses that the clonal distribution of T cells in the TME of DLBCL is influenced by 
malignant cell Β2M expression and that tumours with high Β2M expression will have more 
clonally-restricted TILs, consistent with infiltration by antigen-specific T cells.  
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5.3. Β2M Results 
5.3.1 TCR repertoire vs Β2M mutation status 
The relationship between Β2M mutation status and intratumoural T cells clones was first 
assessed. While Β2M mutation status was not significantly associated with the number of T 
cells as measured by gene expression or immunohistochemistry in previous analyses, the effect 
on T cell clonality remained to be examined.  
Of 56 samples that underwent both TCRβ and NGS sequencing, 11 were Β2M mutated and 45 
were Β2M wild type. There were no significant differences in the number of unique TCRs 
sequenced, the number of clones present and the size of the dominant clone or the diversity of 
clones between Β2MMut and Β2MWT samples, Table 5-1, Figure 5-1 and Table 8-11 (raw 
data). Given the high frequency of initiation codon mutations observed in this cohort and the 
expected functional impact of surface protein loss, the effect on the intratumoural TCR was 
assessed compared to the other mutation types identified (frameshift, missense and splice donor 
variant). No significant differences in the number or clonality of T cells were observed between 
samples with a Β2M initiation codon mutation (n=7) and those without (n=4). 
5.3.2 TCR repertoire vs tumour mutation burden 
The effect of tumour mutation burden (TMB) on intratumoural T cell clones was next assessed, 
while remaining aware of the limitations of our TMB assessment as discussed in chapter 3, 
namely a small panel size. There was no correlation and no associations between TMB and 
metrics of T cell number or clonality either when the TMB was stratified into high and low by 
the median value or when stratified by the top quartile of mutation burden.  
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A) 
TCR Metric Definition 
Total TCRs All CDR3 (TCRs) sequenced including functional and non-functional TCRs 
Unique TCRs All unique sequences identified (functional and non-functional) 
Productive Total  Number of in-frame fully functional TCRs 
Productive uniques 
or ‘richness’ 
Number of fully functional clones. Each clone is counted once; a productive 
unique can be one or many T cells expanded from each other 
Entropy Highly clonal samples have low entropy, very diverse have high entropy 
Clonality 
A statistic for how much of the repertoire is made up of expanded clones, 
range: 0 (each clone appears once) to 1 (monoclonal) 
Max frequency % The percentage frequency of the largest dominant clone 
Productive gene 
rearrangements 
Number of rearranged genomes present 
Diversity Productive uniques (clones)/ productive gene rearrangements (T cells) 
 
B) 
 
Table 5-1: A) T cell receptor (TCR) metrics. All metrics were examined in each analysis however 
Diversity, Clonality and the % maximal frequency clones were the best measures to normalise for 
sample size and sequencing depth. B) Illustrative example of the composition of TCR repertoires that 
may be seen in a sample; the whole represents the full complement of TCRs as determined by TCRβ 
sequencing while each wedge represents an individual clone and the degree of expansion, identified by 
its unique CDR3 region. Figure courtesy of and adapted from Dr Mohamed Shanavas, UQDI.  
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Figure 5-1: Relationship between Β2M mutation status and TCR metrics. A) - F) There were no 
significant differences in the number of T cells or T cell clonality metrics between Β2MMut and Β2MWT 
samples. All p = NS. Mann-Whitney. Mean with SD shown.   
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5.3.3 TCR repertoire vs Β2M expression 
In chapter 3 we observed that Β2M gene expression reflected an immunologically active 
tumour microenvironment, including the number of T cells as determined by gene and protein 
expression, thus we next assessed the impact of Β2M gene expression on the clonal repertoire 
of intratumoural T cells. We were interested to assess whether the increased number of T cells 
identified by gene expression was represented by a small number of highly expanded clones, 
suggesting a highly targeted anti-tumour response versus a more diverse clonal repertoire.  
We first assessed for consistency in the number of T cells determined by TCRβ sequencing and 
gene and protein expression. As TCRβ sequencing did not distinguish between CD4 or CD8 
cells the comparison was general in nature. There was a positive correlation between Total 
TCRs sequenced and CD4 and CD8 gene expression (n = 56; Spearman r = 0.65, p <0.0001; r 
= 0.39, p = 0.0024, respectively) but not protein expression (n = 20; Spearman r = 0.11, p = 
NS, r = 0.30 p = NS, respectively). 
As for previous analyses, Β2M gene expression was stratified into high and low by the median 
value (n = 28 vs 28; difference between groups p <0.0001). Β2M gene expression was 
significantly associated and positively, but weakly, correlated with Total TCRs sequenced (p 
= 0.0297, Spearman r = 0.33), Unique TCRs sequenced (p = 0.0401, r = 0.33), Productive Total 
(p = 0.0272, r = 0.32)  Productive Uniques (richness) (p = 0.0418, r = 0.33) and Productive 
Gene Rearrangements (p = 0.0249, r = 0.35) and showed a significant association and inverse 
correlation with Diversity (p = 0.0101, r = -0.36), Figure 5-2 and Table 5-2. Β2M gene 
expression was also positively correlated with entropy (r = 0.28) and samples with high Β2M 
gene expression tended to have higher entropy but this association did not reach statistical 
significance (p = 0.12). There were no significant associations or correlation between the 
remaining TCR metrics of Clonality and Maximum Frequency %.  
In summary, high Β2M gene expression was significantly associated and correlated with a 
higher number of intratumoural T cells with less TCR diversity compared to low Β2M gene 
expression. While the absolute magnitude of these changes is modest, this data supports our 
previous findings which show that high Β2M gene expression reflects an immunologically 
active TME and expands on this to suggest that clonal T cell expansions are more likely with 
intact antigen presentation. While we may speculate that the non-diverse intratumoural T cell 
repertoire indicates the presence of tumour-specific clones, future studies are needed to 
determine the antigen-specificity and anti-tumour reactivity of these cells. 
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We next assessed the effect of Β2M protein expression on the clonal repertoire of intratumoural 
T cells. There were no associations between any protein loss (n = 36) or normal expression (n 
= 9) and any TCR metrics. Additionally, there was no correlation and no association between 
the percentage of protein loss and any TCR metrics. Samples with complete loss were 
compared to those with partial loss and no significant differences in TCR metrics observed.  
Samples were also stratified into ‘high’ and ‘low’ groups by the median percentage of protein 
loss and compared, again with no significant differences in TCR parameters observed. Protein 
loss was also stratified by the median value and compared. Interestingly, of the top four samples 
in the cohort that had the highest number of Total and Unique TCRs and the greatest Productive 
Total and Productive Uniques, 2/4 had 100% Β2M protein loss, 1/4 had no Β2M loss and 1/4 
had 60% loss. This variability in protein loss and lack of correlation to TCR repertoire reaffirms 
our previous findings that gene expression rather than protein expression serves as a better 
indicator of the immune microenvironment. 
 
Metric Correlation Significance 
Total TCRs  0.33 * 
Unique TCRs  0.33 * 
Productive Total 0.32 * 
Productive Uniques 0.33 * 
Entropy 0.28 * 
Clonality -0.03 NS 
Diversity -0.36 ** 
Productive Gene 
Rearrangements 
0.35 ** 
Max. Freq Dominant Clone -0.09 NS 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 
 
Table 5-2: Β2M gene expression is positively, but weakly, correlated with the number of intratumoural 
T cells and is inversely correlated with TCR diversity, suggestive of an active immune response 
composed of  clonally restricted T cells.
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Figure 5-2: Relationship between Β2M gene expression and TCR metrics. A) - F) Samples with high Β2M gene expression had higher higher number of 
intratumoural T cells and less TCR diversity, consistent with an immunologically active TME. Plots for Entropy, Clonality and Maximum Frequency of 
Dominant Clone not shown: all p = NS. Mann-Whitney. Mean with SD shown.
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5.4. CD58 Results 
5.4.1 TCR repertoire vs mutation status 
The relationship between CD58 mutation status and intratumoural T cell clones was next 
assessed. The small CD58-mutated cohort meant that we were likely underpowered to detect 
any significant effects however given the important role of CD58 in the activation of T cells, 
we still sought to examine for a possible relationship with T cell clonality. 
Of 56 samples that underwent both TCRβ and NGS sequencing, 6 were CD58 mutated and 50 
were CD58 wild type. There were no significant differences in the number of TCRs sequenced, 
the number of clones present, and the size of the dominant clone or the diversity of clones 
between CD58Mut and CD58WT samples, Table 8-11 (raw data). The small number of mutated 
samples assessed is a limitation to this analysis and makes it difficult to determine whether 
there is a true lack of relationship versus a false negative assessment due to inadequate sample 
size. 
5.4.2 TCR repertoire vs CD58 expression 
In chapter 3 we showed that CD58 gene expression was associated with the gene expression of 
CD4, CD8 and other immune markers, however this could not be confirmed in the large, 
external validation cohort. Nonetheless, the effect of CD58 gene expression on T cell clonality 
remained to be examined.  
CD58 gene expression was stratified into high and low by the median value (n = 28 vs 28; 
difference between groups p <0.0001). CD58 gene expression was not correlated or associated 
with any TCR repertoire metrics. 
As discussed in previous chapters, CD58 immunohistochemistry data could not be obtained 
thus the effect of CD58 protein expression on the intratumoural T cell clonal repertoire could 
not be assessed. 
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5.5. Discussion 
Neoantigens arising from somatic mutations and tumour-associated antigens can stimulate an 
anti-tumour immune response and result in selection pressures for the development of tumour 
immune escape mechanisms including loss of antigen presentation components. Examining the 
intratumoural TCR repertoire can give insight into the extent and strength of the T cell response 
and research in this field has grown considerably in recent years, aided by the development of 
high throughput sequencing technology. To date, most investigations of intratumoural TCR 
repertoires have been in solid malignancies.245-254 There is emerging evidence that the TCR 
repertoire is associated with response to checkpoint inhibition in some cancers, hypothesised 
to be due to increased neoantigens in the setting of high TMB which can be recognised by a 
reactivated immune system following checkpoint blockade.255-257  Studies investigating the 
TCR repertoire in B cell lymphomas are lacking, apart from our own study which demonstrated 
that tumours with a highly dominant clonal expansion were associated with poor outcomes in 
DLBCL.159 
To our knowledge, this chapter is the first exploration of the relationship between the loss of 
antigen presentation components and the intratumoural T cell repertoire by TCRβ sequencing 
in any malignancy. Our key findings were that Β2M gene expression was significantly 
associated and proportional to the number of intratumoural T cells and was inversely 
proportional to T cell diversity. This data supports our earlier finding that high Β2M gene 
expression reflects a ‘hot’ or immunologically active TME and expands on this to suggest that 
clonal T cell expansions are more likely with intact antigen presentation. 
Consistent with the lack of relationship identified between Β2M mutation status and the 
immune TME in chapter 3, we did not identify a significant relationship with the intratumoural 
TCR repertoire in this study. Similarly, we found no significant relationship between Β2M 
protein expression and the TCR repertoire which was also consistent with the lack of 
relationship observed between Β2M protein expression and the TME. These findings reaffirm 
our earlier conclusions that Β2M gene expression is the better indicator of the immune 
microenvironment in this study. 
Characterisation of the TMB and its role as a prognostic marker in non-Hodgkin's lymphoma 
is largely unknown. Strong evidence showing that tumour mutational burden correlates with 
the number of and clonality of TILs is lacking however several studies in solid tumours, 
including computational assessments of large public data sets, indicate that this relationship 
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varies between tumour type and is generally observed in tumours arising from highly 
immunogenic environments such as lung and colorectal cancer and melanoma.255,258-262  We 
did not identify a relationship between TMB and either the number or clonality of TILs in this 
cohort, which may be due to several reasons. Firstly, B cell lymphoma has a lower mutation 
burden compared to some of the highly immunogenic tumours263 thus the same relationships 
between TMB and TILs may not be seen. Additionally, immunological findings from solid 
organ malignancies are not necessarily comparable to lymphoma, given that the tissue and 
malignant cell type in lymphoma are components of the immune system. Finally, as discussed 
in chapter three, our small panel size may result in the inaccurate determination of TMB in this 
project and thus affect our findings. 
There are several technical limitations inherent to the TCRβ sequencing performed in this 
project. Tissue heterogeneity has a significant impact on our findings; the DNA used for this 
testing was extracted from FFPE tissue sections which were predominantly lymph node 
biopsies containing DLBCL but would have contained variable amounts of background normal 
lymphoid tissue. Due to this, when commenting on the number and clonality of intratumoural 
T cells it is not possible to distinguish between anti-tumoural T cells and by-stander T cells 
without an active role in the anti-tumour immune response. Depending on tissue heterogeneity, 
small but significant clonal expansions of anti-tumour T cells may be masked by an increased 
number of non-clonally expanded by-stander T cells. This is a significant limitation and may 
explain why the prognostic relevance of tumour infiltrating lymphocytes in solid malignancies 
has more readily been established compared to B cell lymphomas, where the significance and 
role of intratumoural T cells is confounded by the fact that they normally reside in the tissue of 
origin. We were unable to assess tumour burden for our samples prior to testing however in an 
attempt to reduce and standardise the effect of tissue heterogeneity on results, it is important to 
review tumour burden and set a minimum threshold prior to testing. 
A limitation of the TCRβ sequencing methodology is that it provides information based on 
CDR3 sequences only and is not able to distinguish between CD4 or CD8 cells and their 
functional subsets, for example CD4+ Treg cells, which have been shown to have a prognostic 
impact in DLBCL.129,152,157,264 Our results showed a strong correlation between the total 
number of TCRs sequenced and both CD4 and CD8 gene expression but beyond a global 
assessment on total number and clonal diversity, we cannot make a comment regarding the 
relative proportions of CD4 and CD8 and their functional subsets or how clonal expansion 
within these subsets was affected by the loss of antigen presentation components. Additionally, 
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TCRs are composed of both α and B chains and to a smaller extent, γ and δ chains and the 
sequencing that we had performed was restricted to the TCRβ chain only. Therefore, we 
measured a limited range of TCRs and likely underestimated the degree of intratumoural 
diversity. Technology has advanced since our project and now permits the sequencing of all 
TCR chains on the immunoSEQ platform, so any future projects will contain more 
comprehensive data. 
An additional limitation of the TCRβ sequencing was that some metrics were affected by the 
number of TCRs sequenced which may have been due to either PCR bias or differences in 
sample size. While all TCR metrics were examined during the data analysis for this chapter, 
findings for those metrics which were normalised for the number of TCRs sequenced, i.e.: 
clonality, diversity and maximum frequency of the dominant clone were considered the most 
reliable due to correction from sampling and/or sequencing artefact. 
To build upon our findings, future studies should be aimed at identifying which subsets undergo 
clonal expansion and to assess the functional state of these cells for anti-tumour specificity and 
for T cell exhaustion/dysfunction phenotypes. Data in solid tumours indicates that only a small 
proportion of intratumoural  T cells are capable of recognising autologous tumour265 which has 
implications for the efficacy of immune-based therapies and in particular, immune-checkpoint 
blockade. 
In summary we have shown for the first time that Β2M gene expression is proportional to the 
number of intratumoural T cells and inversely proportional to T cell diversity in DLBCL. This 
is consistent with our earlier finding that high Β2M gene expression reflects a ‘hot’ or 
immunologically active TME and expands on this to suggest that clonal T cell expansions are 
more likely with intact antigen presentation. 
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6. CHAPTER 6: Final Discussion 
The work presented in this thesis tests the overarching hypothesis that the expression of the 
immune cell recognition components Β2M and CD58 affect the composition of intratumoural 
immune cells in the tumour microenvironment of diffuse large B cell lymphoma. The data 
generated provide valuable insights into the TME of DLBCL including that Β2M gene 
expression reflects an immunologically ‘hot’ tumor microenvironment and demonstrating its 
potential role as a biomarker of an active intratumoural immune response in DLBCL. Work 
was also undertaken to investigate the causes of Β2M protein loss, given that this method of 
immune evasion frequently occurs in DLBCL and the underlying mechanisms are not fully 
elucidated. They key findings and future directions of this thesis are discussed below. 
Β2M and CD58 genetic aberrations and protein loss are frequent events in DLBCL although 
the effect of these changes on the composition of the immune microenvironment is 
unknown.78,125  We sought to assess the relationship between genetic aberrations of Β2M and 
CD58 and the gene and protein expression of these molecules. Our first key finding was to 
demonstrate a direct relationship between Β2M mutation status, gene expression and protein 
expression. Β2M mutated samples had lower Β2M gene expression than Β2M wild type cases 
and that in the mutated cases, Β2M gene expression was inversely proportional to variant allele 
frequency. Additionally, all Β2M mutated cases demonstrated Β2M protein loss, although a 
significant proportion of non-mutated cases also showed protein loss. These findings are 
consistent with previous studies which show that Β2M mutations contribute towards but don’t 
account for all protein loss seen in DLBCL.78 
To investigate causes of Β2M protein loss further, we considered other biological mechanisms 
that influence gene expression and thus performed copy number analysis (CNA) and Β2M 
promoter methylation analysis. The copy number analysis was limited by a significant number 
of indeterminate samples, most likely due to degraded DNA. There was insufficient DNA 
remaining to test CNA using an alternative method to qPCR and the amplicon sequencing data 
was not compatible with existing bioinformatics-based prediction algorithms, thus we were 
unable to obtain reliable copy number information for this cohort.  We assessed whether Β2M 
protein loss may be due to epigenetic regulation via determination of promoter methylation 
status. While we found that the Β2M promoter in DLBCL was not differentially methylated 
compared to normal controls in our cohort, very recent evidence implicates epigenetic changes 
in the loss of surface MHC expression in DLBCL and solid malignancies via methylation of 
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the MHC transcriptional regulators and other genes critical to antigen processing by MHC 
Class I.79,129  While Β2M was not specifically examined in these recent studies, it is plausible 
that widespread epigenetic changes affecting the expression of MHC and related genes would 
contribute to the loss of surface Β2M expression seen in DLBCL, although this requires further 
investigation. In summary, while we could not identify novel mechanisms contributing to the 
loss of surface B2M in our cohort, the causes are likely multifactorial and include mutations 
and copy number changes and also hitherto uncharacterised post-transcriptional and/or post-
translational modifications and other epigenetic phenomenon. 
Given that the loss of surface Β2M is a mechanism of immune escape from T cell-mediated 
immunity, we sought to examine the relationship between Β2M expression and the gene and 
protein expression of immune effector and inhibitory molecules to assess for the intratumoural 
effect of Β2M loss. The next key finding was that high Β2M gene expression was associated 
with an increased immune cell infiltrate in the TME of DLBCL. We identified that Β2M gene 
expression was associated and positively correlated with gene expression of the key immune 
effector and inhibitor molecules: CD4, CD8, CD56, CD137, CD68, CD163, LAG3, TIM3, 
PD1, PDL1 and PDL2 and that Β2M gene expression was also associated with the protein 
expression of CD8, CD56, CD137, PDL1 and LAG3, suggestive of an adaptive immune 
response by tumour cells. Despite our finding that Β2M gene expression was inversely 
associated with the amount of protein loss, we could not expand the above findings to show 
that Β2M protein expression also associated with immune cell protein expression. However, 
due to the small cohort size (n = 25) of samples with immune cell immunohistochemistry data 
we were unlikely to be powered to detect these relationships. Therefore it would be valuable 
to confirm our Β2M and immune protein expression findings in a larger cohort, particularly 
given the strength of associations identified for gene expression.  
Our gene expression findings were confirmed in a large validation cohort of approximately 
1000 DLBCL cases with whole transcriptome RNASeq data.125 The additional genes studied 
in the validation cohort showed that high Β2M gene expression was also 
significantly associated and correlated with increased gene expression of: HLA Class I and II 
molecules, HLA Class I regulatory molecules (NLRC5, IFN-y) and Β2M transport and 
assembly molecules (TAP1, TAP2, TAPBP, CALR, CANX, PDAI3). The validation cohort 
containing approximately 1000 clinically annotated cases afforded the ability to perform a 
robust survival comparison and did not show a differential survival benefit in patients with 
high versus low Β2M gene expression.  While B2M gene expression was not shown to be a 
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prognostic marker in a cohort of patients treated with standard immunochemotherapy, 
including rituximab, an anti-CD20 monoclonal antibody which works via complement-
mediated destruction and antibody-dependent cell-mediated cytotoxicity, it may have utility as 
a predictive biomarker of response to novel immune-based therapies such as immune 
checkpoint blockade. 
While WES data from the validation cohort did not confirm the relationship that we identified 
between Β2M mutation and reduced Β2M gene expression, this is likely due to differences in 
coverage between the sequencing methodologies used. The validation cohort had reduced 
coverage over the start codon mutational hotspot compared to our targeted data and detected 
Β2M variants in just 21% of samples compared to our 71%. Therefore, it is likely that the 
reduced number of hotspot variants detected contributed to the lack of relationship between 
mutation and gene expression status in the validation cohort. 
The next key findings were that Β2M protein loss was a frequent event in DLBCL. We detected 
loss in 80% of all DLBCL samples, including 77% of Β2M wild-type cases. These frequencies 
were higher than reported in the literature but for reasons discussed in chapter four, were most 
likely due to differences in the threshold used to define protein loss with a smaller contribution 
due to technical differences and an overestimation of our wild type cohort. While our wild type 
samples were non-mutated, we were unable to exclude the possibility of underlying copy 
number or structural changes which would be expected to affect protein expression. 
Additionally, we identified that Β2M protein expression showed intratumoural heterogeneity 
and the effect of partial loss warrants further study for the potential impact on efficacy of 
immune-based therapies.  
A relevant question arising from these analyses is what contribution B2M aberrations may have 
on MHC Class I expression in tumours which display MHC Class I loss despite no detected 
epigenetic or genetic aberrations in MHC Class I genes, i.e: what proportion of these cases are 
due to defective B2M?  While MHC Class I expression was not examined in this study and 
thus could not be correlated to underlying changes in B2M promoter methylation, mutation 
status, gene expression and protein expression, examining how these changes in Β2M might 
account for MHC Class I loss would be a potential area for future study. 
An additional aim of this project was to assess the localisation of intratumoural immune 
effector cells in the context of deficient Β2M protein expression. This project used 
immunohistochemistry to obtain information on protein expression and this technique is unable 
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to reliably assess spatial relationships. Recently, NanoString have developed the GeoMx™ 
digital spatial profiling platform which facilitates tumour microenvironment profiling of tissue 
sections and provides information on both gene and protein expression at the cellular level. To 
advance the understanding of the composition and spatial relationships in the TME of DLBCL 
future studies should consider utilising the digital spatial profiling technology. Functional 
studies would be required to assess the full impact of Β2M loss on response to immune-based 
therapies and represent an avenue for future studies.   
We next tested the hypotheses that the clonal distribution of T cells in the TME of DLBCL is 
influenced by Β2M expression on malignant cells and that tumours with high Β2M expression 
will have more clonally-restricted TILs, suggestive of infiltration by antigen-specific T cells. 
To our knowledge, this study was the first examination of the relationship between the loss of 
Β2M and the intratumoural T cell repertoire by TCRβ sequencing in any malignancy. The key 
findings from this study were that Β2M gene expression was significantly associated and 
proportional to the number of intratumoural T cells and was inversely proportional to T cell 
diversity. This data is consistent with our finding that high Β2M gene expression reflects a 
‘hot’ or immunologically active TME and expands on this to suggest that clonal T cell 
expansions are more likely with intact antigen presentation. Limitations of the TCRβ 
sequencing are discussed in chapter five but of importance is that beyond a general assessment 
of total T cell number and clonality, we cannot comment on the relative proportions of CD4 
and CD8 cells and their functional subsets or how clonal expansion within these subsets was 
affected by the loss of Β2M and whether these T cells are antigen-specific or bystander cells. 
Data in solid tumours has revealed that only a small proportion of intratumoural T cells have 
the capacity to recognise autologous tumour which has implications for the efficacy of 
immune-checkpoint blockade.265 Given that the TCR repertoire has been shown to stratify 
response to immune-based therapies in solid tumours255-257 and that studies investigating the 
TCR repertoire in B cell lymphomas are markedly lacking, this is a critical field for future 
research. In particular, future studies should aim to identify which T cell subsets undergo clonal 
expansion in the setting of an anti-tumoural immune response and what the antigen specificity 
and functional state of the clonally expanded cells are in addition to how these findings change 
in the setting of impaired antigen presentation due to MHC Class I loss. Additionally, we did 
not identify significant relationships between either Β2M mutation status or Β2M protein 
expression and the number and clonality of the intratumoural TCR repertoire in this cohort of 
DLBCL. This finding is consistent with the lack of relationship between the TME and Β2M 
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mutation status and protein expression observed in chapter three and four and supports our 
previous finding that gene expression rather than mutation status or protein expression is a 
more robust marker of the intratumoural immune response in DLBCL.  
A significant limitation throughout this project was the lack of CD58 data which meant that it 
was not possible to draw robust conclusions regarding the impact of deficient CD58 on the 
TME in DLBCL. In particular, only eight out of 97 samples harboured CD58 variants and while 
this mutation frequency is consistent with the literature, the overall small sample size means 
that further analyses are likely to be underpowered to detect significant relationships due to 
mutation status. Additionally, the lack of protein data by immunohistochemistry prevented 
analysis of the relationship between mutation status, gene and protein expression and the TCR 
repertoire. In view of these limitations, all CD58 findings must be interpreted with caution. 
Based on our limited findings and those of the validation cohort, which showed that CD58 
mutated DLBCL cases had higher CD58 gene expression compared to CD58 wild type and that 
there was no association with the gene expression of immune markers, we have found no 
evidence to suggest that CD58 is a key determinant of the TME in DLBCL.  
In summary, the novel findings that this project has identified are: 
 There is a direct relationship between Β2M mutation status, gene expression and protein 
expression in DLBCL. 
 The Β2M promoter is not differentially methylated compared to normal controls in 
DLBCL and in conjunction with our own findings and the literature, this suggests that 
there are additional, currently uncharacterised causes of Β2M protein loss. 
 High Β2M gene expression is associated with an increased immune cell infiltrate in 
DLBCL including a higher number of intratumoural T cells and reduced T cell 
diversity. This suggests the presence of an adaptive immune response and that clonal T 
cell expansions are more likely with intact antigen presentation. Both findings have 
implications for the identification of patients who are more likely to respond to 
checkpoint inhibitors. 
 Despite B2M gene expression reflecting an immunologically active TME, no survival 
differences were observed between high versus low B2M gene expression  
In conclusion, this project confirms our hypothesis that Β2M expression is relevant to TME 
in DLBCL and its co-ordinate expression with other key components of the immune 
system, irrespective of whether they were immune effector cells, inhibitor cells or 
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checkpoint molecules, suggests the presence of an adaptive immune response. We have 
shown that high Β2M gene expression reflects an immunologically active or ‘hot’ tumor 
microenvironment in DLBCL characterised by higher levels of immune cell infiltration and 
a more clonal TCR repertoire, consistent with a co-ordinately regulated immune response. 
Additionally, we have shown that gene expression is a robust measure of Β2M 
quantification in the TME compared to protein expression by immunohistochemistry. 
These findings indicate that Β2M gene expression level could be used as a biomarker of an 
active intratumoural immune response in DLBCL. Prospective studies are required to 
determine if Β2M gene expression may have a role as a predictive biomarker in stratifying 
the selection of patients in whom immune-based therapies are more likely to be effective. 
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Table 8-1: Annotated validated B2M variants  
 
HGNC 
Symbol
NCBI Build Chr Start End Reference
Tumor 
Allele 1
Tumor 
Allele 2
Amino acid 
change
VAF Coverage Sample ID Ensembl Gene
Ensembl 
Transcript
B2M hs37d5 15 45003746 45003746 T A A p.M1 0.3 242 CN57 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003745 45003745 A G G p.M1 0.45 115 CN58 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003813 45003813 T C C . 0.1 232 CN64 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T A A p.M1 0.17 59 DL11 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T G G p.M1 0.15 124 DL116 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T A A p.M1 0.1 200 DL118 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003780 45003780 ACT A A p.L15fs 0.46 223 DL16 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T A A p.M1 0.38 189 DL17 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003747 45003747 G C C p.M1 0.28 189 DL17 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003780 45003780 ACT A A p.L15fs 0.57 308 DL18 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T G G p.M1 0.8 64 DL29 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T G G p.M1 0.3 131 DL46 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T A A p.M1 0.18 119 DL65 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T C C p.M1 0.3 50 DL75 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003746 45003746 T A A p.M1 0.24 141 NHL-21-018 ENSG00000166710 ENST00000544417
B2M hs37d5 15 45003767 45003767 CT C C p.V9fs 0.3 142 NHL-21-018 ENSG00000166710 ENST00000544417
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SAMPLES - B2M CNV 
Sample ID 
Copy number 
Mean 
Copy number 
SD 
Ratio (to 
normal) 
Interpretation 
DL10 undetermined       
DL103 45550424 5402482.484 0.173643455 Loss 
DL105 37336780 4466205.224 0.142332099 Loss 
DL110 17150106 4101579.75 0.065378176 Loss 
DL111 86269560 1331406.625 0.328869484 Loss 
DL115 6293557248 499967008 23.99176404 Gain 
DL117 undetermined       
DL14 7126848 519406.0625 0.027168364 Loss 
DL16 undetermined       
DL22 undetermined       
DL23 413123840 83481120 1.574875591 Neutral 
DL3 undetermined       
DL4 undetermined       
DL46 2367933.25   0.009026834 Loss 
DL47 undetermined       
DL65 undetermined       
DL67 undetermined       
DL75 8007339.5 999229 0.030524899 Loss 
DL78 1343513.625   0.005121628 Loss 
DL79 12653481 1630497 0.048236525 Loss 
DL84 195931728 44370152 0.746914281 Neutral 
DL86 238673792 20629616 0.909851945 Neutral 
DL87 undetermined       
CN4 14257468 1817089.5 0.054351108 Loss 
CN5 undetermined       
CN6 undetermined       
CN8 1264473.625 295927.1875 0.004820319 Loss 
CN14 2621418.75 159234.9688 0.00999315 Loss 
CN16 undetermined       
CN19 877863 81153.57813 0.003346515 Loss 
CN23 3976376320 615328832 15.15840385 Gain 
CN32 2800734.25 403372.9688 0.010676721 Loss 
CN41 undetermined       
CN44 1895088.625 355939.0625 0.007224296 Loss 
CN47 24450668544 11701814272 93.20876053 Gain 
CN52 undetermined       
CN57 undetermined       
CN58 4948858 354465.3125 0.018865616 Loss 
CN62 undetermined       
CN69 undetermined       
CN81 361757344 125614888 1.379060601 Neutral 
CN92 2852263.25 853799.75 0.010873156 Loss 
CN110 14000800 2182701.25 0.05337266 Loss 
CN111 undetermined       
CN114 6882868.5 792343.625 0.026238286 Loss 
CN115 undetermined       
CN119 1683808.625 140718.2344 0.006418872 Loss 
CN126 undetermined       
CN127 954830784 850883520 3.639924763 Gain 
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CONTROLS - B2M CNV 
Sample ID 
Copy number 
Mean 
Copy 
number SD 
Ratio (to 
normal) 
Interpretation 
NLN10 1.01E+10 1.12E+09     
NLN11 6.08E+08 3.33E+08     
NLN12 6.22E+06 1.57E-01     
NLN13 2.44E+06 3.84E+05     
NLN6 3.59E+08 5.74E+07     
C11 undetermined       
C12 undetermined       
C13 1.91E+07 1.28E+06     
C14 undetermined       
C9 7.39E+06 8.92E+05     
C10 undetermined       
C15 1.37E+09 4.21E+08     
C16 3.17E+06 1.98E+05     
C17 1.73E+06 3.94E+05     
C18 7.72E+08 1.37E+08     
LN2 1.34E+06 4.22E+05     
LN4 5.26E+05       
LN5 undetermined       
LN7 undetermined       
LN8 undetermined       
SUDHL2 2.11E+11 1.41E+10 1 NEG ctrl 
 
Table 8-2: B2M Copy Number Analysis by qPCR for samples (top) and controls (bottom) 
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Table 8-3: Annotated validated CD58 variants 
 
 
 
HGNC 
Symbol
NCBI 
Build
Chr Start End Reference
Tumor 
Allele 1
Tumor 
Allele 2
Amino acid 
change
VAF Coverage Sample ID Ensembl Gene
Ensembl 
Transcript
CD58 hs37d5 1 117078654 117078654 A T T p.C187* 0.2 121 CN4 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117113529 117113529 G T T p.C22* 0.28 61 DL17 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117113531 117113531 AGT A A p.H21fs 0.28 61 DL17 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117064606 117064606 C G G . 0.52 61 DL30 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117064599 117064599 G T T p.S212* 0.43 74 DL84 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117113594 117113594 T C C p.M1 N/A N/A DL78 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117087037 117087037 GAC G G p.S87fs 0.64 439 DL114 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117078708 117078708 GTTACGTTTACA G G p.C166fs 0.36 103 NHL-21-053 ENSG00000116815 ENST00000369489
CD58 hs37d5 1 117113592 117113592 C T T p.M1 0.4 118 NHL-21-103 ENSG00000116815 ENST00000369489
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SAMPLES - CD58 CNV 
Sample ID 
Copy number 
Mean 
Copy 
number SD 
Ratio 
(to 
normal) 
Interpretation 
DL3 Undetermined       
DL4 Undetermined       
DL16 Undetermined       
DL22 Undetermined       
DL46 Undetermined       
DL47 Undetermined       
DL65 9,262,499 2,087,788 0.007 Loss 
DL67 Undetermined       
DL79 58,103,968 8,454,595 0.045 Loss 
DL87 Undetermined       
DL103 76,287,432 4,943,085 0.059 Loss 
DL105 29,231,086 7,411,948 0.023 Loss 
DL110 4,497,077 786,528 0.003 Loss 
DL111 632,839,104 7,234,604 0.488 Loss 
DL115 Undetermined       
CN4 155,558,528 59,976,440 0.120 Loss 
CN5 Undetermined       
CN6 Undetermined       
CN8 Undetermined       
CN14 14,739,592 1,735,043 0.011 Loss 
CN16 Undetermined       
CN18 Excluded as only one data point 
CN23 1,431,346,304 324,109,760 1.103 Neutral 
CN32 Undetermined       
CN41 Undetermined       
CN44 Undetermined       
CN47 5,792,542,720 669,402,688 4.463 Gain 
CN52 Undetermined       
CN57 Undetermined       
CN58 Undetermined       
CN62 Undetermined       
CN69 Undetermined       
CN92 Undetermined       
CN110 114,796,056   0.088 Loss 
CN111 Undetermined       
CN114 28,583,188 1,598,153 0.022 Loss 
CN115 Undetermined       
CN119 Undetermined       
CN126 Undetermined       
CN127 1,687,940,096 245,239,568 1.301 Neutral 
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CONTROLS - CD58 CNV 
Sample ID 
Copy number 
Mean 
Copy number 
SD 
Ratio (to 
normal) 
Interpretation 
C9 156,357,056 24,902,032     
C10 Undetermined       
C11 Undetermined       
C12 Undetermined       
C13 86,984,200       
C14 Undetermined       
C15 1,377,632,000 197,446,032     
C16 Undetermined       
C18 1,449,528,320 242,221,568     
LN4 Undetermined       
LN5 Undetermined       
LN7 Undetermined       
LN8 Undetermined       
NLN6 923,471,552 110,952,560     
NLN11 2,595,463,168 453,950,272     
NLN12 3,542,333,440 525,984,960     
NLN13 250836304 17344434     
C17 Excluded as only one data point 
NLN10 11391249408 2403074816     
Karpas1106P Undetermined     NEG Control 
 
Table 8-4: CD58 Copy Number Analysis by qPCR for samples (top) and controls (bottom) 
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Sample ID 
Number bases 
10x coverage 
Total 
number 
mutations 
Total mutations 
normalised to bases 
sequenced 
CN81 135742 0 0.00 
NHL-21-044 132365 0 0.00 
NHL-21-049 133241 0 0.00 
DL85 136480 1 0.73 
CN19 135502 1 0.74 
CN125 135121 1 0.74 
DL30 131912 1 0.76 
NHL-21-106 139705 2 1.43 
CN69 133941 2 1.49 
DL103 126996 2 1.57 
CN57 138312 3 2.17 
DL16 137088 3 2.19 
CN47 136517 3 2.20 
NHL-21-090 136482 3 2.20 
NHL17 134493 3 2.23 
CN23 133612 3 2.25 
DL79 132560 3 2.26 
CN126 132536 3 2.26 
CN115 130233 3 2.30 
DL23 127540 3 2.35 
CN114 125196 3 2.40 
DL111 120000 3 2.50 
NHL-21-062 137832 4 2.90 
NHL-21-054 137542 4 2.91 
CN92 133293 4 3.00 
CN32 132290 4 3.02 
NHL-21-129 127487 4 3.14 
DL67 127367 4 3.14 
DL116 124968 4 3.20 
NHL-21-145 138854 5 3.60 
NHL-21-115 136454 5 3.66 
CN110 134977 5 3.70 
DL48 134900 5 3.71 
CH16 133365 5 3.75 
NHL-21-022 133120 5 3.76 
NHL-21-060 134135 6 4.47 
CN111 133929 6 4.48 
CN127 130470 6 4.60 
NHL-21-122 127973 6 4.69 
NHL-21-132 137566 7 5.09 
CN62 137154 7 5.10 
DL17 136027 7 5.15 
DL114 135589 7 5.16 
DL46 135155 7 5.18 
NHL-21-065 134739 7 5.20 
CN41 131446 7 5.33 
DL44 126319 7 5.54 
NHL-21-091 137022 8 5.84 
NHL-21-018 136717 8 5.85 
DL117 136480 8 5.86 
NHL-21-103 136270 8 5.87 
CN52 134986 8 5.93 
DL87 134041 8 5.97 
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DL84 131914 8 6.06 
NHL-21-063 137578 9 6.54 
CN83 134017 9 6.72 
CN44 132119 9 6.81 
CN113 133156 10 7.51 
NHL-21-053 132666 10 7.54 
DL78 130032 10 7.69 
CN14 136046 11 8.09 
DL118 135775 11 8.10 
DL86 135453 11 8.12 
DL75 132029 11 8.33 
DL32 124097 11 8.86 
NHL-21-138 135751 13 9.58 
CN119 132314 14 10.58 
CN64 132394 15 11.33 
CN58 134760 16 11.87 
NHL-21-130 135114 17 12.58 
DL115 119756 17 14.20 
DL18 134944 22 16.30 
DL47 128416 23 17.91 
DL110 119517 24 20.08 
CN6 134571 32 23.78 
DL14 116332 28 24.07 
DL29 129904 35 26.94 
CN8 123857 34 27.45 
CN5 123945 37 29.85 
DL65 128272 39 30.40 
DL22 116734 41 35.12 
DL105 122386 45 36.77 
CN4 129757 48 36.99 
DL76 128072 48 37.48 
DL10 134931 52 38.54 
DL3 122697 84 68.46 
DL4 129679 95 73.26 
DL11 112533 150 133.29 
 
 Table 8-5: Total number of mutations detected for each sample, ranked lowest to highest. 
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Table 8-6: Quantitative and qualitative B2M staining characteristics by IHC. *Not tested in duplicate.
Sample ID
Protein loss             
0 = N, 1 = Y
Percentage of 
negative cells (%)
Mislocalised 
staining (if 
present)
DL3 1 5
DL4 1 80 Golgi
DL11 1 50
DL16 1 60
DL18 1 80
DL22 1 5
DL30 1 25
DL32 1 10
DL44 1 60 Golgi
DL47 1 20
DL48* 0 NA
DL67 0 NA
DL75 1 85
DL76 1 65
DL78* 0 NA
DL79 0 NA
DL84 0 NA
DL87 1 15
DL103 1 99
DL110* 0 NA
DL114 0 NA
DL115* 1 40 Golgi
DL116 1 50
DL117 1 100
DL118 1 70
CN4 1 3
CN5 1 100
CN6 0 NA
CN8 1 100
CN14 1 98
CH16 1 100
CN19 1 90 Golgi
CN23 1 60
CN32 1 10
CN41 1 100
CN44 1 65
CN52 1 70
CN57 1 100
CN58 1 90
CN62 1 100
CN81 1 30
CN92 1 90
CN110 1 5
CN111 1 5
CN113 1 100
CN114 1 100
CN115 0 NA
CN119 1 20
CN126 0 NA
CN127 1 80
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Table 8-7: Immunohistochemistry and gene expression counts by Β2M protein status 
 
 
Sample ID
Protein loss             
0 = N, 1 = Y
Protein loss 
%
CD4 CD8 CD56 CD137 CD68 CD163 PD1 PDL1 LAG3 B2M CD4 CD8 CD56 CD137 CD68 CD163 LAG3 PD-1 PD-L1 PD-L2
DL48 0 NA 16.6 10.7 0.0 NP 3.3 49.7 2.7 0.1 1.2 21520 96 84 4 16 272 476 63 48 20 35
DL67 0 NA 26.1 22.3 0.2 0.9 13.2 35.4 1.8 22.2 13.7 57930 533 272 42 177 1069 2269 651 131 212 144
DL78 0 NA 5.8 59.4 0.1 3.9 1.9 24.5 0.0 78.7 16.2 54697 284 2302 12 287 1288 750 780 91 497 1417
DL79 0 NA 1.2 0.6 0.0 0.5 6.4 2.9 0.2 1.3 0.6 12640 120 144 10 63 291 128 63 24 17 24
DL84 0 NA 13.8 9.4 0.0 0.3 6.2 31.8 1.7 16.9 2.6 21976 240 105 3 23 259 323 120 162 49 40
DL110 0 NA 12.8 32.6 0.2 3.2 14.3 36.3 0.5 31.2 9.1 50940 169 539 7 151 765 252 309 80 95 162
DL114 0 NA 12.5 10.3 0.1 0.3 7.4 21.9 0.5 14.1 0.6 37886 108 174 37 72 273 264 102 169 59 41
DL117 1 100 15.7 4.3 0.1 0.7 6.3 17.8 0.3 15.5 1.0 19643 85 35 2 29 300 87 44 49 32 59
DL103 1 99 2.1 0.0 0.1 0.7 3.1 3.9 0.2 4.4 7.1 27596 353 229 27 121 432 281 84 58 55 57
DL75 1 85 11.6 5.1 0.0 1.2 8.6 22.8 0.6 12.9 1.6 16327 92 62 7 44 305 151 116 51 61 46
DL4 1 80 31.4 27.2 0.0 0.7 3.9 19.9 1.3 26.5 3.3 19928 117 348 10 79 423 465 209 38 53 57
DL18 1 80 0.4 12.3 0.2 0.6 2.7 12.4 0.1 13.9 1.2 10583 123 261 104 68 344 189 191 65 24 42
DL118 1 70 20.2 9.6 0.1 1.1 6.7 29.9 1.4 22.5 8.5 16287 82 79 12 45 313 505 238 66 54 45
DL76 1 65 5.5 2.2 0.0 0.5 1.7 17.0 1.0 4.7 0.7 15400 62 41 7 25 148 73 34 14 24 34
DL16 1 60 24.9 10.8 0.0 0.3 7.1 26.9 0.3 2.2 2.7 18031 267 340 8 85 1148 488 155 36 85 90
DL44 1 60 18.9 15.4 0.0 0.9 2.7 12.2 0.3 22.7 4.2 34660 333 851 34 84 1306 251 219 64 143 84
DL11 1 50 17.0 10.2 0.0 1.2 6.6 28.7 0.0 14.6 4.2 21480 187 320 12 84 957 825 173 27 89 128
DL116 1 50 41.8 19.0 NP 1.0 4.5 18.6 0.1 49.1 12.5 43733 397 443 19 225 963 308 408 64 223 180
DL115 1 40 5.8 2.5 1.1 0.2 4.3 28.4 0.1 2.2 0.7 9466 61 13 9 10 186 375 12 17 13 18
DL30 1 25 11.7 16.7 0.3 0.6 4.8 29.0 0.0 18.8 7.4 33685 211 286 16 98 858 777 234 194 140 114
DL47 1 20 43.2 23.6 0.1 5.0 2.5 15.0 0.4 26.7 7.9 54180 238 372 13 167 779 127 496 142 85 91
DL87 1 15 25.4 19.8 0.1 1.5 5.8 28.9 6.6 40.3 10.0 44511 230 179 11 70 602 909 429 45 104 181
DL32 1 10 42.4 9.1 0.0 0.6 3.9 4.3 4.7 3.5 3.0 28716 378 542 63 193 429 93 471 315 50 71
DL3 1 5 15.2 13.9 0.2 0.7 2.9 11.8 0.3 5.9 1.7 36936 169 443 22 137 339 194 119 35 49 84
DL22 1 5 7.9 10.5 0.1 0.2 5.2 1.1 0.6 7.5 1.7 15056 67 81 30 51 194 20 36 87 32 37
Immune marker immunohistochemistry (%) Gene Expression B2M Protein Status
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Table 8-8: Visiopharm® (automated) and manual count comparison  
Sample ID TIM3 %
Visiopharm Manual Visiopharm Manual Visiopharm Manual Visiopharm Manual Visiopharm Manual Visiopharm Manual Visiopharm Manual Visiopharm Manual Visiopharm Manual Manual
DL27/54 23.3 30.0 29.9 50.0 0.0 0.0 2.3 2.0 2.9 15.0 33.2 35.0 0.4 0.1 27.6 65.0 11.3 25.0 3.0
DL120 5.5 7.0 10.7 20.0 0.0 0.0 2.5 3.0 2.6 2.0 11.0 8.0 0.5 0.5 9.1 15.0 2.8 1.0 0.6
DL119 8.2 7.0 7.7 15.0 0.0 0.0 1.6 1.0 0.9 5.0 36.9 15.0 0.0 0.0 3.1 2.0 1.0 0.1 <0.1
DL118 19.8 10.0 7.9 10.0 0.3 0.0 1.3 1.0 10.2 12.0 28.9 20.0 0.9 1.0 21.7 20.0 6.1 12.0 0.5
DL117 12.4 10.0 5.3 7.0 0.0 0.0 1.0 0.0 6.5 1.0 18.7 10.0 0.1 0.0 N/A N/A 0.3 0.1 <0.1
DL116 N/A N/A N/A N/A N/A N/A N/A N/A 1.4 2.0 N/A N/A N/A N/A N/A N/A N/A 1.5
DL115 5.8 5.0 2.2 5.0 1.8 0.0 0.2 1.0 4.3 12.0 33.1 20.0 0.1 0.1 1.5 3.0 0.3 0.3 N/A
DL114 14.8 10.0 12.6 10.0 0.3 0.0 0.3 1.0 9.6 15.0 27.5 25.0 1.0 0.1 14.4 12.0 0.7 0.1 0.2
DL110 N/A N/A N/A N/A N/A N/A N/A N/A 13.8 37.0 N/A N/A N/A N/A 31.2 80.0 NA 1.0
DL103 1.2 N/A 0.0 0.0 0.0 0.0 0.9 1.0 0.9 1.0 4.0 1.0 N/A N/A 5.3 1.0 7.1 0.1 <0.1
DL87 15.9 35.0 21.1 20.0 0.1 0.0 3.6 4.0 5.0 20.0 35.4 30.0 12.0 3.0 41.8 70.0 13.3 10.0 10.6
DL86 6.5 8.0 5.8 3.0 0.0 0.0 N/A N/A 1.9 2.0 19.2 5.0 N/A N/A N/A N/A N/A 0.0 N/A
DL84 19.6 20.0 7.6 10.0 0.1 0.0 0.2 1.0 9.0 25.0 36.2 50.0 1.4 5.0 24.9 35.0 2.8 1.0 2.0
DL81 25.1 40.0 15.9 15.0 0.2 0.0 0.6 1.0 6.6 10.0 24.6 40.0 1.9 1.0 20.2 20.0 5.7 3.0 0.8
DL79 1.6 0.0 0.3 1.0 0.0 0.0 0.3 0.0 4.8 10.0 1.9 2.0 0.2 0.0 0.3 1.0 0.5 0.1 <0.1
DL78 3.4 3.0 65.1 85.0 0.0 0.0 6.2 8.0 1.9 10.0 25.6 50.0 0.0 0.0 N/A N/A 12.3 28.0 9.0
DL76 3.7 1.0 2.2 2.0 0.1 0.0 0.9 1.0 0.5 2.0 17.6 8.0 1.5 0.0 5.0 12.0 0.6 0.0 <0.1
DL75 13.0 15.0 7.2 8.0 0.0 0.0 1.6 1.0 7.5 18.0 28.0 15.0 0.2 1.0 18.7 10.0 2.5 3.0 <0.1
DL67 12.4 18.0 25.4 20.0 0.5 0.0 0.8 1.0 16.4 30.0 27.6 40.0 1.6 0.0 10.6 70.0 14.6 8.0 0.2
DL55 5.8 15.0 0.7 1.0 0.0 0.0 0.8 1.0 3.3 20.0 11.7 10.0 0.1 0.1 8.3 60.0 0.7 0.1 <0.1
DL48 16.5 30.0 12.9 10.0 0.0 0.0 N/A N/A 4.9 2.0 N/A N/A 2.1 0.5 N/A N/A 1.3 0.1 N/A
DL47 N/A N/A 22.0 25.0 0.1 0.0 4.4 10.0 1.2 1.0 11.3 15.0 0.1 0.0 24.8 80.0 6.3 1.5 3.3
DL44 20.0 15.0 12.6 20.0 0.1 0.0 0.9 3.0 1.1 7.0 12.1 18.0 0.3 0.0 26.3 20.0 1.2 0.4 0.3
DL39 52.6 15.0 5.3 3.0 N/A N/A N/A N/A 4.2 5.0 0.4 0.1 6.7 5.0 N/A N/A 0.3 0.0 <0.1
DL36 21.9 30.0 3.8 5.0 N/A N/A 1.1 0.0 0.6 8.0 7.9 2.0 1.6 0.5 6.4 7.0 1.8 0.0 0.1
DL33 N/A N/A 19.5 20.0 0.2 0.0 5.5 10.0 0.1 1.0 N/A N/A N/A N/A N/A N/A 11.4 10.0 <0.1
DL32 24.4 60.0 13.0 10.0 0.0 0.0 0.7 1.0 4.4 10.0 7.9 2.0 0.3 0.1 4.3 8.0 2.4 3.0 0.2
DL30 44.6 15.0 16.6 17.0 0.6 0.0 1.3 2.0 4.4 15.0 3.0 40.0 0.8 0.0 23.1 20.0 8.4 4.0 2.1
DL29 16.4 10.0 8.0 7.0 N/A 0.0 N/A N/A 5.2 3.0 N/A N/A N/A N/A 0.2 1.0 0.9 0.0 0.1
DL28 28.0 30.0 17.9 20.0 0.1 0.0 1.9 3.0 2.7 8.0 32.3 60.0 0.0 0.0 58.4 95.0 9.6 2.0 0.3
DL22 8.9 10.0 10.3 15.0 0.1 0.0 0.2 1.0 5.5 7.0 2.1 1.0 0.1 0.5 13.8 10.0 2.2 0.1 0.1
DL18 0.3 0.0 12.1 15.0 0.3 0.0 0.7 1.0 1.8 1.0 12.7 20.0 0.1 0.0 N/A N/A 1.1 0.0 0.8
DL17 N/A N/A 2.0 1.0 N/A 0.0 N/A N/A N/A 1.0 5.4 3.0 N/A N/A N/A N/A 0.3 0.0 N/A
DL16 19.0 10.0 6.7 5.0 0.0 0.0 0.7 0.0 5.3 18.0 18.5 25.0 0.3 0.0 5.3 8.0 2.2 0.2 0.7
DL14 1.7 0.0 11.3 5.0 0.0 0.0 1.2 5.0 0.6 1.0 12.9 15.0 0.8 0.0 N/A N/A 3.0 0.3 0.2
DL11 15.9 13.0 9.4 10.0 0.0 0.0 1.2 3.0 5.8 8.0 24.6 20.0 0.0 0.0 N/A N/A 4.0 0.8 <0.1
DL10 2.9 1.0 3.4 1.0 N/A 0.0 N/A N/A 1.6 2.0 30.0 10.0 0.3 0.0 1.6 2.0 1.2 0.1 <0.1
DL9 8.7 3.0 8.9 5.0 0.3 0.0 0.3 0.0 11.5 10.0 83.6 35.0 0.1 0.0 13.5 20.0 7.0 2.0 1.0
DL5 3.8 7.0 7.7 5.0 0.1 0.0 0.2 1.0 6.4 15.0 33.6 20.0 0.2 0.0 10.4 1.0 5.8 0.5 <0.1
DL4 35.1 70.0 27.7 30.0 0.0 0.0 0.2 0.0 N/A 5.0 13.5 10.0 0.1 0.0 N/A N/A 1.2 0.3 <0.1
DL3 15.6 5.0 15.7 15.0 0.5 0.0 0.9 1.0 1.7 8.0 18.6 5.0 0.3 0.0 7.1 18.0 0.3 0.0 <0.1
DL2 1.5 1.0 10.5 15.0 0.0 0.0 0.3 1.0 N/A N/A 30.2 25.0 0.0 0.5 39.1 80.0 7.8 3.0 2.5
PD1 % PDL1 % LAG3 %CD4 % CD8 % CD56 % CD137 % CD68 % CD163 %
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Table 8-9: Linear regression of Visiopharm® (automated) versus manual IHC scores 
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Table 8-10: Bland-Altman comparison plots of Visiopharm® (automated) versus manual immunohistochemistry scores for each immune marker 
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Sample ID
B2M 
mutation      
1 = Y, 0 = N
CD58 
mutation 
1= Y, 0 = N
B2M Gene 
Expression
CD58 Gene 
Expression
Total TCRs
Unique 
TCRs
Productive 
Total
Productive 
Uniques
Entropy Clonality
Max 
Frequency 
(%)
Productive 
Rearrange
ments
Total Gene 
Rearrange
ments
Diversity 
(Prod.Uniq/
Prod.Gene 
Rearr)
DL17 1 1 18451 525 128339 1522 95680 1175 9.320554 0.086081 2.1264 1323 1719 0.888133
DL116 1 0 43733 370 52631 940 36183 700 8.706583 0.078787 1.065912 735 995 0.952381
CN64 1 0 25207 321 485840 10568 389051 8544 11.73172 0.101754 1.620081 10306 12832 0.8290316
DL16 1 0 18031 316 406495 5016 326560 3965 10.86444 0.091078 1.511458 4845 6099 0.8183695
DL18 1 0 10583 298 145822 3448 112664 2673 10.09847 0.112944 3.769664 2903 3732 0.9207716
CN57 1 0 20484 219 388892 7792 313494 6305 11.65426 0.076691 0.716651 7397 9187 0.8523726
DL75 1 0 16327 200 353955 3889 270701 2960 10.52298 0.087448 1.786103 3308 4357 0.8948005
DL29 1 0 6570 154 90135 1754 67404 1325 9.537238 0.080462 0.574694 1413 1860 0.9377212
DL46 1 0 23396 137 459184 11633 375077 9471 12.15477 0.079832 0.710608 10897 13369 0.8691383
CN8 1 0 16847 125 212904 7133 172456 5757 11.35667 0.090819 2.949686 6296 7769 0.9143901
CN58 1 0 8056 89 95107 1412 75365 1148 9.34583 0.080579 0.808563 1201 1478 0.9558701
DL114 0 1 37886 892 14312 289 9947 191 6.479384 0.14491 6.721632 256 391 0.7460938
DL78 0 1 54697 550 852180 14967 701288 12289 12.62373 0.070765 0.347696 14545 17744 0.8448952
DL30 0 1 33685 240 237736 3641 180825 2850 10.14553 0.115993 2.591109 3617 4654 0.7879458
CN4 0 1 29125 139 285373 6139 237040 5154 11.22959 0.089355 1.878244 5883 6996 0.8760836
DL84 0 1 21976 120 419193 4398 328506 3418 10.58795 0.098048 1.595208 3987 5132 0.8572862
CN115 0 0 24546 1151 253462 2702 212015 2215 9.895462 0.109567 1.917447 2584 3146 0.8571981
CN23 0 0 37334 519 1224142 22101 958278 17501 12.98901 0.078477 1.580209 20893 26515 0.837649
DL48 0 0 21520 443 99181 1931 77139 1522 9.369776 0.113697 1.211926 1732 2199 0.8787529
DL22 0 0 15056 439 8281 221 5242 145 6.346008 0.116144 2.994807 157 238 0.9235669
DL32 0 0 28716 421 308539 7607 251081 6227 11.80006 0.063809 0.371428 6510 7960 0.9565284
CN69 0 0 40009 391 151948 2116 116558 1655 9.034823 0.155041 1.848001 2366 3057 0.6994928
CH16 0 0 58147 384 1081577 17027 873899 13751 12.14823 0.116316 2.936823 17133 21199 0.8026032
CN83 0 0 36616 377 473038 4797 354640 3713 9.603246 0.190171 5.011014 5099 6716 0.728182
CN47 0 0 31473 350 788453 9325 653753 7724 11.73737 0.091192 0.662944 10033 12189 0.7698595
CN127 0 0 39156 338 374490 6188 291503 4787 11.3283 0.073343 0.693209 5191 6711 0.922173
CN5 0 0 32122 326 245054 3929 196621 3206 10.36327 0.110186 1.714724 3747 4604 0.8556178
DL65 0 0 30747 313 155293 1901 117614 1450 9.625081 0.083486 1.477852 1567 2061 0.925335
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Table 8-11: Β2M, CD58 mutation status and gene expression compared to TCRβ metrics 
CN52 0 0 17164 303 288506 7420 229903 6056 11.70898 0.068064 1.248154 6355 7790 0.9529504
DL47 0 0 54180 290 349966 6744 279316 5454 11.45809 0.076936 0.826366 6400 7967 0.8521875
CN32 0 0 26195 284 74926 1069 52129 794 8.663098 0.100685 5.449377 894 1212 0.8881432
DL3 0 0 36936 282 136442 2681 101234 2073 10.14044 0.079606 0.61418 2204 2854 0.9405626
CN41 0 0 62619 277 572204 11623 464648 9372 12.28117 0.069195 0.872766 11054 13701 0.8478379
DL85 0 0 14167 273 295714 4851 234020 3861 11.21417 0.0588 0.336136 4033 5094 0.9573518
CN126 0 0 40034 266 172308 5124 138875 4144 11.22957 0.065511 0.640133 4733 5863 0.8755546
CN114 0 0 12819 256 139757 1542 116538 1223 9.149774 0.10788 4.614438 1382 1723 0.8849493
CN92 0 0 11171 254 579740 6557 467033 5323 10.2886 0.168802 11.87498 6538 8120 0.8141634
CN44 0 0 17421 253 146421 1880 111588 1478 9.53493 0.09445 1.906147 1726 2182 0.8563152
DL76 0 0 15400 240 8207 115 3590 63 5.204836 0.12923 5.202876 71 126 0.8873239
CN125 0 0 44643 240 711088 7044 613309 5826 10.06653 0.195211 1.631725 12299 14496 0.473697
CN81 0 0 25336 237 666282 5507 559216 4253 8.220281 0.31806 12.10313 8688 10694 0.4895258
DL111 0 0 27149 205 56936 325 39823 212 6.425425 0.168544 5.924196 318 466 0.6666667
DL87 0 0 44511 200 474044 4539 373703 3399 10.00225 0.147358 3.153505 4753 6241 0.7151273
CN119 0 0 20133 174 293930 4703 233199 3689 10.83348 0.085707 2.585309 4006 5095 0.9208687
CN113 0 0 17049 163 281762 2022 207916 1483 9.062265 0.139738 3.274395 1957 2666 0.7577925
CN111 0 0 60092 161 370055 8995 237926 7153 11.98356 0.064101 18.28755 7684 10408 0.9308954
DL79 0 0 12640 155 501776 11016 399343 8737 12.24292 0.06492 0.685764 9228 11613 0.9467924
CN6 0 0 19635 152 563289 11550 463835 9643 11.42072 0.1371 2.395751 14890 18037 0.6476159
CN19 0 0 15005 149 70313 1075 51536 807 8.849456 0.083568 1.001237 908 1207 0.8887665
CN110 0 0 21032 145 212005 3343 169813 2739 10.69782 0.063192 0.426877 2872 3523 0.9536908
CN14 0 0 8105 113 243998 2593 197736 2033 9.393088 0.145259 2.568464 2695 3406 0.7543599
DL4 0 0 19928 107 126307 1921 98486 1526 8.804264 0.167488 6.07884 1765 2211 0.8645892
DL105 0 0 14071 99 56380 651 40977 508 7.706783 0.142613 9.542391 565 725 0.899115
DL10 0 0 8531 77 28524 340 16303 228 7.077211 0.096475 2.506661 234 350 0.974359
CN62 0 0 8197 74 767690 19230 623848 15638 12.97222 0.068941 1.149032 18412 22652 0.8493374
DL117 0 0 19643 37 29919 357 17420 247 7.15695 0.09957 14.09138 272 423 0.9080882
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